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Summary
EGFR/MAPK signalling has been implicated in mediating tamoxifen- 
resistant breast cancer cell growth in the clinic and in preclinical 
models. However, ERa expression and functionality has also been 
shown to be maintained in this condition. ERa transcriptional activity 
can be driven, in a ligand-independent manner, via growth factor 
signalling-mediated phosphorylation of ERa. The aim of this thesis was 
to investigate whether growth factor signalling pathways regulate 
phosphorylation and functionality of ERa in tamoxifen-sensitive (WT) 
and -resistant (TAM-R) MCF-7 breast cancer cell lines and if so 
whether this cross-talk mechanism plays a role in the generation and 
maintenance of die tamoxifen-resistant phenotype. Western blotting and 
immunocytochemistry assays revealed increased levels of serine 118 
(SI 18), but not serine 167, phosphorylated ERa in TAM-R compared to 
WT cells. Basal SI 18 ERa phosphorylation was regulated by both 
EGER and IGF-IR signalling pathways, via MAPK, in Tam-R cells and 
by IGF-1 R/phosphatidylinositol 3-kinase signalling in WT cells. ERa 
transcriptional activity, assayed by oestrogen response element (ERE) 
activity and pS2 and amphiregulin (AR) mRNA levels, was similarly 
IGF- lR/EGFR/MAPK-regulated in TAM-R cells, whereas, ERE 
activity was only IGF-1 R-dependent in WT cells. AP-1 and serum 
response element activity was EGFR/IGF-1 R-independent in both cell 
lines. Recruitment of the co-activators p68 RNA helicase and SRC1 
was EGFR/MAPK- and SI 18 phosphorylation-dependent in TAM-R
m
cells indicative of a role for SI 18 phosphorylation in mediating ERa 
transcriptional activity. The ability of ERa to regulate AR mRNA 
expression also suggested the existence of a self propagating autocrine 
growth regulatory loop in TAM-R cells. This was confirmed by the 
presence of ERa on the AR gene promoter, elevated basal AR mRNA 
expression, inhibition of EGFR, MAPK and ERa SI 18 phosphorylation 
by AR neutralising antibodies and growth promotion by AR and 
inhibition by the selective EGFR tyrosine kinase inhibitor gefitinib and 
the pure antioestrogen fiilvestrant
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1.0 INTRODUCTION
1
1.1 Breast cancer
1.1.1 Today’s breast cancer rates
Breast cancer incidence rates in Wales and England have escalated to the 
current day level of 114 sufferers per 100,000 women, ranking the disease as 
the most common cancer in these countries (Office for National Statistics).
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Age-standardised incidence of and mortality from female breast cancer, Wales and 
England, rate per 100,000.
Figure 1.1: Incidence and mortality rates of breast cancer in Wales and England between 1971 
and 2002 (adapted from Office for National Statistics).
Paradoxically however, the past 16 years has seen a decrease in the mortality 
rate of breast cancer patients (Office for National Statistics), which can only be 
attributed to revolutionary advances in systemic therapy, screening and 
surgery. To fully understand the rationale behind these current treatment 
strategies, one would benefit from a historical perspective of the disease.
2
1.1.2 History of breast cancer
Breast cancer has been an affliction on humanity for centuries as investigations 
into the disease have been recorded as far back as the ancient Egyptians. In 
1862 Edwin Smith discovered a papyrus dating from the seventeenth century 
B.C, containing writings by an Egyptian physician who distinguished between 
abscesses which were considered treatable by the knife, and cancers which 
were deemed inoperable (Wilkins). The writings suggested that the Egyptians 
could distinguish between inflammatory mastitis and carcinoma of the breast 
and that the wisdom of the ancient anonymous author caused them to consider 
surgical intervention of the latter futile (Baum and Henderson 2004).
Centuries later, the Humoral theory was developed by the ancient Greek 
physician and philosopher Aristotle (384-322 BC), who implied that breast 
cancer was a local manifestation of a systemic disease. The Greek physician 
Galen (200-130 AD) later used this theory to explain that the systemic disorder 
resulted from the accumulation of black bile (melancholia). Consequently, 
therapy for breast cancer during the following 1600 years involved cupping, 
leaching, venesection, purgation and crank diets, which in fact did nothing 
beneficial to treat the disease, although, highlighted the danger of basing 
therapeutic strategies on an unproven disease model (Baum and Henderson 
2004; Breast Cancer 2000).
During the mid 17th century the development of the microscope by Anthony 
van Leeuwenhoek allowed Muller at the beginning of the 19th century to 
identify the cellular nature of breast cancer. These developments, and the 
elegant microscopic analysis of anatomical dissections from advanced breast
3
cancer patients lymph nodes, allowed Rudolf Ludwig Karl Virchow (1821- 
1902), a leading German pathologist, in the middle of the 19th century to 
suggest a mechanistic model of breast cancer, with the regional nodes acting as 
filters to inhibit the onward spread of the cancer cells (Baum and Henderson 
2004). This revolution behind the understanding of the disease made 
Aristotle’s Humoral theory redundant and led to the assumption that cancer 
could be cured at an early stage with adequate surgery. Consequently, a radical 
surgical technique was developed which involved removal of the affected 
breast, total ipsilateral axillary lymph node dissection, resection of pectoral 
major and minor muscles and routine resection of thoracodorsal neurovascular 
network including the long thoracic nerve (Baum and Henderson 2004). 
Although Halsted takes credit for the development of this technique at the end 
of the 19th century, similar radical surgical techniques had been carried out in 
centuries previous to this, however the arrival of Virchow’s theory, the timely 
developments throughout the 19th century in germ theory by Pasteur, antisepsis 
by Lister, and anaesthesia by Simpson, made Halsted’s en bloc radical 
mastectomy a success story in controlling local breast disease (Baum and 
Henderson 2004; Pasteur; Lister and Antiseptic surgery; Caton 1997).
A short time after the announcement by Halsted describing his surgical 
procedure to treat breast cancer, a new theory was initiated. Sir George Thomas 
Beatson, a surgeon at the Glasgow Royal Infirmary, studied the physiology of 
farm animal lactation for his MD. At the time, it was assumed that lactation 
was controlled by nervous stimuli, yet dissections failed to demonstrate the 
nerves associated with lactation. Beatson made an observation that lactation
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terminates when menses restarts after a calf has been weaned and that in 
Australia cows are spayed to prolong lactation, which lead to his hypothesis 
that a link might exist between the breast and the ovary. When he observed 
similarities in the microscopic appearance of the lactating breast and the 
neoplastic breast he made the conceptual leap that if castration effects lactation 
then it may also affect breast cancers (Robertson, Nicholson and Hayes 2002). 
Beatson decided to test his hypothesis. He first reported a single case study of a 
young woman who had previously had a mastectomy but subsequently returned 
with inoperable local recurrence. He carried out bilateral oopherectomy and the 
patient’s cancer responded. However the cancer eventually progressed and the 
patient died. The following week he reported a second case where a young 
woman presented with inoperable locally advanced breast cancer. This patient 
did not respond to bilateral oopherectomy. Thus in the very first two reported 
patients, Beatson identified the major issues that we still struggle to fully 
understand today. First; why do some tumours respond (endocrine sensitive), 
but others do not (de novo endocrine resistant)? Second; even when tumours do 
respond to endocrine treatment, why do they eventually progress (acquired 
endocrine resistance) (Robertson, Nicholson and Hayes 2002)?
Recent work by David Smith of Glasgow using the original operative records 
of Beatson’s operating theatre showed that he had completed nine cases of 
oopherectomy before his report in the Lancet. Three out of the nine treated 
were a success, which is the anticipated 30% response rate for unselected cases 
of breast cancer to endocrine manipulation (Baum and Henderson 2004).
5
Continued research in the field at the beginning of the 20th century confirmed a 
link between the ovary and the breast but the seemingly low response rates to 
this first form of endocrine therapy meant that the Halstedian mastectomy, 
capable of removing all local disease and proving effective at reducing local 
recurrence, appeared to be more successful at treating breast cancer.
During the 1950s faith in the radical surgical technique began to wane firstly 
due to statistical analyses, which suggested that surgery alone had no effect on 
overall survival, and secondly due to a growing body of evidence which 
demonstrated that cancer cells were present in the blood of cancer patients 
(Ashworth 1869; Engell 1955; Fisher 1955). Fisher and Fisher confirmed these 
findings by demonstrating that less than 40% of 51Cr labelled V2 carcinoma 
cells (cells isolated from Shope virus-induced papillomas) were retained in a 
rabbit's popliteal node, suggesting that Virchow’s mechanistic model of breast 
cancer progression was not the case and that cancer cells can bypass the nodes 
via lymphovenous channels or by direct invasion of the venous system. This 
hypothetical model of ‘biological predeterminism’ meant that the Halstedian 
radical mastectomy was like shutting the stable door after the horse had already 
bolted (Baum and Henderson 2004; Kufe et al 2003).
Following reports of favourable effects of chemotherapeutic agents on the 
destruction of disseminated tumour cells in experimental animals, a rationale 
for embarking on clinical trials of adjuvant therapy was established. The 
findings during the 1950’s, of tumour cells in the blood of breast cancer 
patients prompted the NSABP in 1958 to begin the first clinical trial of 
adjuvant chemotherapy for breast cancer. Women entered into this study were
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treated by both conventional Halsted radical mastectomy and triethylene 
thiophosphoramide (Thiotepa) or by radical mastectomy and placebo. Because 
of its effectiveness in the palliation of advanced mammary cancer, Thiotepa 
was administered at the time of operation and on each of the first 2  
postoperative days. The results reported in 1968 indicated a significant increase 
in the 5-year survival of pre-menopausal women who received Thiotepa. In 
1973, a second clinical trial was begun at the Istituto Nazionale Tumori in 
Milan to evaluate the effectiveness of a three-drug combination, 
cyclophosphamide, methotrexate and 5-fluorourocil (CMF) as an adjuvant to 
surgery. Significant reductions in treatment failure occurred in all subgroups of 
patients treated with CMF, however, about two-thirds of patients experienced 
toxicity, indicated by nausea, vomiting, anorexia, alopecia, cystitis, or 
amenorrhea.
During this period it was established that the ovaries mediated their effects on 
breast tissue, normal or cancerous, through 17(3-oestradiol (oestrogen), which 
maintained strong interest in the possibilities of endocrine therapies despite the 
promising early results with chemotherapy. The understanding that treating 
women with oestrogenic compounds within 24 hours of coitus prevented 
pregnancy lead the British scientist Arthur Walpole in 1963 who was working 
on a morning after birth control pill at Imperial Chemical Industries (ICI), to 
develop the hypothesis that as his molecule ICI 46, 474 (Tamoxifen) increased 
fertility that it might have anti-oestrogenic properties and this might reduce 
breast cancer growth (Baum 1997). A publication in the British Journal of 
Cancer in 1971 confirmed his idea and demonstrated that 10 out of 46 patients
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with late or recurrent breast cancer showed a good response to tamoxifen. 
Although, this was of the same order as that produced by oestrogens and 
androgens, which were also in use at the time, importantly tamoxifen showed 
very low incidence of side effects (Baum and Henderson 2004). The 
responsiveness of the patients to tamoxifen also meant that the drug provided a 
safer alternative to the invasive and disruptive surgical removal of the ovaries. 
These early results demonstrated tamoxifen’s potential as a breast cancer agent, 
re-emphasising the need for effective endocrine therapy, prompting increased 
research in the field.
Jensen and his colleagues in the 1960’s found a protein that bound oestrogen at 
high affinity in the cytosol of tissues responsive to the hormone. This led to the 
discovery that this same protein existed in approximately 80% of breast 
carcinomas. It was also clear that 4-hydroxytamoxifen (4-OH-tamoxifen) an 
active metabolite of tamoxifen, caused displacement of oestrogen from this 
protein and led researchers to believe that 4-OH-tamoxifen was a competitive 
antagonist of oestrogen. The oestrogen binding protein was named the 
oestrogen receptor (ER) and the application of specific antibodies to ER 
allowed pathologists to predict whether a patient would respond to endocrine 
therapy depending on the level of ER present.
1.2 Oestrogen Receptor (ER)
1.2.1 ER structure/function relationship
The discovery of the oestrogen receptor initiated decades of investigations 
leading us to our current understanding of the importance of the
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structure/functional relationship of the receptor in the growth of breast cancer 
cells. There are two known subfamilies of oestrogen receptor, ERa and ER{3, 
each encoded by unique genes that belong to the nuclear receptor family, a 
large group currently totalling approximately 150 related proteins 
(Lewandowski et al 2002; White and Parker 1998). These family members are 
conserved in both primary amino acid sequence and organisation of their 
functional domains, A-F (Figures 1.2 and 1.3) (White and Parker 1998). The 
A/B domain, also referred to as the variable N-terminal region, contains the 
activation function (AF1) (Levenson and Jordan 1999). Activation function 2 
(AF2) resides in the C terminal E domain and is ligand dependent (Levenson 
and Jordan 1999). In addition, the E domain contains a  helical structures 
intricately arranged to provide the ligand-binding domain (LBD) which has 
high ligand specificity (Levenson and Jordan 1999). Domain C contains the 
DNA binding domain, the most highly conserved region throughout the whole 
receptor family, strongly indicating that these molecules are first and foremost 
transcription factors (Levenson and Jordan 1999). Domain D contains a 
variable hinge region allowing the protein to bend and alter conformation 
(Metivier 2002). It has also been shown to be involved in binding of Hsp90 
whilst both the C and D domains are involved in dimerisation of the receptors 
(Tsai and O’Malley 1994, Levensen and Jordan 1999). ERfS is homologous to 
ERa at the ligand binding (58%) and DNA binding (96%) domains, whereas 
the A/B region, hinge domain and F region are not well conserved (Levenson 
and Jordan 1999).
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Figure 1.2; Map of ERa dojnaffls
P 104/106 P 118
Domain A (1-38) (Metivier 2002) Domain B (39-182) (Metivier 2002) | | |
MTMTLHTKASGMALLHOIQGNELE PLNRPQLKI PLER PTX £'m .D SSK PA \ W 1TEGAAYEraAAW iNAQVN'GCTGLFYGPGSEAAAFGSNGLGGFr^LN:?VSPSFIJ XLHF'^PCI-SPF
P 167
I Domain C (183-263) (DNA binding domam) (Metivier 2002)
LQPHGC&VFYYLENE P3GYTVREAGPPAFYR FNSDNRRQGGRE RLASTNDICGSMAMESAKE TRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSCQAC
I  I________________I___ I Helix 1 T______ t____________I__I
C4 Zinc finger C4 Zinc finger
Domain D (264-302) (Hinge region) (Metivier 2002)
RLRKCYEVGbMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGS { AGDMRAANLWPSPLMIKRSKKNSLALSLTADQMVSALLDAE PPILYSEYPPTRPFSEASNMGLLTNLADRELVHMINW 
Helix 2 Helix 3 Helix 4 Helix 5
AKRVPGFVDLTLHDQVH
Domain E (303-549) (ligand binding domain) (Metivier 2002)
;CAWLEILMIGLVWRSMEHPVKLLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLP 
Helix 6 Helix? Helix 8 Helix 9 Helix 10
P537
I Domain F (550-595) (Metivier 2002)
KITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNW PLYDLLLEMLDAHRL }  HAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV 
Helix 10 Helix 11 Helix 12
= AF1 (Metzger D 1997), AF2 ( AF2a 282-351) (Metivier 2002, Norris JD 1997), Helix and C4 info from ExPASy Proteomics Server
AF-1 AF-2
595184 263 302 549
Simplified map of the ERa 
domains
Figure t-3; Mgp of £Rg domains
Domain A/B (1-148)
MDIKNSPSSLNSPSSYNCSQSILPLEHGSIYIPSSYVDSHHEYPAMTFYSPAVMNYSIPSNVTNLEGGPGRQTTSPNVLWPTPG
P 87 Human (106 Mouse) P 105 Human (124 Mouse)
| | Domain C (149-214) (DNA binding domain)
HLSPLWHRQLSHLYAEPQKSPWCEARSLEHTLPVNRETLKRKVSGNRCASPVTGPGSKRDAHFCAVCSDYASGYHYGVWSCEGCKAFFKRSIQGHNDYICPATNQCTI DKNRRKSCQAC
1 1____________I--- 1 I____ I--------------1—1
C4 Zinc finger C4 Zinc finger
Domain D (Hinge)
RLRKCYEVGMVK' R R FP ' 3 Y R I ' 'ivp ?RSAr)EQLHCAGl'A^.S ^,HAPRVPFLLLDALSPEQLVLTLLEAEPPHVLISRPSAPFTEASht>lMSLTKLADKELVHMISWAKKI  PGFVELS
Helix 1 Helix 2 Helix3
Domain E (304-500) (ligand binding domain)
LFDQVRLLESCWMEVLPMGLMWRSIDHPGKLIFAPDLVLDRDEGKCVEGILEIFDMLLATTSRFRELKLQHKEYLCVKAMILLNSSMYPLVTATQDADSSRKLAHLLNAVTDALVWVIAKSGI 
Helix 4 Helix 5 Helix 6 Helix 7 Helix 8 Helix 9
P488
| Domain F
S SQQQSMRLANLLMLLSH\7RHASNKGMEHLLNMKCKNWPV 'DliLLEMLNAH'.7. ^KSSITGSECSPAEnSKSlEGSQNFQSO
Helix 10 Helix 11 Helix 12
AF-1 AF-2
ZEE ■ c ID E
148 214 257 500
530
Simplified map of the ERJ3 domains
1.2.2 Oestrogen mode of action
In the absence of ligand, ERs are predominantly distributed between the 
nucleus and the cytoplasm as monomers associated with chaperone proteins 
such as the heat shock proteins Hsp90, Hsp70 and cyclophilin 40 and p23, or as 
free dimers (Pratt and Toft 1997).
The classic oestrogen response involves oestrogen (E2) diffusing through the 
cell plasma and/or nuclear membranes where it binds to the ligand-binding 
domain of the receptor (Figure 1.4) (Tsai MJ and O’Malley 1994). Oestrogen 
enters the narrower half of the LBD in a predominantly hydrophobic cavity 
composed of residues from helices 3, 6 , 7, 8 , 11 and 12 as well as the S1/S2 
hairpin. The structure of E2 and the hydrophobic pocket is such, that helix 12 is 
able to change position to pack against helices 3, 5/6, and 11, enclosing the 
ligand within the cavity (Shiau et al 1998).
The interaction between ER and oestrogen, and the resulting change in 
conformation, mainly due to the shift in position of helix 1 2 , triggers the first 
key steps on the path ERa takes towards gene transcription. Namely 
dissociation of the chaperone molecules, dimerisation, translocation and DNA 
binding (Levenson and Jordan 1999).
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Figure 1.4; Simplified model of Oestrogen action.
1.2.3 From DNA to Chromatin; structural organisation
Two meters of DNA are tightly packed into the nucleus of a eukaryotic cell, so 
the DNA needs to be organised into an extremely compact and ordered 
structure. This is achieved by the binding of proteins such as histones that 
mediate successive orders of DNA folding, two copies of each histone H2A, 
H2B, H3 and H4 form a protein octamer core, arranged as a (H3-H4)2 tetramer 
and two H2A-H2B dimers, around which 146 base pairs of DNA is wrapped 
approximately 1.7 times to form the nucleosome (McKenna 1999). Each 
histone consists of two domains, the N-terminal domain and the central
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globular domain which play important structural and functional roles in the 
nucleosome (Brower-Toland et al 2005).
With the aid of additional proteins including histone 1, nucleosomes are 
compacted into a higher order of organisation giving rise to chromatin (Figure 
1.5). Two forms of chromatin exist; heterochromatin and euchromatin 
Although both forms present highly ordered and tightly bound structures, 
heterochromatin represents regions of the genome that cannot be transcribed, 
whilst transcribed genes are present in the more accessible euchromatin 
(Orphanides and Reinberg 2002).
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Figure 1.5: Model of DNA compaction within the cell nucleus; from the nucleosome to the 
chromosome (adapted from Mol biol web book). Illustrates the level of organisation required to 
efficiently package two meters of DNA into the nucleus of a cell.
Specific recognition sites to transcription factors exist within both forms of 
chromatin, however, in heterochromatin they are tightly packaged away and in
: Scaffold 
, Solenoid
Chromosome
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euchromatin these recognition sequences are positioned on the outside of 
nucleosomes so that they are exposed, providing docking sites for transcription 
factors such as activated ERa.
1.2.4 Classic ER/DNA interactions
The specific sequences of DNA recognised by ER are termed oestrogen 
response elements (EREs) and reside in the promoter regions of genes 
responsive to ER transcription. EREs however are not identical within each ER 
responsive gene. For example, while the Vitellogenin A2 ERE (figure 1.7) is a 
consensus palindrome (A2, AGGTCAnnnTGACCT, Klein-Hitpass et al, 
1988), the Vitellogenin B1 ERE is an imperfect palindrome, differing at the 
5’half site (Bl, AGTCAnnnTGACC, Nardulli et al 1996). Similarly, the pS2 
ERE is also an imperfect palindrome, this time differing at the 3’ half site (pS2, 
GGTCAnnnTGGCC, Nardulli et al 1996). The structure of the DBD allows ER 
to recognize and interact with these ERE sequences. The globular structure of 
the DBD can be subdivided into two modules (Figure 1.6). Each module 
consists of a Zinc coordination centre between four cystein residues. The first 
module contains a short segment of an antiparrallel p sheet and ends with an a- 
helical structure between the second pair of Zn coordinating cysteins. The p 
sheet helps to orientate the residues that contact the phosphate backbone of 
DNA. The helical structure (P-box cEGckA and down stream amino acids) 
provides important deoxynucleotide contacts and fits into the major groove of 
the DNA helix (Figure 1.7). The second module (D-box between P222 and 
Q226) is more important for phosphate contacts, but also has a role in
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dimerisation of ER (ERa: ERa/ERp ER(3 homodimers, ERaERp heterodimer) 
(Tsai and O’malley 1994). Minor changes in the amino acid sequence of the 
DBDs of ERa and p act to change the specificity of DNA binding. Indeed, if 
the ER P-box is mutated from cEGckA to cGSckV, then ER recognises and 
binds to a glucocorticoid response element (GRE) rather than an ERE (Tsai and 
O’malley 1994).
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Figure 1.6: Sequence specific recognition. Amino acids of the DBD P-box (Zinc finger IB) 
E=Glutamate, G=Glycine, A=Alanine, and D-box (Zinc finger 2A) P=Proline, A=Alanine, 
T=Threonine, N=Asparagine, Q=Glutamine, are important for the DNA recognition and 
dimerisation respectively (adapted from Tsai and O’Malley 1994)
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Figure 1.7: Diagram showing dimerisation of two ERs and DBD of each receptor slotting into 
the major grooves of DNA helix. The base sequences of the ERE are shown plus the 
palindrome sequence (adapted from Nussey and Whitehead 1999).
1.2.5 Co-activator recruitment to ER
Once the oestrogen-ER complex is firmly associated to the promoter region of 
the target gene it acts as an anchor protein for the recruitment of other proteins. 
These proteins are often termed co-activators since they aid the transcription of 
responsive genes by further protein recruitment or by modulating chromatin 
structure. The most well studied group of co-activators involved in ER 
transcription include the steroid receptor co-activator (SRC) family which 
contain activation domains (AD) that enable them to recruit further co­
activators. In addition to their recruiting capabilities however SRC1 and SRC3 
have shown enzymatic activity capable of altering the structure of chromatin 
(Klinge 2000). SRC proteins also contain nuclear receptor boxes (NR boxes) 
which consist of an LXXLL (where L is leucine and X is any amino acid) 
sequence shown to be important in the binding to the nuclear receptor (Shiau et
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al 1998). X-ray crystallographic analysis of ERa LBD co-crystallized with the 
NR box 2 peptide (area rich in LXXLL motifs) of SRC-2 (GRIP1) revealed 
that the LXXLL motif of the SRC family members interact with a 
complementary groove formed by amino acid residues from helices 3, 4, 5, and 
12 and the turn between helices 3 and 4, otherwise known as the AF-2 surface 
of ERa (Figure 1.9). This becomes highly exposed following agonist ligand 
induced rearrangement of helix 12 (Shiau et al 1998).
Ligand binding to the LBD induces a conformational change that releases 
steric hindrance on the N-terminal of the receptor to unmask phosphorylation 
sites in the B domain. This leads to AF-1 activation and in some genes 
synergism with AF-2 (Kraus 1995; Lannigan 2003; Metivier 2001; Metivier 
2002). Three conserved residues within the B domain, serine 104, 106 and 118, 
have been shown to be phosphorylated in response to oestrogen with residue 
118 being phosphorylated to the greatest degree (Lannigan 2002). Oestradiol 
induced rearrangement of helix 1 2  and exposure of the co-activator binding 
sites, leads to the binding of the general transcription factor TFHH through the 
nuclear receptor box (LXXLL) in its p62 subunit, l r i l r i  also contains a kinase 
subunit termed CDK7 and therefore interactions between ERa and TFllH lead 
to their co-localisation and phosphorylation of serine 118 (Chen et al 2002). 
Significantly, these phosphorylation events also lead to recruitment of 
additional nuclear receptor co-activators and Endoh et al 1999, for example, 
demonstrated that the co-activator p6 8  RNA helicase is recruited to ERa AF-1 
following phosphorylation of the receptor at serine 118. Studies by Metivier et 
al 2003 demonstrated that the recruitment of p6 8  rapidly occured following
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oestradiol activation of ERa. Furthermore, mutants of ERa where their serine 
residues at 104/106/118 were substituted for alanine residues showed reduced 
AF-1 activity in the presence of 17P-oestradiol due to an inability to recruit the 
co-activator steroid receptor RNA activator (SRA) (Coleman KM et al 2004).
The enzymatic co-activators recruited to active nuclear receptors can be 
divided into three major groups: the ATP dependent chromatin re-modellers; 
the histone acetyltransferases (HATs); and the histone Methyltransferases 
(HMTs) (Kraus and Wong 2002).
The ATP-dependent chromatin remodelling complexes, including the 
SWI/SNF family, are multipolypeptide enzymes that contain an ATPase 
subunit and use the energy stored in ATP to mobilize or structurally alter 
nucleosomes (Kraus and Wong 2002). BRG1, a catalytic subunit of 
mammalian SWI/SNF complex, is recruited to ERa due to an interaction 
between the ERa LBD/DBD and the SWI/SNF BAF57 subunit. Such 
interactions are oestrogen dependent and are required for transcriptional 
activation by the estrogen receptor (Belandia et al 2002).
The link between histone acetylation and increased transcriptional activation is 
well established, yet the exact mechanism of how histone acetylation leads to 
this increase in transcription is not completely understood. Recent studies have 
suggested however that the acetylation of the H2A/H2B and H3/H4 N-terminal 
tails interrupts the charge dependent histone/DNA interaction. The reduction in 
electrostatic bond strength is believed to facilitate chromatin remodelling 
making the nucleosomal DNA more accessible to the factors essential to 
transcription (Brower-Toland et al 2005) (Figure 1.8). A number of different
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HATs exist each having different histone targets. The most recognised of these 
HATs are the co-activators p300 and CBP (two closely related factors 
commonly referred to collectively as p300/CBP), as well as PCAF (p300/CBP- 
associated factor). SRC1 and SRC3 have also been shown to possess HAT 
activity (Klinge 2 0 0 0 ).
Histone methylation induces a variety of responses on transcriptional activity. 
H3-K9 dimethylation and H3-K27 trimethylation are associated with gene 
silencing, whilst methylation of H3-K4, H3-K36 and H3-K79 are associated 
with gene activation (Kinyamu and Archer 2004). In addition, the Coactivator- 
associated arginine methyltransferase (CARM1) has been reported to enhance 
steroid dependent transcription by interacting with SRC2 resulting in 
methylation of the arginines 26 and more predominantly 17 of H3 N-terminal 
tail, whilst protein arginine methyltransferase 5 (PRMT5) methylation of H2A 
and H4 results in transcriptional repression (Daujat et al 2002).
1.2.6 Genera] transcription factor (GTF) recruitment
ER/Co-activator induced re-structuring of chromatin leads to the exposure of 
the gene promoter TATA box; a DNA sequence which aids the recruitment of 
the Pre-Initiation complex (PIC) consisting of the TATA binding protein 
(TBP), general transcription factors (GTFs) TFTLA, TFHB, TFI1D, TFIIE, 
TFHF and TMIH and RNA polymerase II (RNA Pol II) (Figure 1.8). 
Recruitment of the PIC also occurs via protein-protein interactions between co­
activators and GTF or co-activators and RNA polymerase n, as well as direct 
interactions between ER and GTF or ER and RNA polymerase II (Metivier et
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al 2003). In addition to the earlier mentioned co-activators, a family of co­
activators has also been shown to be important in recruitment of the PIC called 
the TRAP (Thyroid hormone receptor-associated proteins)/ SMCC (SRB- 
MED-containing factor)/ DRIP (vitamin D receptor-interacting proteins) co­
regulator family (without HAT activity) which were first identified in thyroid 
receptor induced transcriptional events (Ito and Roeder 2001).
The order of formation of the PIC was proposed to occur in a stepwise 
assembly model, initially put forward by Buratowski et al 1988. The PIC 
formation is initiated by the binding of TFIID to the TATA element via the 
TATA-binding protein (TBP) subunit. For some promoters the binding of 
TFIID is stabilized by the further association of 1'FllA. This "DA" complex is 
recognized by TFHB which binds and promotes the recruitment of TFELF and 
RNA Pol II. The subsequent association of TFUJki and TFHH completes PIC 
assembly and initiates mRNA synthesis.
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Figure 1.8: Interaction between ER dimer, co-activators and PIC on a classical Oestrogen 
responsive gene promoter (Modified from Moras and Gronemeyer 1998).
1.2.7 Non-classical ER transcription
Although the classic form of ER directed transcription is well-accepted, the 
receptor is also known to interact with an array of additional transcription 
factors bound to their respective response elements to initiate other 
transcriptional events (Figure 1.9). This is termed non-classical ER 
transcription and in part explains how ER can activate genes deficient of EREs 
in their promoter region. For example, it is well established that ER can 
interact with Jun at 12-O-tetradecanoylphorbol 13-acetate (TPA) response 
elements (AP-1 sites, the cognate binding site for the Jun/Fos complex), which 
underlies the oestrogen dependent transcription of the collagenase and IGF-1
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genes, whilst ER interacts with Jun/ATF (activating transcription factor) at 
cAMP response elements (CRE sites, binding site of the phosphorylated form 
of CRE-binding (CREB) protein), resulting in oestrogen induced Cyclin D1 
transcription (Kushner et al 2000; Webb et al 1999). There are two ways ER 
can activate non-classical transcription, AF dependent and AF independent, 
which in turn depends upon the ER species (a or p) and the interacting ligand 
(figure 1.9).
ER Activation at AP-1 Sites: Two Pathways 
AF Mediated AF independent
ERa with E2 or tam ER0, ERcAAF-1, with SERMs
Figure 1.9: ERs use two separate pathways to AP-1. ERa with estrogen or with tamoxifen 
activate AP-1 through an AF mediated pathway. ER0 and AF-1 deleted ERa potently activate 
AP-1 through an AF independent pathway in the presence of the SERMs, raloxifene and ICI 
182,780 (adapted from Kushner PJ et al (2000)).
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Genetic dissections of ER have shown that the isolated LBD is a strong 
oestrogen-dependent activator of API target genes and this activation requires 
the integrity of AF2. In the context of the full length ERa, mutations in AF1 
also severely compromise oestrogen activation of API, which suggests that 
ERa-oestrogen complex stimulates AP-1 using both the AF-1 and AF-2 
surfaces. The Fos and Jun heterodimer associated with API binding sites 
recruit CBP/p300 and associated proteins, including the pl60 co-activators. 
Thus the co-activator complex of CBP and p i60 that is recruited by ER at an 
ERE is also recruited by Fos/Jun at an API site. The co-activator/transcription 
factor contact sites differ however, as Fos/Jun contact the CBP component and 
the p i60 co-activators associate to the pre-existing Fos/Jun/CBP complex. 
Regions of the p i60 co-activators essential for transcription factor recruitment, 
such as the NR boxes, remain accessible; therefore the oestradiol-ERa 
complex binds to the p i60 co-activators with a high affinity and in doing so 
triggers the API transcription complex into a higher state of activity. This is 
known as the ‘flip horizontal* model (Kushner et al, 2000). Studies by Teyssier 
et al 2001 however demonstrate that the non-classical ERa AF dependent 
recruitment to AP-1 sites is a result of a direct interaction between the C- 
terminal part of Jun and the amino acids 250-303 of ERa (DBD and hinge 
region), which leads to the recruitment of GRIP1. This ER/Jun interaction has 
been shown to occur in the presence or absence of oestradiol or 4-OH- 
tamoxifen, and is crucial for the stability of the ER/Jun/GRIPl complex.
AF independent non-classical ER transcription was first shown to occur at AP- 
1 sites in the presence of the pure anti-oestrogen Fulvestrant, which blocks AF-
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2 activity in ERa N-terminal domain-deleted mutants and ER0, both of which 
are deficient of AF-1 (Kushner et al 2000). In addition, 4-OH-tamoxifen was 
shown to induce the ERfl/ERa N-terminal deletion mutant AF independent 
transcription of API mediated genes but to a much lesser extent than 
Fulvestrant. Further studies have shown that AF independent non-classical ER 
transcription also occurred using full length ERa (Jakacka et al 2001; Wang et 
al 2004). AF independent activation, in the presence of the anti-oestrogens, was 
not a result of protein-protein interactions observed in the AF dependent non- 
classical ER transcription, nor was it dependent on sequestration of co- 
repressors away from the Fos/Jun complex towards the LBD of ERp or the 
truncated ERa (Kushner et al 2000). Wang et al (2004) demonstrated, 
however, that AF independent non-classical ER transcription depended on 
nuclear export. They showed that transcriptional potency of classically acting 
and tethered ERa was unaffected by inhibition by a nuclear export inhibitor 
leptomycin B, yet non-classical AF independent activation of ERa by 
Fulvestrant was completely inhibited by the drug. The study suggets that either 
a critical and unique stimulatory component to this mechanism required 
activation or modification in the cytoplasm, or an inhibitory component of the 
mechanism was exported from the nucleus (Wang et al 2004).
13 Non-nuclear actions of Oestrogen
ER ligands initiate a myriad of responses within minutes or even seconds of 
contact with multiple cell types. Given the rapidity of activation, modulation of 
gene transcription would seem unlikely and moreover inhibitors of protein or
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RNA synthesis do not block the effects. These extra-nuclear mechanisms are 
commonly referred to as non-nuclear or non-genomic (Nadal et al 2001). There 
is considerable controversy as to the nature of the non-nuclear effect of 
oestrogens as many studies suggest that they are mediated through membrane 
associated ERa, whilst others provide contradictory reports suggesting that 
these effects are brought about through a third subtype of ER distinct from 
ERa and ERP (Nadal et al 2001). There have even been reports of non- 
genomic oestrogen effects independent of ER, where oestrogen binds to 
neurotransmitter receptor ion channels such as the 5-hydroxytryptamine 3 (5- 
HT3) receptor and acts as an antagonist (Falkenstein et al 2000). This 
antagonism was not competitive as 17P-estradiol did not reduce the binding 
affinity of 5-HT to 5 -HT3 receptors (Falkenstein et al 2000). In addition, ER 
ligands such as 17p-estradiol, 4-OH-tamoxifen and Fulvestrant have been 
found to activate heptahelical G-protein-coupled receptors (GPCR), such as 
GPR30 via direct interactions (Filardo et al 2002; Thomas et al 2005).
The ER dependent non-nuclear actions of ER ligands have been implicated in 
many signalling pathways, including the second messengers Ca and 
endothelial nitric oxide synthase (eNOS), receptor tyrosine kinases [e.g. 
epidermal growth factor receptor and insulin-like growth factor (IGF) 1 
receptor (IGF-1R)], the heterotrimeric G-proteins (independent of GPCR) and 
protein kinases (e.g. PI 3-kinase, AKT, MAPK family members, the non­
receptor tyrosine kinase Src, and protein kinases A and C) (Liao 2003). There 
are debates, however, as to how the oestrogen receptor associates with the 
membrane since it has no hydrophobic stretches that could represent
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transmembrane domains. Some studies suggest that ERs may associate with the 
membrane through palmitoylation sequences that frequently anchor proteins to 
cell membranes (Acconcia et al 2005), but others suggest membrane 
association with ER is dependent on protein-protein interactions with 
membrane-associated proteins (Liao 2003).
ERa dependent release of NO involves a protein-protein interaction between 
ERa and the p85 subunit of PI-3-Kinase which induces the production of 
specific phosphatidyl inositides that promote the activation of the 
phosphoinositide-dependent protein kinases PDK1 and PDK2 (Simoncini et al 
2000; Hisamoto et al 2001; Liao 2003). These PDKs then phosphorylate 
AKT/PKB which in turn activates endothelial NO synthase (eNOS). The ER 
dependent release of NO was found to be biphasic due to increased signalling 
of the ERK1/2 pathway (Nuedling et al 1999). Song et al (2002) clearly 
demonstrated that this increased ERK1/2 signalling was dependent on a direct 
interaction between ERa and She on the IGF-IR, which in turn leads to She 
activation, recruitment of Grb/Sos and instigation of the Ras/Raf/MAP kinase 
signalling. In addition to the release of NO the interactions between ERa and 
the anchor proteins p85 and She induce a plethora of cellular responses 
including inhibition of apoptosis and promotion of proliferation (Zhang et al 
2004).
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1.4 Tamoxifen
1.4.1 Classical mode of action of Tamoxifen
In most countries throughout the world tamoxifen is currently the first line 
endocrine agent for the treatment of ER positive early breast cancer, whilst 
aromatase inhibitors such as Letrozole are now the front line therapy for ER 
positive late stage breast cancer. Like oestrogens, tamoxifen diffuses through 
the plasma membrane and nuclear envelope (Clarke et al 2001), where it 
interacts with ER to induce a conformational change in the receptor and 
promotes the dissociation of chaperone proteins (such as the heat shock 
proteins), dimerisation and classical/non-classical DNA binding (Nicholson et 
al 2002). The conformation of the AF2 domain in the presence of 4-OH- 
tamoxifen however, shows a higher affinity for proteins that induce 
transcriptional repression (co-repressors), rather than transcriptional elevation 
(co-activators). These corepressor proteins, such as NCoR (nuclear co- 
repressor protein) and SMRT (silencing mediator for retinoid and thyroid 
hormone receptors) mediate transcriptional repression by recruiting a complex 
of histone deacetylases (Cohen et al 2001).
Shiau et al (1998) have revealed the crystal structure of the 4-OH-tamoxifen 
occupied LBD/AF-2 domain versus the full oestrogen diethylstilboestrol (DES) 
occupied LBD/AF-2 domain to provide answers to the mechanism by which 
the AF2 now recruit co-repressors rather than co-activators (Figure 1.10). As a 
consequence of the 4-OH-tamoxifen induced conformational changes in ER, 
many inter-residue van der Waals contacts present in the DES complex are
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absent in the 4-OH-tamoxifen complex. This forces other residues throughout 
the binding pocket to adopt alternative conformations. The alternative 
conformations cause the helices 3, 8  and 11 of ER to shorten by one or two 
turns compared to those observed in the presence of oestradiol or DES. 
Additionally, the loop between helices 11 and 12 then becomes longer allowing 
for more flexibility in the positioning of helix 12.4-OH-tamoxifen binding also 
effects the position of helix 1 2  in a more direct manner, through restricting 
enclosure of the LBD by helix 12. This is a result of the positioning of the 
flexible dimethylaminoethyl region of the 4-OH-tamoxifen side chain which 
protrudes out of the LBD through helices 3 and 11. The interaction between the 
4-OH-tamoxifen side chain and the asparagine 351 of helix 12 is also key to 
the anti-oestrogenic properties of 4-OH-tamoxifen as it controls the 
repositioning of helix 12 (Levenson and Jordan 1999).
Helix 12 is needed to form the complete AF-2 binding surface along with 
additional amino acid residues from helices 3,4, 5 and the turn between helices 
3 and 4. The altered conformation of the LBD in the presence of 4-OH- 
tamoxifen however has surprisingly little effect on the non-helix 1 2  part of the 
binding surface (except for the shortening of helix 3). This region, named the 
static region, is almost identical to that seen in the DES-LBD, 4-OH- 
tamoxifen-LBD and E2-LBD complexes. In the presence of 4-OH-tamoxifen 
helix 12 possess reduced steric hindrance and is unable to enclose the 4-OH- 
tamoxifen bound LBD, mimicking the hydrophobic interactions of co-activator 
NR boxes. It is believed that Helix 12, with a stretch of residues (residues 540 
to 544) that resembles an NR box (LLEML instead of LXXLL), associate with
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the static region of the AF2 thereby concealing the recognition sites for co- 
activator binding (Shiau 1998).
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Figure 1.10: (A) Two views of the DES-ERa LBD-Nuclear receptor box II peptide complex as 
ribbon drawings. Helix 12 traps DES within the LDB. Conformation of helix 12 allows the 
GRIP1 (SRC2) peptide to bind to the AF2 domain. (B) Two views of the 4-OH-tamoxifen- 
E R o r LBD complex as a ribbon drawing. Side chain of Tamoxifen prevents closure of LBD by 
helix 12. (Shiau 1998)
As stated above the co-repressors SMRT and NCoR, rather than the co­
activators, associate to the 4-OH-tamoxifen-ER complex. This is additionally
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due to subtle differences in the nuclear receptor interacting domains (NRID) of 
co-repressors compared to co-activator NRJODs. Significantly, the co-repressors 
both contain a conserved bipartite NRID, each containing a critical L-X-X-X-I- 
X-X-X-I/L motif, which includes the IVI-X-X-I/V-I motif termed the co- 
repressor nuclear receptor (CoRNR) box. The CoRNR box is predicted to form 
an extended a-helix that is one helical turn longer than the co-activator motif. 
This is evidently enough to overcome the obstruction caused by the helix 12 
interaction with the AF2 static region (Jepsen and Rosenfeld 2002).
NCoR
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Interacting Domains 
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Figure 1.11: Interacting and repressing domains of the co-repressors SMRT and NCoR. 
Interacting domains associate with the ER whilst the repressing domains recruit histone 
deacetylases (Cohen et al 2001).
The independent repressor domains within NCoR and SMRT can actively 
recruit histone deacetylases (HDACs), which act as chromatin-remodelling 
factors. Currently three major classes of HDACs have been identified. Class I 
includes HDACs 1, 2, 3 and 8, Class II includes HDACs 4, 5, 6 and 7, and
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Class m  are the NAD+-dependent Sir2 family of proteins. Each HDAC is 
believed to reduce transcriptional activity of nuclear receptors by reducing 
histone acetylation and thereby the accessibility of DNA to the general 
transcription apparatus (Margueron et al 2004). As previously mentioned a 
group of HMTs, including the H3 lysine specific (H3-K9)-specific HMTs 
(Suv39Hl and G9a), also contribute to transcriptional repression.
1.4.2 Tamoxifen response and resistance
Clinical experience with tamoxifen now amounts to over 10 million patient 
years and subsequent meta-statistical analysis have provided conclusive 
evidence as to the effectiveness of tamoxifen (Clarke R et al 2001). As an 
adjuvant to surgery for early stage breast cancer patients, tamoxifen can 
prevent or delay breast cancer recurrence (Early Breast Cancer Trialists' 
Collaborative Group 2001). Post-operative therapy with tamoxifen reduces the 
risk of recurrence and prolongs survival in women with operable breast cancer 
in whom the tumours are confined to the breast or to the axillary lymph nodes 
(Robertson, Nicholson and Hayes 2002). Its benefit in terms of lowering the 
odds of recurrence and death is limited to women whose tumours express ER 
and/or progesterone receptor. This benefit increases with increasing receptor 
level and length of treatment. Benefit progressively increasing from 1 to 5 
years of use. Some studies have indicated however, that more than 5 years is 
not additionally beneficial, and may even be detrimental, while others have not 
confirmed this observation (Robertson, Nicholson and Hayes 2002). Data from 
the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG 2001) 
indicated that tamoxifen was associated with significant reduction in
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recurrence and death after a median follow up of about 10 years. The annual 
reductions in recurrence and death with tamoxifen as compared to placebo 
were 26% and 14%, respectively.
Women with advanced breast cancer have a variety of treatment options, 
including hormonal therapy, chemotherapy and newer biological agents. The 
goals of treatment are palliation of cancer related symptoms and prolongation 
of life. Currently available treatments probably do not cure advanced breast 
cancer, though some women will have sustained and long-lived disease control 
(Burstein HJ. 2003). Tamoxifen can be effective as palliation for women with 
advanced breast cancer. Once again, however, the benefits are primarily 
restricted to ER positive disease (Robertson, Nicholson and Hayes 2002). 
Overall, about 60% of patients with ER +ve tumours treated with tamoxifen 
have objective regression of their disease, lasting on average for 1 2  months. 
Furthermore, another 20% of patients have stabilisation of their disease for 
approximately 6  months (Robertson, Nicholson and Hayes 2002).
Although clearly showing the clinical value of tamoxifen, unfortunately these 
statistical data also highlight the inadequacies of the drug. This is particularly 
evident in advanced disease where ~40% of ER+ve patients derive no apparent 
clinical benefit from tamoxifen treatment, a figure rising to over 90% in ER -  
ve tumours. Such patients constitute women with de novo tamoxifen resistant 
disease (Robertson, Nicholson and Hayes 2002).
Significantly, as also illustrated above, even in initially responsive patients, 
tumour remissions are not long lasting in advanced breast cancer with patients
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eventually acquiring resistance to tamoxifen. The clinical problem of de novo 
and acquired resistance to tamoxifen, which is also evident in primary breast 
cancer patients, is not fully understood and has given rise to a huge effort by 
researchers to identify the precise mechanisms that confer this disease state.
Several possible mechanisms have been proposed that could influence the 
response to tamoxifen and, when altered, contribute to resistance. These 
include changes in host immunity, endocrinology and tamoxifen 
pharmacokinetics (Clarke R et al 2001). Competition with endogenous ligands 
for binding to tamoxifen’s primary intracellular targets (ER), and altered 
function of its targets (ER) may also contribute to tamoxifen resistance (Clarke 
et al 2001).
At the Tenovus Centre for Cancer Research our interests currently lay in the 
role that growth factors and their receptors play in mediating such anti­
oestrogen resistance (Gee et al 2003; Hutcheson et al 2003; Knowlden et al 
2003; Nicholson et al 2005). In clinical and experimental breast cancer it has 
been demonstrated that lack of response to endocrine therapy, together with 
increased metastasis and poor survival, can be associated with over expression 
of the epidermal growth factor receptor EGFR and c-erbB2 (Write et al 1992; 
Nicholson RI et al 1993; Nicholson RI et al 1994), as well as over expression 
of additional growth factor receptors including c-erbB3, c-erbB4 (Lupu R et al 
1996; Tang CK et al 1996) and IGF-IR (Guvakova et al 1997; Stephen et al
2001). In vitro models of acquired tamoxifen resistance have further 
demonstrated that raised levels of EGFR may contribute to increased 
proliferative activity (Knowlden et al 2003; Long et al 1992; El-Zarruk et al
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1999) and transfection of either EGFR or c-erbB2 into hormone-dependent 
breast tumour cells results in hormone-independent cell proliferation and 
tamoxifen resistance respectively (van Aguthen et al 1992; Benz et al 1993; 
Miller et al 1994; Kurokawa et al 2000).
1.4.3 Growth factor receptor signalling and tamoxifen resistance
Growth factor receptors, in particular the c-erbB family including c-erbBl 
(EGFR), c-erbB2, c-erbB3 and c-erbB4 are selectively activated in various 
homo- and hetero-dimer combinations by a large family of peptides known as 
growth factors which bind to the extra-cellular domain of the receptor leading 
to receptor dimerisation, kinase activation and phosphorylation of specific 
tyrosine residues in the carboxylic-terminal domains of the receptors (Miller
2002). It must be noted however, that c-erbB2 has no known complementary 
ligand and c-erbB3 has no C-terminal kinase domain. The mechanism of 
ligand-induced dimerisation of growth factor receptors, leading to receptor 
activation, ultimately involves juxtaposition of the cytoplasmic domains of the 
receptors, allowing the kinase domains to phosphorylate each other at specific 
tyrosine residues. It is not completely clear how such autophosphorylation is 
initiated, however, one possibility is that the monomeric receptor has a low 
enough basal kinase activity to phosphorylate and activate the companion 
receptor. This then being followed by reciprocal phosphorylation. 
Alternatively, the interaction between the intracellular domains of the receptors 
in the dimer may induce conformational changes leading to an increased kinase 
activity (Favoni and Cupis 2000).
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There are several tyrosine residues on the cytoplasmic domain of EGFR that 
become phosphorylated resulting in the activation of specific cell signalling 
pathways (Figure 1.12). Tyrosine 845 resides in the activation loop of the 
receptor kinase domain. Phosphorylation of tyrosine 845 may stabilize the 
activation loop, maintain the enzyme in an active state and provide a binding 
surface for substrate proteins. It has been shown that c-Src is involved in 
phosphorylation of the EGF receptor on tyrosine 845, which is associated with 
modulation of receptor function (Biscardi et al 1999). Phospho-tyrosine 992 of 
activated EGF receptor is a direct binding site for the phospholipase C-gamma 
(PLC-gamma) SH2 domain (Emlet et al 1997). This binding results in 
activation of PLC-gamma-mediated downstream signalling. Phosphorylation of 
Tyrl045 creates a major docking site for c-Cbl (Levkowitz et al 1999). Binding 
of c-Cbl to the activated EGF receptor leads to assembly of ubiquitination 
machinery to the receptor, enabling receptor ubiquitination and degradation 
(Ettenberg et al 1999). Phospho-tyrosine 1068 of activated EGF receptor is a 
direct binding site for the Grb2/SH2 domain (Rojas et al 1996). This binding 
results in Ras activation through a Grb2/Sos-l signalling mechanism (Zwick et 
al 1999). Phospho-tyrosine 1148 provides a docking site for SHC (Zwick et al 
1999). Both 1068 and 1148 are involved in activation of the MAP kinase 
signalling pathway.
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Figure 1.12: Epidermal growth factor (EGF) receptor is a 170 kDa tyrosine kinase. Ligand 
binding results in receptor dimerization, autophosphorylation and activation of downstream 
signaling pathways. Figure adapted from www.cellsignal.com
The ERK1/2 pathway is a key mediator of cell proliferation and increased 
activity of this signalling cascade has been associated with reduced quality and 
duration of response to tamoxifen and shortened disease free survival in ER- 
positive breast cancer patients (Mueller et al 2000; Gee et al 2001). 
Furthermore, constitutive activation of ERK1/2 has also been shown to 
contribute to anti-oestrogen resistance in MCF-7 breast cancer cell lines 
(Kurokawa et al 2000; El-Ashry et al 1997; Donovan et al 1997). In agreement 
with these findings the Tenovus group has demonstrated that an MCF-7 
tamoxifen resistant (TAM-R) cell line which acquired resistance following 
exposure of MCF-7 cells to lOOnM 4-OH-tamoxifen over a period of
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approximately two months showed increased EGFR/c-erbB2/ERKl/2 
signalling activity and enhanced sensitivity to the growth inhibitory actions of 
the EGFR tyrosine kinase inhibitor Gefitinib, the anti-c-erbB2 monoclonal 
antibody Herceptin and the MEK inhibitor, PD098059 (Knowlden et al 2003). 
In addition, similar increases in EGFR/c-erbB2/ERKl/2 expression and 
activity, as well as enhanced sensitivity to the growth inhibitory actions of the 
EGFR tyrosine kinase inhibitor Gefitinib, the anti-c-erbB2 monoclonal 
antibody Herceptin and the MEK inhibitor, PD098059, have also been 
observed in a Fulvestrant-resistant MCF-7 cell line (McClelland et al 2001).
1.4.4 ER and tamoxifen resistance
Significantly, despite TAM-R cell growth often showing a strong dependence 
on EGFR/c-erbB2/ERKl/2 signalling, it is clear that ERa also plays an 
essential role in the growth of such cells. In the study of Knowlden et al 
(2003), ERa was shown to be highly expressed in the TAM-R cells lines to 
levels equalling WT cell ERa expression, a finding mirrored in the clinical 
setting (Encamacion et al 1993; Brunner et al 1993; Lykkesfeldt et al 1994; 
Robertson et al 1996). Furthermore, several reports have demonstrated that 
inhibition of the ERa signalling pathway with the pure anti-oestrogens IC I164, 
384 or Fulvestrant (Faslodex), which act in part, by degrading and down 
regulating ER expression (Dauvois et al 1992; Howell et al 2000; Wakeling et 
al 2000), significantly inhibit TAM-R cell growth both in the clinic (Howell et 
al 1995; Howell et al 1996; Howell et al 2002) and in cell culture models 
(Coopman 1994; Hu et al 1993). Interestingly, evidence is building to suggest
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that the ER signalling pathway mediates its growth promoting effects in TAM- 
R cells through regulation of the EGFR signalling pathway (Hutcheson et al
2003). These findings were expected as the interplay with respect to ERa and 
growth factor signalling has been well documented both at the transcriptional 
regulation of the growth factors themselves (e.g. transforming growth factor- 
alpha (TGF-a) and IGF-II) (Bates et al. 1988; Lee et al. 1994) and their 
respective receptors (e.g., EGFR and IGF-IR) (Nicholson et al 2001). 
Hutcheson et al 2003, suggest that ER control over EGFR signalling in the 
TAM-R cell line may be a result of ER controlling transcription of the EGFR 
ligand TGFa.
Understanding the mechanism by which ERa retains its functionality in TAM- 
R cells, despite the continual presence of tamoxifen, and elucidating the 
mechanisms that TAM-R cells have adopted enabling ERa to regulate 
EGFR/ERK1/2 activity is of key importance to the current project.
1.5 Ligand independent activation of ER
Ligand independent activation of ERa in TAM-R cells may provide a 
mechanism by which ERa retains functionality. After all, this ligand 
independent activation has already been shown to enhance the activity of the 
tamoxifen-ER complex as a positive nuclear transcription factor, increasing its 
transcriptional and growth-promoting properties (Ali et al 1993; Kato et al 
1995). It is now evident that several growth factor-induced protein kinases 
(e.g., ERK1/2 and Akt), in addition to their direct stimulation of proliferation 
and survival signals, are able to target and phosphorylate the oestrogen
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regulated and other phosphorylation sites on the ER A/B domain, leading to 
AF-1 activation and ER transcriptional activity in a ligand independent manner 
(Bunone et al 1996; Kato et al 1995; Campbell et al 2001). In addition to the 
oestradiol effects on ERa phosphorylation at serine 118 there is overwhelming 
in vitro and in vivo evidence linking activation of the ERK1/2 pathway and 
phosphorylation of serine 118 in a ligand independent manner (Bunone 1996; 
Joel et al 1995; Kato et al 1995; Joel et al 1998; Lannigan 2002). Furthermore, 
ERK1/2 has also been implicated in phosphorylation of the ER(3 (mouse) at 
two residues within the A/B region, namely Ser-106 and Ser-124 (Tremblay 
GB 1999; Tremblay A 1999). Interestingly, in cases similar to the TAM-R 
cells, where breast cancer cell lines express elevated growth factor signalling 
pathways, ERa phosphorylation at serine 118 was elevated in a growth 
factor/ERKl/2 dependent manner, suggesting that this event may play a role in 
the maintenance of ER functionality in TAM-R cells and other elevated growth 
factor signalling pathway conditions, such as oestrogen deprivation (Martin et 
al 2003; Shou et al 2004).
Although not located on the AF-1 domain, an additional conserved 
phosphorylation site involved in activation of the ERa AF1 domain is located 
at serine 167. Original studies showed that serine 167 phosphorylation was 
oestradiol dependent, however later studies have shown that this event is in fact 
ligand independent (Arnold 1995; Le Goff 1994). Several kinase pathways 
have been implicated in ligand independent phosphorylation of serine 167, 
including PI3K/AKT (Martin 2000; Campbell 2001; Sun 2001), 
ERKl/2/Rsk90 (Arnold 1995, Joel 1998, Frodin and Gammeltoft 1999) and
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casein kinase II (Arnold 1995). Although ERK1/2 and Rsk90 belong to the 
same signalling pathway, the significance of their co-phosphorylation of ERa 
at serine 167 is not fully understood (Lannigan 2002). Phosphorylation of 
serine 104 and 106 however is believed to be mediated by cyclin A-CDK2 
kinase in an AF2 independent mechanism because the phosphorylation event 
has been shown to occur in the presence and absence of ligand (Rogatsky 
1999). Further phosphorylation sites exist within ER including serine 236, 305 
and tyrosine 537. These sites, however appear to play roles other than 
activation of AF-1 (Chen et al 1999; Lannigan et al 2003; Michalides 2004).
1.6 Ligand independent recruitment of transcriptional co-activators
ER transcriptional functionality requires the recruitment of co-activators 
however tamoxifen is known to block such recruitment to the AF-2 domain 
(Levenson and Jordan 1999). Endoh et al (1999), however, suggested that co­
activator recruitment can also occur in a ligand independent manner. They 
showed that p68 RNA helicase interacted with the A/B domain, but not with 
the LBD of ERa. In addition, p68 enhanced the activity of AF-1, but not AF-2, 
and enhanced the oestrogen and tamoxifen induced transcriptional activity of 
the full-length ERa in a cell-type-specific manner. The study confirmed that 
ERK1/2 dependent phosphorylation of ERa at serine 118 enhanced the 
interaction between ERa and p68 RNA helicase consequently enhancing ERa 
AF-1 activity. Significandy, the RNA helicase activity previously ascribed to 
p68 was shown to be dispensable for the ERa AF-1 co-activator activity but the
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interaction region for p68 in the ERa A/B domain was essential for the full 
activity of ERa AF-1. Taken together, their findings show that p68 acts as a co­
activator specific for the ERa AF-1 and strongly suggest that this interaction 
was regulated by ERKl/2-induced phosphorylation of Serine 118. Such ligand 
independent recruitment of co-activators to ERa AF-1 provides a mechanism 
which potentially maintains ERa functionality despite tamoxifen induced 
inhibition of AF-2.
The p68 RNA helicase belongs to a subfamily of RNA-binding DEAD-box 
proteins (named according to their conserved amino acid sequence motifs), 
which also contain the p72 RNA helicase. p72, like p68 RNA helicase, 
associates to the AF-1 region of ERa, but not ER0. p72/p68 were also shown 
to interact directly with the activation domain 2 (AD2) of SRC family members 
(Watanabe et al 2001) allowing the AF-1 domain to indirecdy recruit the SRC 
family of proteins. Interestingly, HeLa cells transfected with the full-length 
ERa were found to interact physically and functionally with the SRC family 
members and CBP in the absence of ligand and that mutation of Serine 104, 
106 and 118 affects these interactions. Accordingly, ERa dephosphorylation 
decreases its ligand-independent interaction with SRC-1 and CBP in vitro 
(Dutertre and Smith 2003). Such interactions were also evident between ER0 
and SRC-1 which was dependent on ERK2 phosphorylation of ERp at serine 
106 and 124 (Tremblay A 1999).
The co-activator Steroid Receptor RNA activator (SRA) has also been shown 
to interact with the ERa A/B domain in a ligand independent manner following
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ERK1/2 dependent phosphorylation of serine 118 (Deblois 2003), however a 
later investigation by Coleman et al 2004 has suggested that this interaction 
between ERa A/B domain and SRA is not phosphorylation dependent and that 
the co-activator can also interact with ERa and ER(3 AF2 domains.
1.7 Post-translational modification of co-activators
Although the phosphorylation of the ER A/B domain has long been regarded as 
a prerequisite to AF1 dependent activation, more recent studies suggest that 
phosphorylation of co-activators can also influence transcription levels.
Phosphorylation of SRC1 has been shown to occur at several residues which 
were found to cluster into two groups as illustrated in the figure 1.13. All of the 
identified phosphorylation sites have been shown to contain consensus 
sequences for the serine/threonine-proline-directed family of protein kinases. 
Two sites (serine 395 and threonine 1179) contain a perfect consensus 
sequence for ERK1/2, however in vitro studies by Rowan et al 2000 
demonstrated that ERK-2 phosphorylated threonine 1179, serine 1185 (an 
adjacent site containing an imperfect ERK-1/2 motif) and to a lesser extent 
serine 395. Serine 372 was found to be contained within a consensus sequence 
for casein kinase n, although this site was not phosphorylated in vitro by this 
enzyme (Rowan 2000).
43
m m1
AD AD
W W ~  CBP NR
HAT
M M .
Figure 1.13: Model of SRC1. Illustrates phosphorylation residues (P), Activation domains 
(AD), nuclear receptor boxes (NR), CBP interacting region (CBP), P/CAF interacting region 
(P/CAF) and the region containing Histone Acetyl-transferase activity (HAT) (Adapted from 
Rowan et al 2000).
The positioning of the phosphorylation clusters in SRC1 has provided clues to 
their functional significance. The first group of sites involving serine 372, 
serine 395, serine 517 and serine 569. Serine 569 was found to be located 
within 64 amino acids of the first LXXLL motif of SRC-1, suggesting that these 
phosphorylation events influence the interaction between SRC-1 and target 
transcription factors (Rowan BG 2000). The second group of phosphorylation 
sites in the C-terminal, involving serine 1033, threonine 1179 and serine 1185, 
are adjacent to a major nuclear receptor interaction domain and also lie within 
the region of SRC-1 that interacts with the histone acetyltransferase, P/CAF. 
This suggests that as well as influencing the ability of SRC1 to interact with 
nuclear receptors these phosphorylation events may affect the ability of SRC-1 
to recruit enzymatic co-activators (Rowan 2000). Threonine 1179 and serine 
1185 also lie within the region of SRC-1 that was shown to possess HAT
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activity and suggests a role for these phosphorylation events in the modulation 
of SRC-1 HAT activity (Rowan et al 2000).
Such phosphorylation events, in addition to direct phosphorylation of the 
receptor, may enhance transcriptional activity of ERa even in the presence of 
tamoxifen. After all, MCF-7 cell lines exposed to 4-OH-tamoxifen have been 
shown by Shou et al (2004) to recruit phosphorylated SRC3 and ERa (serine 
118) to the pS2 gene promoter when over-expressing both c-erbB2 and SRC3. 
Interestingly ERa/SRC3 phosphorylation and their recruitment to the pS2 gene 
promoter were inhibited in the presence of the EGFR inhibitor gefitinib, 
suggesting that growth factor receptor control over both ERa and SRC3 
phosphorylation dictates recruitment to gene promoters and therefore 
transcriptional activity in the presence of 4-OH-tamoxifen.
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Aims of the study
There is now considerable evidence to indicate that increased expression and 
activity of the EGFR/ERK1/2 signalling pathway mediates tamoxifen-resistant 
growth (Knowlden et al 2003; Long et al 1992; El-Zarruk et al 1999; Mueller 
et al 2000; Gee et al 2003). It has also become evident that ERa expression and 
functionality is retained and mediates tamoxifen-resistant breast cancer growth 
(Robertson, 1996, Brunner et al., 1993, Lykkesfeldt et al., 1994, Encamacion et 
al., 1993, Hu et al., 1993, Coopman et al., 1994, Howell et al 1995; Howell et 
al 1996; Howell et al 2002, Hutcheson et al., 2003). Interestingly, evidence 
suggests that the ER growth regulation of TAM-R cells occurs due to ER 
regulation of EGFR signalling pathway, perhaps through transcriptional 
regulation of EGFR ligands (Hutcheson et al 2003). The EGFR/C- 
erbB2/ERKl/2 signalling pathway, in addition to directly driving cell growth, 
can target and phosphorylate key serine residues within the AF-1 domain of 
ERa (Ali et al 1993; Bunone et al 1996; Kato et al 1995; Campbell et al 2001). 
Phosphorylation of these residues, in particular serine 118 promotes co- 
activator recruitment and activation of ERa transcriptional activity (Ali et al 
1993; Endoh et al 1999; Kato et al 1995).
The aim of this thesis was, therefore, to examine growth factor-mediated 
phosphorylation of ERa, in tamoxifen-sensitive (WT) and -resistant (TAM-R) 
MCF-7 breast cancer cell lines, to elucidate whether such ligand-independent 
activation of ERa plays a role in the maintenance of ERa functionality in 
tamoxifen resistance and whether this in turn regulates EGFR signalling 
activity in these cells. This involved:
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• Development of reproducible western blotting and ICC assays in the 
WT and TAM-R MCF-7 cells to evaluate ERa phosphorylation at 
serine 118.
• Pharmacological manipulation of EGFR and IGF-1R signalling 
pathways in the two cell lines to determine their role in mediating 
serine 118 phosphorylation of ERa.
• Determination as to whether such phosphorylation events contribute to 
maintaining ERa functionality in TAM-R cells by utilising 
immunoprecipitation/westem blotting (to examine associations of ERa 
with transcriptional co-regulators), luciferase reporter gene assays, 
chromatin immunoprecipitation (ChIP) and PCR of possible ERa- 
dependent genes.
• Determine how EGFR signalling activity is modulated by ERa 
functionality in TAM-R cells and whether ERa phosphorylation at 
serine 118 is a contributory factor.
• Development of western blotting assays to measure additional 
phosphorylation sites on ERa, such as serine 167 and if possible further 
assessment as to their contribution to ERa functionality.
• Use of proteomic techniques such as 2D electrophoresis and 
MALDI/TOF mass spectrometry of immunoprecipitated ERa to 
identify additional phosphorylation events and interactions with novel 
co-regulators.
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Hopefully, identification of the mechanisms responsible for the maintenance of 
ERa functionality in tamoxifen-resistant breast cancer cells may provide 
additional therapeutic targets that can be used to combat therapeutic resistance.
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2.0 MATERIALS and METHODS
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2.1 Materials
2.1.1 Equipment
The equipment used in this study is listed below and obtained from the 
following sources: BB16 function line cell incubator (Heraeus Instruments, 
Germany); Nikon eclipse TE200 phase contrast microscope (Nikon, UK); 
MDH intermed airflow vertical circulating air class II biological safety cabinet 
(Bioquell, UK); Beckman Coulter® Counter Multisizer II (Beckman, UK); Finn 
pipettes (1-lOpL, 5-50pL, 20-200pL, 100-1000}!L and 500pL-5mL, Thermo 
Labsystems, Finland); IEC micromax RF micro-centrifuge (Thermo Electron 
Corporation, UK); CECIL CE 2041 spectrophotometer (Cecil, UK); sample 
rotator (Thermo life sciences, UK); Mini-protean® 3 electrophoresis kit and 
powerpac 300 (BioRad laboratories Ltd, UK); Stuart scientific STR6 platform 
rocker (Bibby Sterilin Ltd, UK); Olympus BH-2 phase contrast microscope and 
Olympus DP-12 digital camera (Olympus, UK); E & G Wallac lumat LB 9507 
luminometer (Jensons-PLS, UK); Labconco purifier PCR enclosure, MJ 
research PTC-100 thermocycler, trans-illuminator and polaroid camera (GRI, 
UK); 950 Watt microwave (Curries, UK); MSE soniprep 150 sonicator (Sanyo, 
UK); IPG phor isoelectric focusing unit with 18cm IPG strip holders, 
Immobiline IPG drystrips-18cm, Multiphor II electrophoresis unit (Flatbed 
system), EPS 350 X L power supply, Multitemp HI thermostatic circulator 
(Amersham Pharmacia Biotech, UK).
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2.1.2 Disposables and plastic ware
The disposables and plastic ware used in this study are listed below and 
obtained from the following sources: Sterile disposable pipettes (5mL, lOmL 
and 25 mL), 50mL falcon tubes, lids and cups for coulter counter (Sarstedt AG 
and Co, Germany); 5mL and lOmL syringes (Sherwood Medical Davis and 
Geek, UK); sterile needles (BD microbalance™, Becton Dickinson Ltd, UK); 
Nunc tissue culture plastic ware (12 well plates, universals, plates, flasks and 
dishes) (Fisher Scientific, UK); 5ml bijou tubes (Bibby Sterilin Ltd, UK); 
micro-disposable cuvettes and cell scrapers (Fisher scientific, UK); eppendorf 
tubes (Elkay, Ireland); polypropylene micro-capillary round tips (Sigma 
chemical co Ltd, UK); nitrocellulose membrane® BA 85 (0.2pMeter) 
(Schleicher and Schuell, Germany); filter paper grade 3 (460 X 370 mm) 
(Whatman; UK); luminometer tubes (Becton Dickinson, UK).
2.1.3 Media and supplements
Phenol-red RPMI, phenol-red free RPMI, foetal calf serum, PBS, trypsin, 
antibiotics (streptomycin/penicillin), Fungizone and L-glutamine were 
purchased from Invitrogen, UK.
2.1.4 Treatments
Oestrogen receptor and growth factor signalling pathway agonists and 
antagonists used in this study are listed below and obtained from the following 
sources: 4-hydroxytamoxifen (Sigma Chemical Co Ltd, UK); amphiregulin 
neutralising antibody (R & D systems, USA); EGFR tyrosine kinase inhibitor,
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Gefitinib (Iressa, ZD1839) (gift from AstraZeneca Pharmaceuticals, UK); 
MEK1/2 kinase inhibitor, PD184352 (gift from Pfizer, USA); IGF-IR tyrosine 
kinase inhibitor AG1024 (CalBiochem, EMD Biosciences, USA); IGF-IR 
tyrosine kinase inhibitor ADW742 (Novartis pharmaceuticals Ltd, UK); PI3K 
inhibitor LY294002 and growth factors including epidermal growth factor 
(EGF), transforming growth factor a (TGFa), amphiregulin (Amph) and 
insulin like growth factor II (IGHI) (Sigma chemical Co Ltd, UK).
2.1.5 Chemicals and reagents
The chemicals and reagents used in this study are listed below and obtained 
from the following sources: 5 -bromo-4-chloro-3-indoly 1-p-D-
galactopyranoside (X-gal), acrylamide/bisacrylamide 30% v/v solution, 
ammonium persulphate (APS), aprotinin, bacitracin, bovine serum albumin 
(BSA), dimethyl sulphoxide (DMSO), dithiothrietol (DTT), 
ethylenediaminetetraacetic acid (EDTA), ethidium bromide, gelatine, 
glutaraldehyde, glycerol, glycine, HEPES, potassium chloride, leupeptin, 
magnesium chloride anhydrous, methyl green, mineral oil, N,N,N',N'- 
Tetramethylethylenediamine (TEMED), phenyl methyl sulfonyl 
fluoride (PMSF), pepstatin-A, phenylarsine oxide, potassium ferricyanide, 
potassium ferrocyanide, silver nitrate, sodium carbonate, sodium chloride, 
sodium dodecyl sulphate or lauryl sulphate (SDS), sodium fluoride, sodium 
molybdate, sodium orthovanadate, sodium thiosulphate, TRI reagent (lysis 
reagent), triton X-100, trizma base, trizma-HCL, tween 20 (Sigma chemical Co 
Ltd, UK); BioRad Dc protein assay kit 2, upper buffer pH6.8/lower buffer pH
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8.8 (BioRad laboratories Ltd, UK); bromophenol blue (BDH chemicals Ltd, 
Poole, UK); rainbow marker 10-250 KDa, dNTPs and random hexamers, 
CHAPS, iodoacetamide, urea and Phast Gel™ Blue R-350 coomassie blue 
tablets (Amersham, UK); western blocking reagent (Roche diagnostics, 
Germany), Chemiluminescent supersignal® west Pico, Dura and Femto 
(Pierce, USA); X-O-fix-fixer and X-O-dev-developer (X-0-graph Imaging 
System, UK); acetic acid, acetone, chloroform, dipotassium hydrogen 
orthophosphate anhydrous, ethanol, formaldehyde, isopropanol, methanol, 
hydrochloric acid, potassium dihydrogen orthophosphate and sucrose (Fisher 
Scientific, UK); DPX mountant (Raymond A Lamb Ltd, UK); concentrated 
immunostaining buffered wash solution (Euro/DPC Ltd, UK), however 
production of this product ceased resulting in production of in-house PBS- 
tween (0.02%) as a substitute; liquid DAB+ substrate chromogen system 
(K3468) and mouse/rabbit Envision system HRP DAB+ kits (DAKO, UK); 
lipofectin and MMLV reverse transcriptase (Invitrogen Life Technologies, 
UK); luciferase reagent kit for single luciferase assay (E4030), dual-luciferase 
reporter assay kit (E1910) and recombinant RNasin ribonuclease inhibitor 
(RNase inhibitor) (Promega, UK); Agarose and BioTaq™ DNA polymerase 
(Bioline, UK).
2.1.6 Antibodies
The antibodies used in this study are listed below and obtained from the 
following sources: Monoclonal phospho-ERa serine 118 (#2511), polyclonal 
phospho-ERa serine 118 (#2515), phospho-ERKl/2 (#9101), total ERK1/2
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(#9102), phospho-EGFR tyrosine 1068 (#2234), phospho-AKT serine 473 
(#9271) antibodies (Cell Signalling Technology, New England Biolabs (NEB), 
UK); SRC1 (M341), SRC2 (M343), SRC3 (H270), RNA polymerase H (H- 
224), CBP (C-l) , NCoR (N-19), SMRT (N-20) antibodies (Santa Cruz 
Biotechnology Inc, USA); polyclonal phospho-ERa serine 167 (ab5701) 
antibody (AbCam Ltd, UK); total ERa 1D5 antibody (DAKO corporation, 
UK); total EGFR antibody (# 03-G, Upstate Biotechnology, UK); phospho- 
Y1158-IGF-IR antibody (Biosource, Belgium); total IGF-IR antibody (Insight 
biotechnology, UK); p68 RNA Helicase antibody (gift from Kari L Rossow 
and Ralf Janknecht, Department of Biochemistry and Molecular Biology, 
Mayo Clinic MN 55905, USA); phospho-serine Q5 antibody (Qiagen, UK); 
monoclonal p-actin (A1978) antibody (Sigma, UK); secondary IgG horseradish 
peroxidase labelled, donkey anti rabbit or sheep anti mouse (Amersham 
Biosciences Ltd, UK); total ERa (HC-20) antibody (Santa Cruz; USA); TFTIB 
and the pre-immune IgG antibodies (Active Motif; UK).
2.1.7 Plasmids
All reporter gene constructs used in this study were part of the “Mercury 
profiling system” purchased from Clontech (Becton and Dickinson 
Biosciences, Oxford, UK), with the exception of the ERE-thymidine kinase 
(tk)-Luc reporter plasmid DNA which was a kind gift to our group from Prof. 
Malcolm Parker, Imperial Cancer Research Fund (London, UK).
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2.1.8 Primers
Primers used were designed manually using OLIGO (MedProbe AS, Oslo, 
Norway) primer pair design software. Primers were designed where possible to 
span intron/exon borders and specificity was checked using the European 
Molecular Biology Laboratory (EMBL)-GenBank database software using the 
BLAST program. The following primers were used together with the following 
assay conditions: P-actin forward 5'-GGA GCA ATG ATC TTG ATC TT and 
reverse 5’-CCT TCC TGG GCA TGG AGT CCT (204 bp) (24 cycles, 
annealing at 55°C for 1 minute ); amphiregulin forward 5’-TCC TCG GGA 
GCC GAC TAT GAC and reverse 5’-GGA CTT TTC CCC ACA CCG (350 
bp) (24 cycles, annealing at 55°C for 1 minute); P-cellulin (BTC) forward 5’- 
ACT GCA TCA AAG GGA GAT GC and reverse 5’-CCT GAG ACA CAT 
TCT GTC CA (395 bp) (33 cycles, annealing at 59°C for 30 seconds); EGF 
forward 5-GAG TCT GAC TCA GTC CAG AA and reverse 5-TCT ACT TGG 
AGC AAC AGT GG (478 bp) (33 cycles, annealing at 55°C for 1 minute); 
epiregulin forward 5-TCC ATC TTC TAC AGG CAG TCC and reverse 5- 
AGA ATC ACG GTC AAA GCC AC (304 bp) (30 cycles, annealing at 59°C 
for 30 seconds); HB-EGF forward 5-CGG ACC CTC CCA CTG TAT C and 
reverse 5-TGA CAG CAC CAC AGC CAC (300 bp) (30 cycles, annealing at 
59°C for 30 seconds); TGF alpha forward 5-CCA CAC TCA GTT CTG CTT 
CC and reverse 5-TCT TTA TTG ATC TGC CAC AGT C (379 bp) (33 cycles, 
annealing at 55°C for 1 minute); GAPDH forward 5’-TAC TAG CGG TTT 
TAC GGG CCG and reverse 5’-TCG AAC AGG AGG AGC AGA GAG 
CGA, ChIP kit negative forward 5’-ATG GTT GCC ACT GGG GAT CT and
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reverse 5’-TGC CAA AGC CTA GGG GAA GA (30 cycles, annealing at 55°C 
for 1 minute).
22 Methods
2.2.1 Basic cell culture conditions
Wild type (WT) MCF-7 cells, a gift from AstraZeneca Pharmaceuticals, UK, 
and WT T47D cells, purchased from the American tissue culture collection, 
were routinely maintained in phenol red-containing RPMI medium 
supplemented with 5% (v/v) foetal calf serum (FCS), penicillin-streptomycin 
(10 IU/ml-10 pg/ml), fungizone (2.5 jig/ml) and glutamine (4 mM). Cells were 
grown in 75cm2 flasks and incubated at 37°C in a humidified 5% CO2 
atmosphere. Cultured medium was renewed every 3-4 days and cell passaging 
was carried out at 70-80%confluency. To avoid unwanted oestrogenic effects 
during experiments the WT MCF-7 and T47D cells were transferred to phenol 
red-free RPMI medium supplemented with 5% charcoal-stripped steroid- 
depleted FCS (sFCS), penicillin-streptomycin, fungizone and glutamine. This 
medium will be referred to as W+5% throughout the thesis.
The tamoxifen resistant (TAM-R) MCF-7 and T47D cell lines were established 
within Tenovus tissue culture unit by continually exposing the WT cells to 4- 
hydroxytamoxifen (lOOnM) for three months and a further six months once 
cells established a stable tamoxifen resistant phenotype. MCF-7 and T47D
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TAM-R cells were then routinely maintained in W+5% supplemented with 4- 
hydroxytamoxifen (lOOnM).
The MCF-7 cell line doubly resistant to both tamoxifen and gefitinib 
(TAM/GEF-R) was established in the Tenovus tissue culture unit by exposing 
TAM-R MCF-7 cells to gefitinib (lpM) for a total of six months. TAM/GEF-R 
cells were routinely maintained in TAM-R medium supplemented with 
gefitinib (lpM).
The Fulvestrant resistant (FUL-R) and fulvestrant and gefitinib resistant 
(FUL/GEF-R) MCF-7 cell lines were established in much the same way as the 
TAM-R and TAM/GEF MCF-7 cells, however, fulvestrant (lOOnM), rather 
than 4-hydroxytamoxifen, was included in the culture medium.
The MCF-7 X cells, resistant to severely oestrogen and growth factor deprived 
conditions, were established in the Tenovus tissue culture unit by incubating 
WT MCF-7 cells in a severely oestrogen and growth factor deprived medium 
for six months, after which a stable phenotype developed. The medium 
consisted of phenol red-free RPMI supplemented with 5% stripped serum 
which was heat inactivated at 65°C for 35 minutes (XsFCS medium). MCF-7 X 
cells were then routinely maintained in phenol red-free RPMI + 5% XsFCS.
Routine cell culture for all cell lines involved, at 70-80% confluency, cells 
being detached from the flasks by incubation with trypsin-EDTA (trypsin 0.5%
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v/v) for 2 minutes at 37°C. Cells were then transferred to a sterile universal 
container and pelleted at 1000 rpm for 5 minutes. Cell pellets were re­
suspended in the appropriate cell growth media and seeded into fresh tissue 
culture flasks at a split ratio of 1:10.
2 2 2  Growth Studies
Cell population growth was evaluated by means of trypsin dispersion of the 
cell monolayers (performed in triplicate) following a 7 day incubation with 
either, gefitinib (1 pM), PD184352 (10 pM), AG1024 (20pM), LY2904 
(10|iM) fulvestrant (100 nM) or oestradiol (InM). Controls were incubated for 
the same period of time with the appropriate vehicle. Cells were then measured 
using a coulter counter (Luton, UK). All proliferation studies were performed 
at least 3 times.
2.2.3 SDS-PAGE and Western blotting
22.3.1 Experimental cell culture
Each cell line was removed by trypsination and re-seeded at 5X105 cells per 
60mm dish in their respective medium. Cells were grown to 70% confluency 
(usually after four days) then the medium was aspirated and replaced by 
DCCM for 24hours. Medium was again aspirated and replaced by DCCM 
medium containing treatments at the stated doses and time periods: 
Amphiregulin neutralising antibody at 5, 10 and 20pg/mL for lhour; gefitinib 
at 1, and lOpM for lOminutes; PD184352 at 1 and lOpM for lhour; EGF at
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lOng/mL for 10 minutes; amphiregulin at lOng/mL for lOminutes; ADW742 at 
lOpM for 24 hours; AG1024 at 20pM for 24 hours; LY294002 at lOpM for 1 
hour; and IGFII at 30ng/mL for 10 minutes. Combination treatments involved: 
gefitinib (ljiM) for 10 minutes followed by gefitinib (lpM) in combination 
with EGF (lOng/ml) for 10 mins; PD184352 (lOpM) for lhour followed by 
PD184352 (lOpM) in combination with EGF (lOn/ml) for lOminutes. All 
treatment groups were run along side a control arm consisting of experimental 
medium only. All studies involving TAM-R cells were performed with 4-OH- 
tamoxifen (lOOnM) present in the growth medium, including the TAM-R 
control arms.
2.2.3.2 Cell lysis
After the stated treatments, cells were washed three times with PBS (37°C) and 
excess PBS was aspirated off. 250pL ice cold lysis buffer (50mM Tris-HCL, 
5mM EDTA, 150mM NaCl, 1% Triton X-100 (v/v) in distilled water, pH7.5) 
supplemented with protease and phosphatase inhibitors (2mM Na3Vo4, 20mM 
NaF, ImM PMSF, 10 fig/mL leupeptin, 20jiM phenylarsine oxide, lOpg/mL 
aprotinin and lOmM sodium molybdate) was then added to the 60mm dishes. 
The dishes were then scraped using a cell scraper. Lysate was incubated on ice 
for 10 minutes then the cellular contents were transferred to eppendorf tubes, 
centrifuged at 13,000 RPM (15 minutes at 4°C), then aliquotted and stored at - 
20°C until required.
Earlier assay development experiments also utilised the freeze thaw lysis 
technique; after the stated treatments cells were washed three times with PBS
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(37°C) and excess PBS was aspirated off. 3mL of warm PBS was added to 
150mm dishes and cells scraped off the surface of the plate using a cell scraper. 
The cell/PBS mix were then collected from the dish using a pipette and 
transferred to a universal which was placed on ice whilst harvesting other 
samples. The universals were then centrifuged at 3000RPM for 5 minutes (4°C) 
and placed in dry ice until being stored in a -70°C freezer. The following day, 
samples were removed from the freezer and 200pL of freeze thaw lysis buffer 
(0.477g KCL, 2.984g HEPES in 50mL distilled water (pH to 7.4), plus 20 mL 
glycerol) was added to each sample on ice. Volume of stock was then increased 
to lOOmL with additional distilled water. To every 20mL of stock buffer were 
added, lmM DTT, 5pg/mL Leupeptin, 5pg/mL pepstatin A, lpg/mL 
Apoprotein 5pg/mL bacitracin and lmM PMSF. Lysed cells were then placed 
in an eppendorf after drawing cell mixture through syringe and needle 3 times. 
Eppendorfs were spun down at 13000 RPM for 20 minutes (4°C), the 
supernatants were removed, and the protein concentrations measured, prior to 
storage at -70°C.
2.23.3 Protein concentration assay
Total protein concentrations were determined using the DC BioRad protein 
assay kit (Bio-Rad, UK). Absorbances were analysed at 750nm on a CECIL 
CE 2041 spectrophotometer.
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2.2.3.4 Sample preparation fo r western blot
50jig of protein from each sample under investigation were mixed with 2X 
loading buffer (4mL 10% (w/v) SDS, 2mL of glycerol, 2.4mL of upper buffer 
pH6.8, 1.6mL of distilled water and lmg of bromophenol blue, plus DTT at
15.5 mg per lmL of loading buffer.
2.23.5 Sample preparation for Immunoprecipitation (IP)
Cell lysate calculated to contain lmg protein were immunoprecipitated using 
lpg of a specific antibody and incubated for lhr gently rotating in a cold room. 
Twenty microlitres of protein A/G agarose, was added to the mixture and 
rotated gently in a cold room over night. The immune complex was centrifuged 
at 3500 RPM at 4°C for 5 minutes, the supernatant was removed and the 
complex was washed with PBS (r/t). This procedure was repeated three more 
times and the resultant pellet following the last centrifugation was re-suspended 
in 3X loading buffer (including DTT, 22mg/mL). Samples were heated to 
100°C for 10 minutes to release and denature the bound proteins before gel 
loading.
2.2.3.6 SDS-page and western blotting
Protein samples from total cell lysates and following immunoprecipitation were 
subjected to electrophoresis separation on a 7.5% polyacrylamide gel then 
fra/w-blotted onto a nitrocellulose membrane. Afterwards, blots were blocked 
in a 2:20 solution of western blocking reagent and TBS-tween (lOmM of 
trizma base, 0.1M of NaCl, 0.05% v/v Tween 20 and 0.8pM HCL in water, pH
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7.5) for at least 1 hr to prevent non specific binding of antisera. Blots were then 
incubated in the appropriate primary antibodies; monoclonal phospho-ERa at 
serine 118 for 4 hrs at a 1/20000 dilution (make up fresh each time as 
specificity decreases), total ERa 1D5 for 4 hrs at a 1/1000 dilution, phospho- 
AKT and total AKT, phospho-ERKl/2 and total ERK1/2 at a 1/1000 dilution 
for lhr, phospho-EGFR tyrosine 1068 for 2 nights at a 1:1000 dilution, total 
EGFR over night at a 1:1000 dilution made up in 1% non-fat dried milk in 
TBS-tween. Membranes were washed three times over 15 minutes in TBS- 
tween and then incubated for 1 hour with the required secondary IgG 
horseradish peroxidase labelled, donkey anti rabbit or sheep anti mouse, diluted 
1/10000 in BM Chemiluminescence Blotting Substrate, made up in TBS-tween 
(l:20mLs). Membranes were then washed three times in TBS-tween for 30 
minutes.
2.2.3.7 Western blotting o f IP samples
Blots were incubated in monoclonal phospho-ERa at serine 118 for 4 hrs at a 
1/20000 dilution (make up fresh each time as specificity decreases), total ERa 
1D5 for 4 hrs at a 1/1000 dilution, phospho-tyrosine overnight at 1/1000 
dilution, or total ERK1/2 at a 1/1000 dilution for a 3hr period. Membranes 
were washed three times over 15 minutes in TBS-tween and then incubated for 
1 hour with the required secondary IgG horseradish peroxidase labelled, 
donkey anti rabbit or sheep anti mouse, diluted 1/10000 in BM 
Chemiluminescence Blotting Substrate, made up in TBS-tween (l:20mLs). 
Membranes were then washed three times in TBS-tween for 30 minutes.
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2.23.8 Protein detection
Detection was performed by applying a thin film of Supersignal® WEST 
FEMTO/DURA/PICO chemiluminescent substrate to the membrane for 5 
minutes. Hyperfilm ECL film was exposed to the membrane for between 2-30 
minutes as appropriate. The film was then removed and placed in developer 
and fixer. Results were scanned using a BioRad model GS-700 densitometer.
2.23.9 Statistics
Direct comparisons between WT-MCF-7 and TAM-R cells or between control 
and treatment effects were assessed using a Student’s t test. Differences were 
considered significant at the P < 0.05 level.
2.2.4 Immunocytochemistry (ICC)
2.2.4.1 Experimental tissue culture
Each cell line was removed by trypsination and re-suspended in W+5% and 
seeded onto 22-mm2 3- aminopropyltriethoxysilane (APES)-coated glass 
coverslips contained in 35mm culture dishes at a density of 1X105 cells/dish. 
After 4 days the cells were grown for 24 hrs prior to treatment in DCCM 
medium. Treatments included DCCM supplemented with gefitinib at lpM (10 
minutes), PD184352 at lOpM (lhr) or EGF at lOng/mL (10 minutes). All 
treatment groups were run along side a control arm consisting of experimental 
medium only. All studies involving TAM-R cells were performed with 4-OH-
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tamoxifen (lOOnM) present in the growth medium, including the TAM-R 
control arms. The treatments were removed and the cells were fixed according 
to the immunocytochemical assay to be performed (see below).
2J2.4.2 Cell fixing and staining 
ERa phosohorvlated at serine 118
For the best fixation of the immunochemical assay of ERa phosphorylated at 
the serine 118 residue the cell coated coverslips were immersed in 2% 
paraformaldehyde supplemented with sodium orthovanadate (2mM) for 20 
minutes, washed in PBS for 2X5 minutes and stored in sucrose storage medium 
at -20°C until required.
Coverslips were washed with PBS 2x5minutes. They were then dipped in PBS- 
Tween (0.02%) and blotted on a dry paper towel to remove the excess PBS- 
Tween (0.02%). The monoclonal ERa-phosphoserine 118 primary antibody 
was then added at 1/800 dilution in PBS overnight. The cover slips were 
washed for 2x5 minutes with PBS, then submerged in PBS-Tween (0.02%) 
prior to addition of the secondary antibody. One drop/coverslip of the 
peroxidase labelled polymer conjugated to goat anti mouse immunoglobulins 
from the DAKO mouse envision system HRP K4006, was added to each slip 
for 1 hour. The coverslips were washed (PBS (2x5minutes) and dipped in PBS- 
Tween (0.02%)) prior to addition of the DAKO DAB K3468 chromogen to 
each coverslip for 10 minutes and then removed using 2x5 minutes washes of 
distilled water. A counter stain of 0.5% methyl green was then applied for 10
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seconds each and then rinsed 3 times with distilled water. The coverslips were 
then air dried and mounted onto glass slides using a DPX soluble mountant.
ERK1/2 phosphorvlated at Thr202/Tvr204 assay
For the best fixation for the immunochemical assay of ERK1/2 (phospho- 
Thr202/Tyr204) the cell coated coverslips were immersed in 4% formal saline 
for 10 minutes at room temperature (r/t), followed by 2 washes in 70% ethanol 
over 5 minutes. The coverslips are then stored in 70% ethanol in the fridge 
prior to the assay.
The coverslips were washed in PBS for 6 quick washes to ensure all ethanol 
was removed. They were then blocked in PBS-Tween (0.02%). Excess PBS- 
Tween (0.02%) was removed by dabbing on a dry paper towel, then the 
primary phospho-ERKl/2 antibody was applied at a 1/25 dilution with PBS for 
1 hour. The cover slips were washed for 2x5 minutes with PBS then dipped in 
PBS-Tween (0.02%) prior to addition of the secondary antibody. The Biogenex 
Multi Link (Biotinylated anti-various immunoglobulins (mouse, rabbit, rat, and 
guinea pig) secondary antibody was made up in 1% BSA/PBS and applied for 
20 minutes at a 1/65 dilution. The coverslips were washed (PBS (2x5minutes) 
and dipped in PBS-Tween (0.02%)) prior to addition of the tertiary reagent. 
The Biogenex concentrated label (Streptavidin peroxidase) tertiary reagent was 
also made up in 1% BSA/PBS and applied for 20 minutes at a 1/65 dilution. 
They were washed in PBS for 2x5 minutes and dipped in PBS-Tween (0.02%). 
The DAKO DAB chromogen was then applied to each coverslip for 10 minutes 
and then removed using 3x2 minutes washes of distilled water. A counter stain
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of 0.5% methyl green was then applied for 10 seconds each and then rinsed 3 
times with distilled water, allowed to dry then DPX mounted on slides.
Activated EGFR fBiosource p i068) assay
Coverslips were fixed in 2.5% phenol formal saline for 5 minutes, followed by 
2 X 5  minutes washes in 70% ethanol. After 1 day storage at 4°C in ethanol, 
coverslips were washed in PBS (2 x 5 minutes) and again stored in the sucrose 
medium at -20°C. When required, coverslips were washed in PBS ( 2 x 5  
minutes) then dipped in PBS-Tween (0.02%) prior to addition of primary 
antibody. The primary antibody used in this assay was the Biosource rabbit 
primary antibody EGFR pl068 at 1/40 dilution made up in 1%BSA in PBS. 
This was left to incubate overnight at room temperature then washed for 3 
minutes in PBS, then PBS-Tween (0.02%) for 2 x 5 minutes prior to addition 
of the rabbit Envision peroxidase labelled antibody, which was left on the cells 
for 1 hour at room temperature. The coverslips were washed in PBS ( 2 X5  
minutes), then PBS-Tween (0.02%) ( 2 X 5  minutes) and the DAKO DAB 
chromogen was added for 10 minutes, followed by a distilled water wash (2 X 
5 minutes). Following the counterstain of 0.5% methyl green for 10 seconds 
and additional washes with distilled water (2X5 minutes), the cover slips were 
dried and mounted onto a slide with the DPX mountant.
Assessment of the all slides in each assay was carried out using an Olympus 
BH-2 light microscope by two independent observers and estimates of 
percentages of cells specifically stained and, where appropriate, of staining 
intensity were recorded to give an H-score (range, 0-300). An H-score of 300 
would describe strong staining of all (100%) tumour cells. In addition to the 3
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staining intensity categories (weak, moderate, and strong) previously used, a 
category of very weak staining was incorporated into the H-score calculation as 
shown below: H-score = £ (% very weakly stained cells x 0.5) + (% weakly 
stained cells x 1) + (%moderately stained cells x 2) + (% strongly stained cells 
x 3). Photographs were taken using the Olympus DP-12 digital camera.
2.2.43 Statistics
Direct comparisons of H-scores between WT-MCF-7 and TAM-R cells or 
between control and treatment effects were assessed using a student’s t test. 
Differences were considered significant at the P < 0.05 level.
2.2.5 Transient transfection studies
2.2.5.1 Experimental tissue culture and transfection for dual and
single luciferase assays 
Each cell line was removed by trypsination and reseeded at 3 X 106 cells/12 
well-plate in the W+5% medium for 24 hours prior to transfection. DNA-lipid- 
medium mixture (500pL) was prepared on day of transfection as follows. 
Firstly, 3|iL of Lipofectin was added to 60|iL of transfection medium (per 
well) at room temperature for 45 minutes to equilibrate. The transfection 
medium consisted of DCCM and L-Glutamine (200mM) used at 2% (v/v), 
however no antibiotics were used during the whole transfection time, because 
the cationic lipid reagents increase the cells permeability and allow excess 
delivery of antibiotics into the cells. This decreases the health of the cells and
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lowers transfection efficiency. A solution of DNA (l.lpg) in transfection 
medium was meanwhile prepared, which comprised 400ng of an ERE-tk-luc 
plasmid (a modified pGL2-firefly luciferase vector possessing a thymidine 
kinase (tk) promoter and a single oestrogen response element (ERE) sequence. 
160ng of Renilla-Luc plasmid used as an internal control for the normalisation 
(a modified pGL2-renilla luciferase vector with tk promoter) and 540ng of 
PCR-Script (a blank DNA plasmid)
The DNA mixture for the remaining luciferase assays contained: 400ng of the 
reporter gene construct to be studied X-p-TA/TAL-Luc (X = API, CRE, GRE, 
NFAT, NFkB and SRE). P-TA and p-TAL on their own are used as separate 
internal controls (i.e. in parallel wells) to assess promoter only driven 
transcription. 700ng of a blank DNA plasmid (here PCR-Script). The two 
solutions were then combined and 500pL added/well following aspiration and 
PBS washing of cells of overnight culture medium.
Cells were left to transfect for 6 hours in the incubator with the transfecting 
material (500pL/well). After the incubation time, the DNA-lipid mixture was 
removed, the cells were washed with warm PBS and various treatments were 
added to the cells including: control, EGF at 30ng/mL (overnight in control 
then 6 hours EGF), gefitinib at lpM for 24 hours, PD184352 at lOpM for 24 
hours, fulvestrant at lOOnM for 24 hours, oestradiol at InM for 24 hours, IGF- 
II at 30ng/mL (control overnight then 6hours IGF-II) AG1024 at 20 pM for 24 
hours.
Following these treatments cells were washed with PBS, lysed by scraping in 
the presence of passive lysis buffer (200pL, Promega lysis buffer X5 diluted in
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water), and lysate were stored at -80*C in eppendorf tubes, until analysis for 
the luciferase relative activity.
Z2.5.2 Luciferase assay
The luciferase assay was conducted in one of two ways depending on the 
reporter gene constructs used:
ERE-tk-Luc. dual (fireflv/Renilkfl luciferase assay
In this procedure the dual luciferase kit was used following the instructions 
given in the Promega manual.
The assay is a dual Luciferase assay, were the firefly signal, representing 
transactivation of ERE activity and of TK promoter, is measured following a 
reaction with the first reagent LAR II. The Renilla signal representing TK 
promoter activity only (i.e. minus the ERE), is measured following a reaction 
with the stop and glo reagent, which quenches die firefly luciferase signal 
whilst providing the substrate for the Renilla luciferase reaction.
LAR II
C b r f f r i r t w CMhrtBranrids
Figure 2.1; Chemical reaction involved in the firefly/renilla luciferase assay
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In this assay lOOfiL of LARII was pre-dispensed into an appropriate number of 
luminometer tubes. lOOpL of lysed sample was added to the tube, mixed and 
then placed in the luminometer where the firefly signal was measured. The 
tube was removed and lOOpL of the stop and glo reagent added. The tube was 
placed back into the luminometer to give the Renilla signal.
Single (Firefly) luciferase assay.
In this procedure the single luciferase kit was used following the instructions 
given in the Promega manual:
First an aliquot of lOOpL of luciferase reagent was pre-dispensed into an 
appropriate number of luminometer tubes. lOOpL of lysate was added to the 
tube, mixed and then placed in the luminometer where the luciferase activity 
was measured for 10 seconds.
2.2.5.3 Transfection efficiency using p-galactosidase (0-gal)
Transfection efficiency was determined for each cell line by transfecting a set 
of wells with a 0-gal expression vector (0-gal). The 0-gal is transfected in the 
same way as the plasmids from the mercury profiling system using 400ng of 0- 
gal with 700ng of PCR-script. After the incubation period of 6 hours, the 
transfected cells were stained for 0-gal as follows: Cells were washed with r/t 
PBS and fixed with 0.5% (v/v) glutaraldehyde in PBS (2mLs per well) for 15 
minutes at room temperature. After that time, cells were again washed with
70
room temperature PBS and incubated with a X-gal staining solution containing 
potassium ferricyanide and potassium ferrocyanide prepared as below:- 
Stocks of 300mM potassium ferricyanide/130mM MgC12 in PBS, stored -20. 
Stocks of 300mM potassium ferrocyanide/130mM MgCk in PBS stored at -20 
and
40 mg/mL X-gal dissolved in di-methyl formamide, stored in the dark at -20 
were initially prepared.
The staining solution was then made by diluting 1/100 v/v each of the two 
potassium cyanide solutions in PBS (final concentrations of 3mM for each 
potassium cyanide) with 1/320 v/v of stock solution of the X-Gal (final 
concentration 0.125 mg/mL).
Cells are left with this staining solution (2mL per well) over night at 37°C in 
the incubator. The blue colour could be seen the next day in transfected cells 
only and the percentage of transfection could therefore be estimated by 
counting the relative proportion of stained to non-stained cells.
2.2.5.4 Statistics
Direct comparisons between WT-MCF-7 and TAM-R cells or between control 
and treatment effects were assessed using a Student’s t test. Differences were 
considered significant at the P < 0.05 level.
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2.2.6 Reverse transcription-Polymerase Chain Reaction (RT-PCRJ
2.2.6.1 Experimental tissue culture
Each cell line was removed by trypsination and re-plated at 1.5X106 cells per 
100mm dish in W+5% medium. Cells were grown to 70% confluency (usually 
after four days), then medium was aspirated and replaced by the experimental 
DCCM for 24hours. To study cells under basal conditions medium was again 
aspirated and cells lysed. To study treatment effects medium was aspirated and 
replaced by experimental DCCM medium containing treatments (or control) at 
the stated doses and time periods: Gefitinib at lpM for 1 hour; PD184352 at 
IOjjM  for 4hours or EGF at lOng/mL for 1 hour; AG1024 at 20pM for 24 
hours; fulvestrant at lOOnM for seven days; 17p-estradiol at InM for 7 days. 
All treatment groups were run along side a control arm consisting of 
experimental medium only. All studies involving TAM-R cells were performed 
with 4-OH-tamoxifen (lOOnM) present in the growth medium, including the 
TAM-R control arms.
2.2.6.2 Cell lysis and RNA extraction
Cells were lysed by adding lmL of TRI lysis reagent for 5 minutes at room 
temperature. The lysed solution was then transferred to a sterile eppendorf to 
which 200pL chloroform was added. The tube was gently but thoroughly 
mixed for 15 seconds by shaking and left to stand for up to 10 minutes at room 
temperature before centrifugation at 13000RPM for 30 minutes (4°C). 400pL 
of the top aqueous phase (containing RNA) was carefully removed to a fresh
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sterile tube to which an equal volume of isopropanol was added. The tube was 
then mixed gently again, left to stand for 10 minutes at room temperature and 
centrifuged at 13000RPM for 10 minutes (4°C). The precipitated RNA (white 
pellet) was washed with 75% ethanol, gently vortexed, re-centrifuged (10 
minutes), pellet dried (important not to let pellet dry totally as this decreases 
solubility) and re-suspended in sterile water (30pL).
Concentration of the RNA was measured using a spectrophotometer at 260/280 
wavelength, using 1:500 dilution of RNA in water. The RNA integrity and 
concentration was checked by running RNA through a 2% agarose gel.
2.2.6.3 Agarose gel electrophoresis
lg of agarose was added to 50mL of Tris EDTA acetate (TEA) buffer in a 
200mL glass conical flask. The agarose was dissolved in a microwave at full 
power for 1 minute (stopping to mix and ensure agarose does not boil over) and 
left to cool to approximately 40°C. Following addition of l|iL  Ethidium 
bromide, the gel was poured into a gel tray and well comb added. When the gel 
set, a solution of RNA (equivalent to lfig) was mixed to 6pL loading buffer, 
loaded into the lanes of the gel and run for 30 minutes at 70 volts. The gels 
were then visualised under UV in a dark room.
2.2.6.4 Reverse transcription
To convert the RNA molecules to complementary DNA (cDNA) of a more 
stable form, reverse transcription was performed, lpg of RNA in a total of 
7.5|iL H2O was added to l lpL of the RT master mix solution (comprised of
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5pL dNTPs (2.5mM), 2pL PCR buffer (10X), 2pL DTT (O.IM) and 2pL of 
random hexamers (lOOfiM)), denatured at 95°C for 5 minutes in a PCR 
machine, then cooled to 5°C in Ice for 5 minutes. Mixture was pulse spun in a 
micro-centrifuge to collect the mixture and placed back on ice. lpL MMLV 
(reverse transcription enzyme) and 0.5pL RNase inhibitor is added to give a 
final volume of 20pL. The tubes are then placed in a PCR machine and reverse 
transcribed using the following parameters; 22°C for 10 minutes (annealing 
time), 42°C for 42 minutes (RT extension time) and 95°C for 5 minutes 
(denaturing time). The resultant cDNA was then stored at -20°C until required.
2.2.6.5PCR
To amplify the cDNA produced in the RT step exponentially, lpL of cDNA 
from each sample (equivalent to 50ng mRNA starting material assuming 100% 
efficiency of RT reaction) is added to a PCR master-mix solution (37.25pL of 
sterile distilled water, 5pL of PCR buffer (10X), 4pL of dNTPs (2.5mM), 
1.25pL forward primer, 1.25pL of reverse primer, 0.3125 pL of "P-actin forward 
primer, 0.3125pL of p-actin reverse primer and 0.2pL of the Taq polymerase) 
to give a final volume of 50pL per sample.
Tubes were overlaid with 2 drops of sterile mineral oil and placed in the heated
lid PCR machine and amplified using the following parameters:-
First cycle 95°C 2minutes (denaturing)
55°C 1 minute (annealing)
72°C lOminutes (extension)
PCR cycles 94°C 30secs (denaturing)
55°C lminute (annealing)
72°C lminute (extension) 
repeat appropriate number of times 
Final cycle 94°C lminute (denaturing)
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55°C lminute (annealing)
60°C lminute (extension)
The PCR product was then mixed with loading buffer and run on an agarose
gel for ~30 minutes. Gels were visualised under UV light and photographed
using a Polaroid camera. The signal intensity is then measured on a
densitometer and normalised to the P-actin readings.
2.2,6.6 Statistics
Direct comparisons between WT-MCF-7 and TAM-R cells or between control 
and treatment effects were assessed using a Student’s t test. Differences were 
considered significant at the P < 0.05 level.
2.2.7 Chromatin Immunoprecipitation (ChIP)
The following ChIP studies were carried out under the guidance and 
supervision of Dr Martin Giles.
2.2.7.1 Experimental tissue culture
TAM-R cells cultured as monolayer in flask were removed by trypsination and 
re-plated at 3X106 cells per 150mm dish in W+5% medium + lOOnM 4-OH- 
tamoxifen (three 150mm plates required). Cells were grown to 70% confluency 
(usually after four days), then medium was aspirated and replaced by the 
experimental DCCM + lOOnM 4-OH-tamoxifen for 24hours.
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2.2.7.2 Cell fixation and chromatin isolation
When cells were ready to harvest the medium was poured off the three plates 
and 2QmL of the fixing solution, containing 1% formaldehyde, was added to 
each. The cells were incubated in the fixing solution for 10 minutes at room 
temperature on a rocking platform. The fixing solution was removed and cells 
were washed by adding 15mL of ice cold PBS to each plate, rocking for 5 
seconds and then pouring off the PBS. Fixation reaction was stopped by adding 
15mLs of glycine (0.125M) stop solution to each of the plates, swirling to 
cover and then rocking at room temperature for 5 minutes. Each plate was 
- again washed with PBS following removal of the glycine stop solution. Cell 
collection involved adding 2mLs of the ice cold cell scraping solution, 
containing PMSF/PIC, to each of the plates and scraping with rubber 
policemen. Cells were collected at the bottom edge of the plate by a lmL 
pipette and transferred to a 15mL conical tube on ice. This was repeated in the 
other two plates and lysate from all three plates was pooled in the one 15mL 
conical tube, centrifugation at 2500RPM at 4°C for 10 minutes collected the 
cells at the bottom of the tube, then the supernatant was removed, and cells 
were re-suspended in 1.5mL ice cold lysis buffer for 30 minutes. Cells were 
transferred to an ice-cold Dounce homogeniser, where they were then gently 
dounced on ice with 10 strokes to aid nucleic release. The cell nuclei were 
pelleted by transferring lysate to a 15mL conical tube and centrifuging at 
5000RPM for 10 minutes at 4°C. Supernatant was again carefully removed and 
nuclei pellet re-suspended in lmL shearing buffer (supplemented with 5pL
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PIC) and aliquot into three 1.7mL micro-centrifuge tubes. Each aliquot 
totalling approximately 350pL.
2.2.7.3 Chromatin shearing
Three aliquots of fixed chromatin were sheared at level 5 power using three 
different conditions:
a. Five pulses of 20 seconds each, with a 30 second rest on ice between 
each pulse.
b. Ten pulses of 20 seconds each, with a 30 second rest on ice between 
each pulse.
c. Twenty pulses of 20 seconds each, with a 30 second rest on ice between 
each pulse.
The three sheared chromatin samples were centrifuged at 13,000 RPM in a 4°C 
micro-centrifuge for 12 minutes and the supernatants pooled by transferring 
each to the same fresh tube. 25jiL of the sheared chromatin contained within 
the supernatant is removed and checked for DNA shearing efficiency and DNA 
concentration, whilst the remainder of the sheared chromatin is aliquot into 
four equal aliquots (~220jiL each) and used for 4 ChIP reactions (i.e. each 
aliquot can be tested with four different antibodies).
2.2.7.4 Pre-clearing o f chromatin
Chromatin is pre-cleared with protein G beads to reduce non-specific 
background. 150|iL of chromatin is rotated for 2 hours at 4°C in 300pL protein 
G agarose beads, 177pL of ChIP buffer and 3pL of PIC, in a 1.7mL micro­
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centrifuge tube. Following this, the tube is placed in a micro-centrifuge for 2 
minutes at 4000RPM. After centrifugation, the tube is placed on ice for 2 
minutes to let the beads settle and the supernatant is then transferred to a fresh 
tube. The centrifugation step was repeated several times to ensure that the 
agarose beads were removed from the chromatin supernatant.
2.2.7.5 Immunoprecipitation
Each chromatin preparation was used for several ChlPs (e.g. a negative control 
ChIP, a positive control ChIP (input DNA) and a ChIP with antibody of 
interest (ERa or TFHB)). lOjiL of the pre-cleared chromatin is transferred to a 
micro-centrifuge tube and stored at -20°C. This sample will later be used as the 
‘Input DNA’ and stored for future analysis.
Antibody incubations were performed in 0.65 mL siliconized tubes (provided 
by active motif kit). Tubes were labelled and to each labelled tube, 170pL of 
pre-cleared chromatin was added. 7jig of total ERa antibody was also added to 
the ERa labelled tube, whilst 1.8pg of the negative control IgG and TFTIB to 
their respective labelled tubes. Antibody/chromatin mixture was left to 
incubate overnight on a rotator 4°C. To each of the antibody/chromatin 
incubations, 100 pL of fully re-suspended protein G agarose beads were added 
and incubated on a rotator for 2 hours at 4°C. The beads were then pelleted by 
centrifuging each ChIP reaction for 2 minutes at 4000RPM. Beads were 
allowed to settle and the supernatant removed using a pipette. To each tube, 
400pL of ChIP IP buffer and PMSF/PIC was added, tubes flicked to re­
suspend beads and incubate on a rotator for 1-3 minutes. Again beads were
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pelleted by centrifugation and supernatant removed. 400|iL of wash buffer 1 
was then added, beads re-suspended and incubated on a rotator for 3 minutes, 
beads pelleted then supernatant removed. This step was repeated four times. 
400pL of wash buffer 2 and PIC were then added, beads re-suspended, 
incubated on a rotator then pelleted and supernatant removed. This was 
repeated twice more using wash buffer 3 instead of buffer 2 and PIC.
2.2,7.6DNA elution
In this section immunoprecipitated DNA was collected from the washed 
protein G beads using two elutions with 50pL ChIP elution buffer.
50pL of the ChIP elution buffer was added to each of the washed protein G 
bead pellets in the 0.65 mL tubes, briefly vortexed and incubated for 15 
minutes at room temperature with gentle rotation. Tubes were then centrifuged 
for 2 minutes at 4000RPM to pellet beads and the supernatant transferred to 
appropriately labelled, sterile eppendorf tube. To reverse any cross links 
between the DNA and protein the supernatant were treated with 4pL of 5M 
NaCl and lpL RNase A to each ChIP elution. The reserved Input DNA must 
also be taken through this procedure (90|liL of water was added to Input DNA 
to bring the volume to lOOpL). The ChIP elution and Input DNA sample were 
then briefly vortexed, briefly centrifuged and placed in a heating block over 
night at 65°C. Another brief centrifugation for 1 minute, to collect liquid from 
the side, then addition of 2pL 0.5M EDTA, 2pL 1M Tris-HCl pH6.5 and 2pL 
proteinase K solution. The mixture was briefly vortexed and centrifuged and 
incubated for 2 hours at 42°C to digest the remaining proteins.
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2.2.7.7 DNA purification
To begin, the required number of DNA purification mini-columns are labelled 
on their sides and placed in their provided collection tubes in a rack.
The proteinase K-treated samples from the 42°C incubator were centrifuged 
briefly to collect the liquid condensed at the side of the tubes. 500pL of DNA 
binding buffer were then added to each DNA sample and vortexed to mix 
completely. Each sample was then transferred into a labelled DNA purification 
mini-column and centrifuged for 30 seconds at 10,000 to 15,000 RPM. The 
mini-column was then removed from the collection tube and placed back into 
the tube after discarding the flow through. 600pL of DNA wash buffer was 
added to each mini-column and centrifuged for 30 seconds again at 13,000. 
The flow through was again discarded from the mini-column and the mini­
column placed back onto the collection tube. 300|iL of the DNA wash buffer 
was added to each mini-column and centrifuged for 2 minutes at 13,000 RPM.
2.2.7.8 Primer design
The ChIP assay was used to determine the interaction of ERa with potential 
ERE’s within the promoter region of the amphiregulin gene in TAM-R cells. A 
region of DNA in chromosome 4ql3-q21, consisting of 1542 base pairs 5’ to 
the start of transcription and 148 bp 3’ to the start of transcription were entered 
into the Alibaba 2.1 transcription binding prediction software, which was set to 
the standard default search parameter, to locate potential ERE’s (Grabe N. 
AliBaba2: context specific identification of transcription factor binding sites. In
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Silico Biol. 2002;2(1):S1-1). Five potential ERE’s were found within a 600 bp 
region (GI:37953278, 671—>1270) of 5’ flanking DNA and primers 
encompassing this region were designed using the primer 3 software (Steve 
Rozen and Helen J. Skaletsky (2000) Primer3 on the WWW for general users 
and for biologist programmers. In: Krawetz S, Misener S (Eds) Bioinformatics 
Methods and Protocols: Methods in Molecular Biology. Humana Press, 
Totowa, NJ, pp 365-386
Primer 3 output for targeted area of Amphiregulin gene promoter:
Primer 1 Forward 5 ’ -CTCCTGACCTCAGGTGATCC
858—>877 GI:37953278
Reverse 5 ’ -TGTTC ATTTTCCTTC AACTGGA
10124—991 GI:37953278
Primer 2 Forward 5 ’ -GTAC AGTGGC ATGACCTTGG
682—>701 GI:37953278
Reverse 5 ’ -TGGC AAAACCCC ATCTTTAC
8354—816 GI:37953278
Primer 3 Forward 5 ’ -TTCCTGTCTCCGCTTC ATTT
1092—>1111 GI:37953278 
Reverse 5 ’ - ACTGGTGGC ATACTGGC ATT
1241<—1222 GI:37953278
2.2.7.9PCR
All methods carried out for this experiment are shown in the PCR section. 
Amphiregulin promoter primer 1 (33 cycles, annealing at 55°C for 1 minute) 
Amphiregulin promoter primer 2 (27 cycles, annealing at 55°C for 1 minute)
81
Amphiregulin promoter primer 3 (33 cycles, annealing at 55°C for 1 minute)
2.2.8 Immunoprecipitation, 2D gel electrophoresis and MALDI/TOF 
mass spectrometry
2.2.8.1 Experimental tissue culture and Immunoprecipitation
TAM-R cells cultured as a monolayer in a flask were removed by trypsination 
and re-plated at 1.5X106 cells per 100mm dish in W+5% medium. Cells were 
grown to 70% confluency (usually after four days), then medium was aspirated 
and replaced by the experimental DCCM for 24 hours. Detergent based cell 
lysis was carried out as described previously. Immunoprecipitation in a 1.5mL 
eppendorf required lmg of protein lysate, lpg of ERa 1D5 antibody and 20pL 
of protein A/G agarose. Pellet was collected as described previously. The 
remaining pellet was re-suspended in 400pL of rehydration buffer [Urea (8M), 
CHAPS (65mM) and TRIS base (40mM)], supplemented with dithiothrietol 
(14mg/5mL buffer) IPG-buffer (25pL/5mL buffer) and a few grains of 
bromophenol blue directly prior to use.
2.2.8.2 2D gel electrophoresis (1st Dimension isoelectric focusing)
No more than 350pL of Immunoprecipitate/rehydration buffer was loaded into 
the centre of a clean dry IPG strip holder, taking care not to create bubbles. The 
IPG strip (pH3-10 NL) was gently slid face down into the IP/rehydration buffer 
with the pointed end directed towards the anodic end of the holder, avoiding
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bubbles so that the face of the gel strip was in contact with the anode and 
cathode connections.
To prevent evaporation IPG cover fluid (~lmL) was pipette drop-wise into the 
holder thereby covering the entire length of the strip after which the lid was 
placed on the strip holder. The IPG strip holder was positioned on the IPG phor 
plate, ensuring the anode was in contact with the larger gold plate and the 
cathode was in contact with the smaller gold plate. The lysate was then 
subjected to isoelectric focussing using a programme based on guide lines by 
Amersham Pharmacia Biotech to deal with preparative sample loads (i.e. 
100pg-2mg on the IPG-phor). The protocol used is as follows:-
Rehydration Ovolts Ohrs
Stepl 30volts 12hrs
Step2 200volts lhr
Step3 500volts lhr
Step4 lOOOvolts lhr
Step5 8000volts 6hrs
The current was limited to 50pA per IPG strip
Following Isoelectric focussing, strips can either go for immediate 
equilibration and 2nd dimension electrophoresis or they must be stored at -80°C. 
Storage of strips must ideally be in long screw cap tubes but careful foil 
wrapping may be OK.
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2,2.83 2nd Dimension (Horizontal electrophoresis using pre-cast gel)
Before 2nd dimension electrophoresis, the IPG strips were equilibrated in 
lOmLs of a buffer containing TRIS-HCL (50mM, pH 8.8), UREA (6M), 
glycerol (30% v/v), SDS (2% w/v) and DTT (65mM). The procedure was 
carried out in sealed tubes on a roller for 15 minutes at r/t. TRIS-HCL maintain 
an appropriate pH during electrophoresis. UREA and glycerol protect against 
endosmosis and improve transfer of protein from the first to the second 
dimension, SDS denatures proteins and forms negatively charged protein-SDS 
complexes whilst DTT preserves the fully reduced state of denatured proteins. 
The equilibration buffer was then removed and a second 15 minutes 
equilibration step performed using lOmLs of the above buffer containing 
Iodoacetamide, instead of DTT, which prevents re-oxidation of protein.
The Multiphor II horizontal electrophoresis system was used for the second 
dimension separation of proteins. The system has a water cooled platform 
which is maintained at 15°C throughout electrophoresis by connections to the 
Multitemp HI thermostatic circulator. A pre-cast polyacrylamide SDS gradient 
gel (ExcelGel SDS, 12-14% gel 12-14%) was removed from its packaging and 
orientated correctly on the cooling plate so that the polarity of the gel 
corresponds to that of the plate, taking care to avoid bubbles under the gel. The 
gel surface was left to dry briefly after removal of the coversheet before 
placing the colourless cathodic and yellow anodic SDS buffer strips on the 
respective sides of the gel, avoiding bubbles below the strip. Once drained, the 
IPG strip was placed carefully gel side down and 3mm in front of the clear 
anodic buffer strip with the pointed (acidic) end of the IPG strip directed
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towards the negative side of the cooling plate. The IPG application strips were 
then placed under each end of the IPG strip such that they just touched the 
edges of the gel strip and absorbed away any water which may have leached 
out as electrophoresis begins. 15-20jjL of Molecular weight markers (14.4-97 
KDa) were applied to a separate application strip and positioned adjacent to the 
IPG strip. The electrode plate was positioned above the gel and each electrode 
aligned over the centre of each buffer strip. The electrode plate was then 
lowered carefully so that the electrodes were resting on the respective buffer 
strips. After connecting the cathode and anode electrodes to its appropriate 
points the lid was replaced and the gel run using the following programme:-
Stepl 1000V 20mA 40W 45minutes
Step2 1000V 40mA 40W 1 minute step
Step3 1000V 40mA 40W 3hr 40minutes
After the current had ran for a few minutes and the Bromophenol blue dye 
(thus the sample) had left the IPG strips and entered the second dimension gel 
by about 5mm, the power was paused. The Multiphor was opened and the IPG 
strip and application pieces were carefully removed. The cathode buffer gel 
was advanced to cover the area from which the IPG strip was removed, and the 
cathode electrode repositioned over the cathode buffer strip. Electrophoresis 
was resumed until the dye front was travelled just beneath the anode strip, at 
which point the procedure was terminated. Gel was removed and stained 
immediately as described below.
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2.2.8.4 Coomassie blue (PhastGel blue R350) staining
Stock solution was prepared by dissolving one tablet of Coomassie blue R350 
in 80mL of distilled water and left to stir for 5-10 minutes. 120 mL of methanol 
was then added and left to stir until all of the dye dissolved. Once dissolved the 
solution was filtered and 1 part of the filtered stock solution was mixed with 1 
part of 20% acetic acid in distilled water to give a 0.1% Coomassie blue 
solution.
The Excel gel was briefly washed in distilled water and soaked in the 0.1% 
Coomassie blue stain for a maximum of lhour. De-staining the gel was 
performed over 24hrs with 30% methanol, 10% Acetic acid and 60% distilled 
water. The de-staining fluid during this time required several changes. The gel 
was then wrapped in cling film and stored in the fridge at 4°C.
2.2.8.5 Silver staining
The gel was fixed with a solution containing lOOmL methanol, lOmL acetic 
acid and 90mL of distilled water for 20minutes, followed by washing with 
lOOmL methanol and lOOmL distilled water for lOminutes. The gel was placed 
in distilled water over night then exposed to the sensitising reagent (0.04g 
Sodium thiosulphate in 200mL of distilled water) for lminutesute followed by 
two 1 minute washes with distilled water. The gel was then incubated in the 
silver nitrate solution (0.2g silver nitrate in 200mL of distilled water) at 4°C for 
20 minutes, again followed by two 1 minute washes. On the final wash the gel 
was transferred to another gel chamber.
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2.2.8.6 In Gel Digestion (Carried out by Dr M  Morton) 
Bands were excised from the gel and cut into small pieces (~lxlmm cubes) 
with a clean scalpel. After several washes with water (2 or 3), the silver-stained 
gels were destained with a freshly prepared, 50:50 mixture of 30mM potassium 
ferricyanide and lOOmM sodium thiosulphate. The clear gels were incubated 
with 200mM ammonium bicarbonate (20min), washed with water, dehydrated 
with acetonitrile and dried in a vacuum centrifuge. The dried gel plugs were 
reduced in lOmM dithiothreitol (DTT) in lOOmM ammonium bicarbonate and 
incubated at 56°C for 45 minutes. The gel plugs were cooled to room 
temperature, the DTT removed and alkylated with 55mM iodoacetamide (IAA) 
in lOOmM ammonium bicarbonate at room temperature in the dark for 30 
minutes. The IAA was removed; the gel plugs washed twice with 50:50 
acetonitrile/1 OOmM ammonium bicarbonate and then dried in a vacuum 
centrifuge. The gel plugs were rehydrated in a freshly prepared and chilled 
digestion buffer containing 50mM ammonium bicarbonate and 12.5ng 
sequencing grade trypsin at 4°C. After 45 minutes on ice any remaining 
digestion buffer was removed and replaced with sufficient 50mM ammonium 
bicarbonate (~20 to 1) to keep the gel pieces wet during overnight incubation at 
37°C. Peptides were extracted from the gel by incubation with 25mM 
ammonium bicarbonate (20 to 1) for 10 minutes, without removing the 
supernatant the same volume of acetonitrile was added and incubation 
continued for a further 10 minutes. The supernatant was recovered and the 
peptides further extracted from the gels by two similar extractions with 5% 
formic acid and acetonitrile. All extracts were pooled, dried in a vacuum
87
centrifuge and redissolved in 5% formic acid (10 to 1). The peptide solutions 
were then purified and concentrated U-C18 ZipTips (Millipore) using the 
manufacturers protocol for wetting, equilibration, bonding and washing and 
peptides eluted directly onto the MALDI target with the matrix solution 
(saturated solution of -cyano-4-hydroxycinnamic acid in 50:50 
acetonitrile/0.2% triflouroacetic acid (TFA), diluted 1:5 with 60:40 
acetonitrile/0.2%TFA).
2.2.8.7 MALDI-TOF mass spectrometry (Carried out by Dr M  
Morton)
Peptide mass fingerprinting was carried out using a Bruker Reflex HI MALDI- 
TOF mass spectrometer in the reflectron mode. All mass spectra were 
externally calibrated with a peptide mixture containing Angiotensin I and n, 
Substance P, Bombesin, ACTH (1-17 and 18-39) and Somatostatin. Mascot 
software (Matrix Science, London, UK) was used for searching the NCBInr 
database using monoisotopic mass values for each peptide mass spectrum. 
Protein identity was based a MOWSE score with a * significant value of <0.05 
within the Mascot software.
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3.0 RESULTS
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3.1 Development of western blot assay measuring ERa phosphorylation at 
the serine 118 residue
Aim
The aim of this section was to develop a western blotting assay capable of 
detecting oestrogen receptor phosphorylation at the serine 118 residue. The cell 
line of choice for assay development was the breast cancer MCF-7 model. Joel 
et al 1998 demonstrated, using gel shift assays, that these cells showed 
measurable levels of phosphorylation at this residue and that oestrogen 
markedly increased the level of phosphorylation, providing a potentially 
appropriate positive control for use in subsequent experiments.
Results
Two cell lysis methods were investigated to maximize the yield of ERa 
extracted from WT cells, a freeze thaw lysis procedure and a detergent based 
lysis technique. Comparable results were obtained, as demonstrated by figure 
3.1a. Subsequent experiments utilised the detergent based lysis technique as 
this was the more straight forward procedure.
BSA is a highly abundant protein in cell culture growth medium and has a 
molecular mass of -68 KDa, which is very similar to the ERa molecular mass 
of 66-67KDa. As these values are so close there was a possibility that any band 
produced at this size by an ERa antibody may be due to non-specific binding to 
residual BSA, rather than specifically binding to ERa. To ensure that the 
66KDa band detected by the NEB monoclonal ERa phospho-serine 118
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antibody was not BSA, the cells were washed for an increasing number of 
times with PBS at 37°C prior to lysis and run on the gel illustrated in figure 
3.1b. The NEB monoclonal antibody was used at varying concentrations as 
recommended by the data sheet (1:20000, 1:1000 and 1:500 dilutions). Only 
the 1/20000 antibody dilution was illustrated in figure 3.1b as this gave the 
cleanest results.
A clear strong band was present at approximately 66KDa when the cells were 
washed three to five times with PBS prior to lysis. In contrast, the band at 68 
KDa was lost with increased washes. Where no washes were used prior to lysis 
it was clear that the 68 KDa protein was so abundant that it interfered with the 
signal from the 66KDa band. The results suggest that the band at 66KDa 
observed in figure 3.1b (lane 4) was in fact specific for ERa phosphorylated at 
serine 118 whilst the band at 68KDa was probably BSA. Subsequent 
experiments measuring ERa phosphorylation at serine 118 were washed three 
times in PBS at 37°C prior to lysis.
Further confirmation that the band detected by the ERa phospho-serine 118 
antibody was in fact ERa was provided by measuring the position of the ERa 
band detected by the total ERa 1D5 antibody in relation to the rainbow 
molecular weight markers (Figure 3.2a). These measurements were then used 
when additional ERa phospho-serine 118 antibodies were tested to establish 
whether they were more efficient at detection than the NEB monoclonal ERa 
phospho-serine 118 antibody on WT MCF-7 cells under basal conditions, as 
illustrated in figure 3.2b. Each antibody was used at varying concentrations as 
recommended by the respective data sheets. The NEB polyclonal ERa
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phospho-serine 118 antibody was used at 1:10000, 1:1000 and 1:500 dilutions, 
the Santa Cruz polyclonal ERa phospho-serine 118 antibody at 1:1000, 1:500 
and 1:100 dilutions and the NEB monoclonal ERa phospho-serine 118 
antibody at 1:20000 (previously shown to be optimum dilution). Only antibody 
concentrations which gave the cleanest results are illustrated in Figure 3.2b. 
The only ERa phosphoserine 118 antibody to reproducibly detect a clean, 
strong band at this position was the monoclonal NEB antibody when used at a 
concentration of 1:20000 (Lane 4).
Evidence that the 66KDa band was indeed ERa phosphorylated at serine 118, 
was provided by the study illustrated in figure 3.2c. Following protein transfer 
the nitrocellulose membrane was stained in Ponceau S dye and cut through the 
middle of the WT control lane as indicated on figure 3.2c. One half of the blot 
was incubated in the total ERa 1D5 antibody, whilst the other half was 
incubated with antibody to ERa phosphorylated at serine 118 (Figure 3.2c). 
Following incubation with the appropriate antibody and luminol reagents, the 
blot was reassembled to reveal that the band corresponding to ERa 
phosphorylated at serine 118 was slightly up shifted from the band 
corresponding to total ERa. This is consistent with studies by Joel et al (1998) 
demonstrating an upshift in ERa phosphorylated at serine 118 compared to the 
unphosphorylated form of the protein. Furthermore, the band produced by the 
monoclonal anti-ERa (phospho-ser 118) NEB antibody showed much greater 
intensity in the lane containing WT cells treated with oestradiol compared to 
the same band in the lane containing the WT control sample. This band was not 
present in the lane containing the negative control. These results were
92
consistent with the literature and support the view that the band was in fact 
specific to ERa phosphorylated at serine 118.
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Figure 3.1. Development of western blot assay measuring ERa 
phosphorylation at serine 118
& Freeze Detergent
thaw
ERa
p act in
No. o f PBS washes
75KDa f
■BSA (68 KDa)
1 p ERa serl 18 (66KDa)
50KDa £
50 pg protein
a. Level of ERa extracted from WT cells using freeze thaw cell lysis and 
detergent based cell lysis technique. p-actin levels show equal loading, b. 
Western blot of protein from WT cell samples washed with PBS 0, 1, 3 
and 5 times prior to lysis, then probed for ERa phosphorylated at serine 
118 with the monoclonal NEB antibody.
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Figure 3.2. Development of western blot assay measuring ERa 
phosphorylation at serine 118
a:
75KDa
b:
75KDa
ERa
50KDa
50KDa
(25KDa/10mm)X6.5min=16. 25KDa 
50KDa+16. 25KDa= ~66KDa
Lane
2
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3
Lane
4
p ERa 
ser ll8
PolyclonalPolyclonalMonoclonal 
Ab (NEB) Ab (Santa Ab (NEB) 
1:1000 Cruz) 1:20000
dilution 1:1000 dilution
dilution
14mm X 0.65 = ~9 mm above 50KDa marker
c: WT
C
75KDa
50KDa-
WT
C
WT
Eo
ERa 
1D5 Ab
p ERa 
serll8  Ab
-ve
C
p ERa 
serll8
a: Lane 1 shows position of 50KDa and 75KDa rainbow markers. Lane 2 shows position 
of total ERa from WT cells in relation to rainbow markers, fr Lane 1 shows position of  
50KDa and 75KDa rainbow markers. Lane 2 shows protein bands identified by the 
polyclonal NEB pERaSER118 antibody (#2515) at 1:1000 dilution (WT C). Lane 3 
shows protein bands identified by the polyclonal Santa Cruz pERaSER118 
antibody(#sc-12915) at 1:1000 dilution (WT C). Lane 4 shows protein bands identified 
by the monoclonal NEB ERapSERl 18 antibody (#2511) at 1:20000 dilution. The figures 
are representative of two separate experiments (WT C). c . Western blot cut through lane 
containing WT control (WT C) sample. One half of blot, containing WT C samples was 
incubated in total ERa 1D5 antibody, while the other half, containing WT C, WT cells 
treated with E2 (WT £ 2) and Du 145 Cells (-ve C) was incubated in monoclonal NEB 
pERaSERl 18 antibody.
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3.2 Role of ERa in mediating growth of wild type (WT) and tamoxifen-
resistant (TAM-R) MCF-7 breast cancer cell lines.
Aim
Tamoxifen resistant breast cancer appears to stably express ERa both in the 
clinical setting and in pre-clinical cell models (Robertson, 1996, Brunner et al., 
1993, Lykkesfeldt et al., 1994, Encamacion et al., 1993). Furthermore, a 
number of reports have indicated that down regulation of the ER with the pure 
anti-oestrogen, fulvestrant, inhibits tamoxifen-resistant growth in the clinic and 
in vitro suggesting that the ER has a continued role in growth regulation in this 
condition (Brunner et al., 1993, Lykkesfeldt et al., 1994, Coopman et al., 1994, 
Hu et al., 1993, Howell & Robertson, 1995, Howell et al., 1996, 2002). 
Similarly, the Tenovus laboratory has shown that growth of tamoxifen resistant 
MCF-7 breast cancer cells was sensitive to the inhibitory actions of Fulvestrant 
(Knowlden JM et al, 2003, Hutcheson et al 2003). This section aims to confirm 
these studies.
Results
At 7 days oestradiol significantly increased growth of WT (P < 0.05) and 
TAM-R MCF-7 cells (P < 0.05, n=3) (Figure 3.3a/b), whilst lOOnM fulvestrant 
significantly blocked basal cell growth in both cell lines (P < 0.05, n=3 for both 
cell lines). Total ERa levels were comparable between the WT and TAM-R 
cells and 7 days exposure to lOOnM fulvestrant significantly decreased ERa in 
each cell line (P < 0.0001, n=3 for both cell lines) (Figure 3.3c/d). The total
96
ERa densitometry readings were normalised to densitometry readings of p- 
actin to account for any errors in protein loading.
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Figure 3 .3. TAM-R versus WT MCF-7 cells: role of ERa in growth.
a b
TAM-R
C FUL Oest radio 1 c  FUL Oest radio 1
WT WT TAM-R TAM-R 
c Control FUL Control FUL
p actin
TAM-R TAM-R
Control FUL Control FUL
Growth responses o f a) WT MCF-7 and b) TAM-R MCF-7 cells after 7 days in 
phenol red-free RPMI medium contamg 5% charcoal-stripped serum in the absence 
and presence of either fulvestrant (FUL, 100 nM) or oestradiol (1 nM) (TAM-R cells 
are continually exposed to 100 nM TAM) (n=3). c: Western blot analysis and d;. 
Mean densitometry readings (± SEM) of Western blots demonstrating ERa expression 
in WT and TAM-R cells in either the absence or presence of fulvestrant (FUL, 
lOOnM) for 7 days. For densitometry readings total ERa expression levels were 
normalised using total P-actin expression levels. * = PO.OOl compared to control.
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33 ERa phosphorylation at serine 118 in a tamoxifen-resistant breast
cancer (TAM-R1 cell line.
Atm
Growth factor signalling pathways have been shown to induce phosphorylation 
of ERa at serine 118 via activation of ERK1/2 in multiple cell lines (Kato et al 
1995; Bunone et al 1996; Lannigan et al 2003). We have previously reported 
that our “in-house” TAM-R cell line, under basal growth conditions, 
demonstrated increased EGFR/ERK1/2 signalling pathway activity when 
compared to the parental WT cell line. The aim of this section, therefore, was 
to establish whether the elevated EGFR/ERK1/2 signalling in this cell line was 
accompanied by increased ERa phosphorylation at serine 118.
Results
TAM-R versus WT MCF-7 cells: phosphorylation (activity) of EGFR and 
ERK1/2
EGFR expression and phosphorylation (tyrosine residue 1068) was 
significantly greater in the TAM-R cells compared to the WT cell line under 
basal growth conditions (P < 0.005, n=3 for both total and phosphorylated 
EGFR, figure 3.4). Phosphorylation of ERK1/2 was also significantly greater 
in the TAM-R cells compared to the WT cells (P < 0.05, n=3), whilst total 
ERK1/2 and P-actin expression levels remained unchanged between the sample 
groups (Figure 3.4).
99
TAM-R versus WT MCF-7 cells: ERa phosphorylation at serine 118
ERa phosphorylation at serine 118 was significantly greater in the TAM-R 
cells compared to the WT cells under basal growth conditions (P < 0.05, n=3), 
correlating with the elevated level of phosphorylated EGFR/ERK1/2 in this cell 
line. The level of ERa phosphorylation at serine 118 in the TAM-R cells was 
also significantly greater than that observed following treatment of WT cells 
with oestradiol (P < 0.05, n=3) (Figure 3.5). Total ERa expression levels were 
comparable between the two cell lines.
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Figure 3.4. TAM-R versus WT MCF-7 cells: phosphorylation 
(activity) o f EGF-R and ERK1/2.
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EGFR
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ERK1/2
a; Expression of total and phosphorylated EGFR and ERK1/2 phosphorylation 
in WT and TAM-R cells under basal growth conditions (Knowlden et al 2003). 
b; Mean densitometry readings (± SEM) of Western blots for total and 
phosphorylated EGFR and phosphorylated ERK1/2 expression in WT and 
TAM-R cells (n=3). ERK1/2 phosphorylation levels were normalised using 
total ERK1/2 expression levels. Total and phospho-EGFR levels were 
normalised using total P-actin expression levels. * = P<0.05 compared to 
control. ** = P<0.01 compared to control.
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Figure 3.5. TAM-R versus WT MCF-7 cells; ERa phosphorylation at
serine 118
p-ERa 
SERI 18
WT
C
WT
E-,
TAM-R
C
Total ERa
TAM-R
a. Western blot analysis and b. Mean densitometry readings (± SEM) of Western blots 
demonstrating expression of ERa phosphorylation at serine 118 in WT cells, either in the 
absence or presence o f oestradiol (1 nM) for 5days, and in TAM-R cells under basal growth 
conditions. Total ERa expression demonstrates equal loading. Densitometry values for ERa 
phosphorylation at serine 118 were normalised using total ERa expression levels. * = P<0.05 
compared to control.
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Section 3.4 Development of Immimocvtochemical (ICC) assay measuring
ERq phosphorylation at the serine 118 residue in TAM-R cells
Aim
ERa phosphorylation at serine 118 in the TAM-R cells had not previously been 
researched at the time of this investigation and therefore immunocytochemical 
(ICC) evidence in addition to western blotting was sought. The aim was to 
develop an ICC assay capable of measuring the effects of pharmacological 
agents on ERa phosphorylation at serine 118 in the TAM-R cell line. ICC has 
the advantage of revealing the cellular localisation of investigated proteins and 
is also of emerging importance in monitoring signal transduction using 
phospho-specific antibodies.
Results
When developing a new ICC assay it is essential to determine the most 
appropriate fixative. Based on previous laboratory experience the ability of 2% 
Paraformaldehyde with sodium orthovanadate (2mM) (20 minutes) to fix cells 
and preserve phosphorylated epitopes was compared to a range of other 
fixatives including 2% paraformaldehyde (lOmins), 4% formaldehyde in PBS 
(lOmins) or formal saline (lOmins). These reagents retained adequate 
morphology and comparable levels of the antigen directed to the antibody for 
ERa phosphorylated at serine 118 at a 1/800 dilution as revealed by figure 
3.6a, b, c and d. The decision to use a 1/800 dilution of primary antibody was 
also based on previous laboratory experience. Closer inspection of the cells
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revealed that the highest level of nuclear staining in the TAM-R cells was 
obtained using the monoclonal antibody to ERa phosphorylated at serine 118, 
when cells were fixed with either 2% paraformaldehyde vanadate for 20 mins 
or 4% formaldehyde for 10 minutes or (figure 3.6 a and c respectively). TAM- 
R cells fixed with 2% paraformaldehyde or formal saline for 10 minutes did 
not produce slides with sharp enough staining (Figure 3.6b and d respectively). 
The polyclonal NEB antibody at a range of dilutions was also tested with the 
two most successful fixatives, 2% paraformaldehyde vanadate or 
4%formaldehyde, in the WT versus TAM-R cells (Figure 3.7). An increased 
antibody dilution of 1 in 20 produced immunostaining in both WT and TAM-R 
cells following fixation with either fixative (Figure 3.7). However, the 
polyclonal ERa phosphoserine 118 antibody was not used for further studies 
for several reasons. Many non-specific bands were observed in western 
blotting experiments when the polyclonal antibody was used at such high 
concentrations. This therefore suggests that the staining in the polyclonal 
stained cells may refer to non-specific interactions with the antibody. The 
images did not appear to produce such sharp and clear signals as the 
monoclonal antibody. Furthermore the price of using this antibody at such 
concentrations was far greater than using the monoclonal.
WT cells compared to TAM-R cells fixed with 4% formaldehyde in PBS for 10 
minutes, showed lower levels of staining using the monoclonal antibody to 
ERa phosphorylated at serine 118 (figure 3.8a). However, the difference 
between the level of ERa phosphorylation at serine 118 in WT and TAM-R
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cells was more evident using 2% paraformaldehyde orthovanadate (Figure 
3.8b). Furthermore, across the several coverslips examined, paraformaldehyde 
orthovanadate produced the lowest level of background staining out of all the 
fixatives tested.
In agreement with the western blotting results and correlating with the elevated 
levels of phosphorylated EGFR/ERK1/2, TAM-R cells fixed with 2% 
paraformaldehyde orthovanadate, immunostained with monoclonal antibody to 
ERa phosphorylated at serine 118 have significantly greater nuclear H-score 
values than the WT cells (P < 0.001, n=3) (Figure 3.8c). The increase in 
staining between the two cell lines appears to be predominantly nuclear, 
although cytoplasmic staining also increased slightly. Interestingly, intensity of 
immunostaining of the cells for ERa phosphorylated at serine 118 was not 
uniform from one cell to another. There was considerable heterogeneity even 
within the intensely stained TAM-R cells. This correlates with the 
heterogeneity observed in TAM-R cells immunostained for EGFR and ERK1/2 
(Kno widen et al 2003).
The ER negative MDA 231 cells were also fixed with 2% paraformaldehyde 
vanadate then immunostained for ERa phosphorylated at serine 118 and used 
as a negative control (Figure 3.8d). Although the slides produced extremely 
weak signals, immunostaining was detected in the nucleus of approximately 
5% of cells. There was also evidence of weak membrane staining. Additional 
studies are needed to determine whether such staining was unspecific or 
whether low levels of ERa exist in the MDA 231 cells, a finding not observed 
with several total ERa antibodies. Determination of the origin of the MDA 231
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cytoplasmic staining could provide further clues as to the origin of the 
cytoplasmic staining observed in the WT and TAM-R cells.
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Figure 3.6. Development of Immunocytochemical assay to measure 
the level of ERa phosphorylation at serine 118
* i r
/V
• 'f r a f r  • v
E ftv  U.itJu 1 ..SM
- a *
*
*►
Immunocytochemistry o f TAM-R cells under basal growth conditions fixed with; a) 2% 
Paraformaldehyde Vanadate 20 mins, b) 2% Paraformaldehyde 10 mins, c) 4% 
Formaldehyde in PBS 10 mins, d) Formal Saline 10 mins and immunostained using the 
monoclonal ERa serl 18 NEB Ab (1/800). Magnification X20.
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Figure 3.7. Development of Immunocvtochemical assay to measure
the level of ERa phosphorylation at serine 118
WT TAM-R
a
Immunocytochemistry o f WT and TAM-R cells fixed with either a. 2% 
Paraformaldehyde Vanadate for 20 mins or b. 4%  Formaldehyde in PBS for 10 mins 
and incubated with polyclonal ERa ser 118 NEB Ab (1/20). Magnification X20.
Figure 3.8. Development of Immunocvtochemical assay to measure 
the level of ERa phosphorylation at serine 118
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Immunocytochemistry o f WT cells and TAM-R cells under basal growth conditions 
fixed with either a. 4% Formaldehyde in PBS (10 mins) or b. 2% Paraformaldehyde 
orthovanadate (PFV) (20mins), All slides at X20 magnification. Following fixation 
cells were immunostained with monoclonal ERa ser ll8  antibody (1/800). c: Mean H- 
score values (± SEM) from three separate experiments measuring nuclear ERa 
phosphorylation at serine 118 in TAM-R versus WT cells under basal growth 
conditions (n=3). * = P < 0.001 compared to control, d. Negative control consisting o f 
ERa negative MDA231 cells fixed with PFV and immunostained for ERa (phospho-ser 
118).
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3.5 Modulation of the EGFR/ERK1/2 signalling pathway and its effects on
ERa phosphorylation at serine 118 in TAM-R MCF-7 cells
Aim
Section 3 demonstrated increased levels of ERa phosphorylation at serine 118 
in association with enhanced phosphorylation (activity) of EGFR/ERK1/2 in 
TAM-R cells. The influence of EGFR/ERK1/2 signalling on ERa 
phosphorylation at serine 118 was therefore investigated further in this cell 
line.
Results
Effects of the EGFR ligand EGF on TAM-R MCF-7 cells 
Treatment of TAM-R cells with EGF significantly increased levels of 
phosphorylated EGFR (P < 0.01, n=3) and ERK1/2 (P < 0.05, n=3) (Figure 
3.9). These increases in EGFR/ERK1/2 phosphorylation were accompanied by 
significant increases in ERa phosphorylation at serine 118 (P < 0.05, n=3), as 
shown by the western blots in Figure 3.9. There was no effect of this ligand on 
total EGFR, ERK1/2 and ERa protein expression. ICC also demonstrated that 
EGF significantly increased levels of phosphorylated EGFR (P < 0.0001, n=3), 
ERK1/2 (P < 0.0001, n=3) and ERa at serine 118 (P < 0.0001, n=3) (Figure 
3.lOb/c). Closer inspection of the slides in figure 3.10a revealed that EGF 
induced a substantial increase in the frequency and intensity of nuclei 
positively immunostained for ERa phosphorylated at serine 118. Cytoplasmic
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and membrane staining for ERa phosphorylated at serine 118 in these samples, 
however, remained unchanged. Phosphorylated ERK1/2 showed obvious 
increases in cytoplasmic and nuclear staining when treated with EGF, whilst 
phosphorylated EGFR displayed an increased frequency of strong membrane 
immunostaining. The low levels of cytoplasmic phosphorylated EGFR staining 
appeared to be unchanged by this treatment.
Effects of EGFR and MEK inhibition on the EGF-induced increases in ERa 
and ERK1/2 phosphorylation in TAM-R MCF-7 cells
Western blotting demonstrated that the selective EGFR tyrosine kinase 
inhibitor gefitinib prevented increased phosphorylation of both ERK1/2 and 
ERa in response to EGF in TAM-R cells. The MEK1/2 inhibitor PD184352 
also clearly inhibited the EGF-induced increases in ERa and ERK1/2 
phosphorylation although its effectiveness on EGF-induced ERa 
phosphorylation was less pronounced than that of gefitinib. There was no effect 
of these treatments on total ERa and ERK1/2 levels (Figure 3.11, n=2).
I l l
3.6: Modulation of the IGF-IR signalling pathway and the effects on ERa 
phosphorylation at serine 118 in TAM-R MCF-7 cells
Aim
Studies by Kato at al 1995 have demonstrated that the IGF-IR signalling 
pathway, in addition to EGFR signalling, can regulate the level of ERa 
phosphorylation at serine 118 in breast cancer cells. As TAM-R cells also 
express IGF-IR the current section investigated whether the IGF-IR signalling 
pathway contributed to ERa phosphorylation at serine 118 in the TAM-R cell 
line.
Results
Insulin like growth factor II (1GF-II) effects on TAM-R MCF-7 cells 
IGF-H treatment significantly increased phosphorylation of IGF-IR (P < 0.05, 
n=3), ERK1/2 (P < 0.05, n=3) and ERa (serine 118) (P < 0.05, n=3) in TAM-R 
cells, whilst having no effect on total expression levels of these proteins 
(Figure 3.12a/b).
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Figure 3 .9. Epidermal growth factor (EGF) effects on TAM-R
MCF-7 cells
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a: Western blot analysis of ERa (SER 118), ERK1/2 and EGFR phosphorylation in 
TAM-R MCF-7 cells in either the absence or presence o f EGF (lOng/ml) for 10 
minutes. Equal loading demonstrated by no change in total protein expression 
levels, b; Mean densitometry readings (+/-SEM) from Western blots for ERa (SER 
118), ERK1/2 and EGFR phosphorylation in TAM-R cells in either the absence or 
presence o f EGF (lOng/ml) for 10 minutes (n=3). Phosphorylation levels were 
normalised using total protein expression levels. * = P<0.05 compared to control. 
** = P<0.01 compared to control.
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Figure 3.10. Epidermal growth factor (EGF) effects on TAM-R
MCF-7 cells
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a: Immunocytochemistry and b/c. Mean H-scores values (±SEM) of ERa (SER 118), 
ERK1/2 and EGFR phosphorylation in TAM-R cells in either the absence or presence of 
EGF (lOng/ml) for 10 minutes (n=3) (X20 magnification for ICC). * = PO.OOl 
compared to TAM-R control.
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Figure 3.11. Gefitinib/PD184352 +/- EGF effects on TAM-R
MCF-7 cells
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Western blot analysis o f ERa (SER 118) and ERK1/2 phosphorylation in TAM-R 
MCF-7 cells a* in the absence and following treatment of cells with either EGF or a 
combination of EGF and gefitinib (1 pM, lOmins). K in the absence and following 
treatment of cells with either EGF (10 ng/ml, lOmins) or a combination of EGF and 
PD184352 (10 pM, lhr). Each blot is representative o f two separate experiments 
(n=2).
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Figure 3.12. Insulin like growth factor II (IGFID effects on TAM-R
MCF-7 cells
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a: Western blot analysis of total and phosphorylated ERa (SER 118), ERK1/2 and 
IGF-IR expression levels in TAM-R MCF-7 cells in the absence and presence of 
IGF-II (lOng/ml) for 10 minutes. Equal loading is demonstrated by equal levels of 
the respective total proteins. _b: Mean densitometry values (±SEM) o f ERa (SER 
118), ERK1/2 and IGF-IR phosphorylation in TAM-R cells in the absence and 
presence o f IGF-H (lOng/ml) for 10 minutes (n=3). Phosphorylation levels were 
normalised using total protein expression levels. * = P<0.05 compared to control.
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3.7 Regulation of ERa phosphorylation at serine 118 in TAM-R cells
under basal growth conditions
Aims
The previous sections demonstrated that stimulating the EGFR and IGF-IR 
signalling pathways induced elevated ERa phosphorylation at serine 118 in the 
TAM-R cells. The role of the current section is to understand whether these 
pathways are important in regulating phosphorylation at serine 118 under basal 
growth conditions and whether, as a consequence, they influence basal TAM-R 
cell growth.
Results
Effects of gefitinib (GEF) on TAM-R MCF-7 cells under basal growth 
conditions
Growth of TAM-R MCF-7 cells at 7 days was significantly reduced in the 
presence of gefitinib at concentrations of lfiM (P < 0.05, n=3) and lOpM (P < 
0.01, n=3; Figure 3.13a). Furthermore, gefitinib treatment significantly 
inhibited phosphorylation of EGFR (P < 0.05, n=3) and ERK1/2 (P < 0.01, 
n=3) in TAM-R cells in a concentration dependent manner. Such decreases in 
EGFR/ERK1/2 phosphorylation in response to gefitinib were accompanied by 
a significant reduction in the levels of phosphorylated ERa at serine 118 (P < 
0.05, n=3) (Figure 3.13b/c). There was no effect of either concentration of 
gefitinib on total EGFR, ERK1/2 and ERa expression levels.
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In agreement with western blotting the immunocytochemical studies revealed 
that exposure of TAM-R cells to gefitinib significantly reduced H-score values 
for phosphorylated EGFR (P < 0.0001, n=3), ERK1/2 (P < 0.0001, n=3) and 
ERa at serine 118 (P < 0.0001, n=3, figure 3.14b/c). Gefitinib significantly 
decreased the frequency and intensity of nuclei positively immunostained for 
ERa phosphorylated at serine 118 with cytoplasmic and membrane staining in 
these samples remaining predominantly unchanged. Phosphorylated ERK1/2 
showed dramatic reductions in cytoplasmic and nuclear staining, whilst EGFR 
showed dramatic reductions in membrane staining following exposure to 
gefitinib.
Effects of PD184352 (PD) on TAM-R MCF-7 cells under basal growth 
conditions
Growth of TAM-R MCF-7 cells at 7 days was significantly reduced in the 
presence of PD184352 at concentrations of lpM (P < 0.05, n=3) and lOpM (P 
< 0.005, n=3; Figure 3.15a). Western blotting further revealed that PD184352, 
like gefitinib, significantly reduced phosphorylation of ERK1/2 (P < 0.005, 
n=3) and ERa at serine 118 (P < 0.05, n=3) in a concentration dependent 
manner whilst having no effect on total ERK1/2 and ERa protein levels (Figure 
3.15b/c). H-Score results from 3 separate experiments confirmed the western 
blotting findings with PD184352 significantly reducing ERK1/2 (P < 0.0001, 
n=3) and ERa phosphorylation (P < 0.0001, n=3) in the TAM-R cells (Figure 
3.16b/c). TAM-R cells immunostained for ERa phosphorylated at serine 118 
showed a dramatic reduction in the intensity and frequency of positively
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stained cell nuclei following exposure to lOpM PD184352 (Figure 3.15a), 
however, cytoplasmic and membrane staining remained unchanged in these 
samples. TAM-R cells immunostained for phosphorylated ERK1/2 showed a 
parallel reduction in nuclear staining following exposure to PD184352. The 
phospho-ERKl/2 cytoplasmic staining was also reduced considerably.
Effects of the IGF-IR inhibitor AG1024 on TAM-R MCF-7 cells under basal 
growth conditions
TAM-R cells treated with AG1024 for 7 days showed a significant decrease in 
growth compared to control (P < 0.05, n=3, Figure 3.17a). Furthermore, 
AG1024 significantly reduced phosphorylated IGF-IR (P < 0.05, n=3), ERK1/2 
(P < 0.05, n=3) and ERa at serine 118 (P < 0.05, n=3). Total ERa, ERK1/2 and 
IGF-IR protein levels remained unchanged following this treatment (Figure 
3.17b/c).
Effect of AG1024 and Gefitinib in combination on TAM-R MCF-7 cells under 
basal growth conditions
TAM-R cells treated with either AG1024 or gefitinib alone, exhibited 
significant reductions in ERa and ERK1/2 phosphorylation. However, a 
combination of these two agents had no significant further effect on ERa and 
ERK1/2 phosphorylation when compared to the effects observed following 
treatment with gefitinib alone (Figure 3.18). There was again no effect of these 
treatments on total ERa and ERK1/2 expression levels.
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Figure 3.13. Gefitinib (GEF) effects on TAM-R MCF-7 cells
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a: Growth responses o f TAM-R MCF-7 cells after 7 days in phenol red-free RPMI 
medium containg 5% charcoal-stripped serum in the absence and presence of gefitinib 
(GEF, 1 and 10 pM) (n=3). b: Western blot analysis of total and phosphorylated ERa 
(SER 118), ERK1/2 and EGFR expression levels in TAM-R MCF-7 cells in the 
absence and presence of gefitinib (1 and 10 pM) for 10 minutes. Equal loading 
demonstrated by equal levels o f total proteins, c; Mean densitometry readings (±SEM) 
of ERa (SER 118), ERK1/2 and EGFR phosphorylation in TAM-R cells in the absence 
and presence of gefitinib (1 and 10 pM) (lOminutes). Phosphorylation levels were 
normalised using the respective total protein expression levels (n=3). * = P<0.05 
compared to control. ** = PO.Ol compared to control
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Figure 3.14. Gefitinib (GEF) effects on TAM-R MCF-7 cells
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Figure 3.15. PD184352 (PD) effects on TAM-R MCF-7 cells
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hour). Phosphorylation levels were normalised using the respective total protein 
expression levels (n=3). * = P<0.05 compared to control. ** = P<0.01 compared 
to control
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Figure 3.16. PD184352 (PD) effects on TAM-R MCF-7 cells
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Figure 3 .17. Effects of the IGF-IR inhibitor AG1Q24 on TAM-R
MCF-7 cells
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a: Growth responses of TAM-R MCF-7 cells after 7 days in phenol red-free RPMI 
medium containing 5% charcoal-stripped serum in the absence and presence of 
AG 1024 (20 pM) (n=3). b; Western blot analysis o f total and phosphorylated ERa 
(SER 118), ERK1/2 and IGF-IR expression levels in TAM-R MCF-7 cells in the 
absence and presence of AG1024 (20 pM) for 24 hours. Equal loading 
demonstrated by equal levels of total proteins, c: Mean densitometry readings 
(±SEM) of ERa (SER 118), ERK1/2 and IGF-IR phosphorylation in TAM-R cells 
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were normalised using the respective total protein expression levels (n=3). * = 
P<0.05 compared to control.
124
Figure 3.18. Effect of AG1024 and Gefitinib in combination
on TAM-R MCF-7 cells
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a; Western blot analysis o f total and phosphorylated ERa (SER 118) and 
ERK1/2 expression levels in TAM-R MCF-7 cells in the absence and following 
treatment of cells with either gefitinib alone (1 pM), AG1024 alone (20 pM) or 
the two agents in combination. Equal loading is demonstrated by equal levels of 
the respective total proteins. _b; Mean densitometry values (±SEM) of ERa (SER 
118) and ERK1/2 phosphorylation in TAM-R cells in the absence and 
following treatment of cells with either gefitinib alone (1 pM), AG1024 alone 
(20 pM) or the two agents in combination. (n=3). Phosphorylation levels were 
normalised using total protein expression levels. * = P<0.05 compared to 
control.
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3.8 Modulation of the EGFR/ERK1/2 signalling pathway and its effects on
ERa phosphorylation at serine 118 in WT MCF-7 cells
Aim
EGFR/ERK1/2 signal transduction pathways clearly play a role in the 
phosphorylation of ERa in TAM-R cells. The WT cell line also showed 
measurable levels of ERa phosphorylation at this residue, yet expressed 
significantly less phosphorylated EGFR and ERK1/2, therefore this section 
investigated whether EGFR/ERK1/2 signalling is involved in the 
phosphorylation of ERa at serine 118 in the WT cell line.
Effects of EGF on WT MCF-7 cells
EGF significantly increased levels of phosphorylated EGFR (P < 0.01, n=3) 
and ERK1/2 (P < 0.05, n=3) in the WT cells (Figure 3.19). These EGF-induced 
increases in EGFR/ERK1/2 phosphorylation were accompanied by significant 
increases in ERa phosphorylation at serine 118 (P < 0.05, n=3), as shown by 
the western blots in Figure 3.19. There was again no effect of this ligand on 
total protein expression in these cells.
Effects of EGFR and MEK inhibition on EGF-induced actions in WT MCF-7 
cells
EGF-induced increases in ERa and ERK1/2 phosphorylation were completely 
inhibited by both gefitinib and PD184352 in the WT cell line (Figure 3.20).
126
There was again no effect of these inhibitors on total ERa and ERK1/2 
expression levels in these cells.
3.9 Modulation of the IGF-IR signalling pathway and the effects on ERa 
phosphorylation at serine 118 in WT MCF-7 cells
Aims
IGF-IR signal transduction pathway has been shown to induce phosphorylation 
of ERa in the TAM-R MCF-7 cell line. As WT cells also express 
phosphorylated IGF-IR this section investigated whether the IGF-IR is 
involved in the phosphorylation of ERa at serine 118 in WT cells.
Results
Insulin like growth factor-II (IGF-ID effects on WT MCF-7 cells 
IGF-II significandy increased phosphorylation levels of IGF-IR (P < 0.01, 
n=3), ERK1/2 (P < 0.01, n=3) and ERa at serine 118 (P < 0.01, n=3) in WT 
cells but had no effect on total expression levels of these proteins in this cell 
line (Figure 3.21).
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Figure 3 .19. Epidermal growth factor (EGF) effects on WT
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a: Western blot analysis of ERa (SER 118), ERK1/2 and EGFR phosphorylation in 
WT MCF-7 cells in either the absence or presence of EGF (lOng/ml) for 10 
minutes. Equal loading demonstrated by no change in total protein expression 
levels, b: Mean densitometry readings (±SEM) from Western blots for ERa (SER 
118), ERK1/2 and EGFR phosphorylation in WT cells in either the absence or 
presence of EGF (lOng/ml) for 10 minutes (n=3). Phosphorylation levels were 
normalised using total protein expression levels. * = P<0.05 compared to control. 
** = P<0.01 compared to control.
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Figure 3.20. PD184352/Gefitinib +/- EGF effects on WT MCF-7
cells
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Western blot analysis o f ERa (SER 118) and ERK 1/2 phosphorylation in 
WT MCF-7 cells a, in the absence and following treatment of cells with 
either EGF (10 ng/ml) or a combination of EGF and gefitinib (1 pM). b, in 
the absence and following treatment of cells with either EGF (10 ng/ml) or a 
combination of EGF and PD184352 (10 pM). Each blot is representative of 
two separate experiments (n=2).
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Figure 3.21. Insulin like growth factor II (IGFII) effects on WT
MCF-7 cells
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a: Western blot analysis o f total and phosphorylated ERa (SER 118), 
ERK1/2 and IGF-IR expression levels in WT MCF-7 cells in the absence and 
presence o f IGF-H (lOng/ml) for 10 minutes. Equal loading is demonstrated 
by equal levels of the respective total proteins, b: Mean densitometry values 
(±SEM) of ERa (SER 118), ERK1/2 and IGF-IR phosphorylation in WT 
cells in the absence and presence o f IGF-Q (lOng/ml) for 10 minutes (n=3). 
Phosphorylation levels were normalised using total protein expression levels. 
* = P<0.05 compared to control.
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3.10 Regulation of ERa phosphorylation at serine 118 in WT cells under
basal growth conditions
Aims
As demonstrated above, stimulation of the EGFR and IGF-IR signalling 
pathways induced increased phosphorylation of ERa at serine 118 in the WT 
cells. As such the current section seeks to understand whether these pathways 
play a role in regulating ERa phosphorylation at serine 118 under basal growth 
conditions and whether, as a consequence, they influence basal WT MCF-7 
cell growth.
Results
Effects of Gefitinib (GEF) on WT MCF-7 cells under basal growth conditions 
Gefitinib was considerably less effective at reducing basal growth of WT cells 
than TAM-R cells. Statistically, growth of WT MCF-7 cells on day 7 was not 
significantly reduced by lpM Gefitinib. Gefitinib at 10pM produced a 
significant reduction in growth (P < 0.05, n=3, Figure 3.22a), however, at this 
concentration gefitinib has been previously shown to loose selectivity for the 
EGFR (Jones et al 2004; Morris et al 2002). Gefitinib treatment at both 
concentrations significantly inhibited phosphorylation of EGFR (P < 0.05, n=3) 
and ERK1/2 (P < 0.05, n=3) in WT cells under basal growth conditions. 
Despite such EGFR/ERK1/2 inhibition, gefitinib was ineffective at reducing 
basal ERa phosphorylation at serine 118. Total EGFR, ERK1/2 and ERa levels 
remained unchanged throughout the study (Figure 3.22b/c).
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Effects of PD184352 (PD) on WT MCF-7 cells under basal growth conditions
As with gefitinib, PD184352 was less effective at reducing growth of WT cells 
than TAM-R cells. Growth of WT MCF-7 cells on day 7 was not significantly 
reduced by 1 pM PD184352. Increasing the PD184352 concentration to lOpM 
however, produced a significant reduction in growth (P < 0.05, n=3, Figure 
3.23a).
Both concentrations of PD184352 induced significant reductions in ERK1/2 
phosphorylation (P < 0.001, n=3), yet unlike in the TAM-R cells, this reduction 
in ERK 1/2 phosphorylation was not accompanied by a reduction in ERa 
phosphorylation at serine 118 with levels of this phosphorylated protein 
remaining mainly unchanged even following treatment with 10 pM PD184352 
(Figure 3.23b/c). There was no effect of PD184352 on total ERa and ERK1/2 
levels in these cells.
Effects of the IGF-IR inhibitors AG1024 and ADW742 on WT MCF-7 cells 
Growth of WT MCF-7 cells after 7 days was significantly reduced by both 
AG1024 (P < 0.05, n=3) and ADW742 (P < 0.05, n=3) (Figure 3.24a). Western 
blots demonstrate that treatment with either AG1024 or ADW742 significantly 
decreased IGF-IR phosphorylation (P < 0.05, n=3) and ERa phosphorylation at 
serine 118 (P < 0.05, n=3) in this cell line whilst having no effect on total ERa 
and IGF-IR expression (Figure 3.24 b/c).
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Effects of a PI3 kinase inhibitor LY294002 on WT MCF-7 cells
PI3K is an important down stream kinase of the IGF-IR signalling pathway 
therefore its role was investigated in WT cell growth and ERa phosphorylation 
at serine 118.
7 day exposure to LY294002 significantly reduced WT cell growth by 85 +/- 
5% (P < 0.05, n=3; Figure 3.25a). Westerns demonstrate that LY294002 
significantly reduced levels of phosphorylated AKT (P < 0.05, n=3) and ERa at 
serine 118 (P < 0.05, n=3) in WT cells (Figure 3.25 b/c). Interestingly, ERa 
was also significantly reduced in theses cells following treatment with 
LY294002 (P < 0.05, n=3).
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Figure 3.22. Gefitinib (GEF) effects on WT MCF-7 cells
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a: Growth responses of WT MCF-7 cells after 7 days in phenol red-free 
RPMI medium containing 5% charcoal-stripped serum in the absence and 
presence of gefitinib (GEF, 1 and 10 pM) (n=3). b: Western blot analysis of 
total and phosphorylated ERa (SER 118), ERK 1/2 and EGFR expression 
levels in WT MCF-7 cells in the absence and presence of gefitinib (1 and 10 
pM) for 10 minutes. Equal loading demonstrated by equal levels o f total 
proteins, c; Mean densitometry readings (±SEM) of ERa (SER 118), ERK 1/2 
and EGFR phosphorylation in WT cells in the absence and presence of 
gefitinib (1 and 10 pM) (10 minutes). Phosphorylation levels were 
normalised using the respective total protein expression levels (n=3). * = 
P<0.05 compared to control. ** = P<0.01 compared to control
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Figure 3.23. PD184352 (PD) effects on WT MCF-7 cells
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a; Growth responses of WT MCF-7 cells after 7 days in phenol red-free 
RPM1 medium containing 5%  charcoal-stripped serum in the absence and 
presence o f PD184352 (PD184, 1 and 10 pM) (n=3). b; Western blot 
analysis of total and phosphoiylated ERa (SER 118), and ERK1/2 
expression levels in WT MCF-7 cells in the absence and presence of 
PD184352 (1 and 10 pM) for lhour. Equal loading demonstrated by equal 
levels o f total proteins, c: Mean densitometry readings (±SEM) of ERa (SER 
118), and ERK 1/2 phosphorylation in WT cells in the absence and presence 
of PD184352 (1 and 10 pM) (1 hour). Phosphorylation levels were 
normalised using the respective total protein expression levels (n=3). * = 
P<0.05 compared to control. ** = P<0.01 compared to control
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Figure 3 .24. Effects o f the IGF-IR inhibitors 
AG1024 and ADW on WT MCF-7 cells
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a; Growth responses of WT MCF-7 cells after 7 days in phenol red-free 
RPM1 medium containing 5% charcoal-stripped serum in the absence and 
presence of AG1024 (20 pM) or ADW (lOpM) (n=3). b: Western blot 
analysis of total and phosphorylated ERa (SER 118) and IGF-IR expression 
levels in WT MCF-7 cells in the absence and presence o f AG1024 (20 pM) 
or ADW (lOpM) for 24 hours. Equal loading demonstrated by equal levels 
of total protein, c: Mean densitometry readings (+/-SEM) of ERa (SER 118) 
and IGF-IR phosphorylation in WT cells in the absence and presence of 
AG1024 (20 pM) or ADW (lOpM). Phosphorylation levels normalised using 
respective total protein expression levels. * = P<0.05 (significant) compared 
to control.
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Figure 3.25. Effects of the PI3 kinase inhibitor LY294Q02 on
WT MCF-7 cells
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a: Growth responses of WT MCF-7 cells after 7 days in phenol red-free 
RPM1 medium containing 5% charcoal-stripped serum in the absence and 
presence of LY294002 (10 pM) (n=3). _b; Western blot analysis of total and 
phosphorylated ERa (serine 118) and AKT expression levels in WT MCF-7 
cells in the absence and presence of LY294002 (10 pM) for 1 hour. Equal 
loading demonstrated by equal levels of total proteins c; Mean densitometry 
readings (+/- SEM) of ERa (SER 118) and AKT phosphorylation in WT 
cells in the absence and presence o f LY294002 (10 pM) for 1 hour. ERa 
phosphorylation levels were normalised using total ERa protein levels. AKT 
phosphorylation levels normalised to actin. * = P<0.05 (significant) 
compared to control.
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3.11 Cross talk between erowth factor signal transduction pathways and 
ERa at serine 118: effect on transcription at ERE containing reporter 
genes in TAM-R and WT MCF-7 cell lines
Aims
Several pharmacological and mutational studies have demonstrated that 
phosphorylation of ERa at serine 118 can contribute to the transcriptional 
activity of ERa at reporter gene constructs containing EREs within their 
promoter regions (Bunone et al 1996; Joel et al 1995; Kato et al 1995). The 
previous sections have shown that EGFR and IGF-IR signal transduction 
pathways, via ERK1/2, regulate the phosphorylation of ERa at serine 118 in 
TAM-R cells under basal conditions. IGF-R and not EGFR however, was 
shown to regulate ERa phosphorylation at serine 118 in the WT cells under 
basal conditions. The aim of this section, therefore, is to elucidate whether the 
cross talk between growth factor receptor signalling pathways and ERa at 
serine 118 effects ER function at ERE dependent reporter genes in TAM-R and 
WT MCF-7 cells.
Results
Transfection efficiency of reporter gene plasmids in WT and TAM-R cells 
An estimate of the transfection efficiency of WT and TAM-R cells was 
required in order to normalise any results from subsequent comparative 
investigations between the two cell lines. A higher proportion of the WT cells 
were successfully transfected with the plasmid containing the P-galactosidase
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gene (blue stained cells), in comparison with transfected TAM-R cells (Figure 
3.26a). A quantitative difference in transfection efficiency was shown to exists 
between the two cell lines by counting the percentage of transfected (blue 
stained) cells compared to unstained cells. The p-Galactosidase assay shows 
that the transfection efficiency of TAM-R cells is approximately 30% that of 
WT cells (Figure 3.26b).
Level of transcriptional activity at ERE containing reporter genes transiently 
transfected into WT and TAM-R cells.
Basal ERE-dependent luciferase activity was approximately 85% lower in 
TAM-R cells than in the WT cells (P < 0.05, n=7; Figure 3.27a). However, 
following normalisation according to the relative transfection efficiency of the 
cells, basal ERE dependent luciferase activity in TAM-R cells was seen to be 
approximately 50% of basal WT ERE activity (P < 0.05, n=7) (Figure 3.27b).
Pharmacological modulation of ERE activity in TAM-R cells 
Significantly, while ERE activity in TAM-R cells is strongly enhanced by 
oestradiol (P > 0.05, n =3) and reduced by fulvestrant (P < 0.05, n =3; Figure 
3.28) it is also influenced by modulators of EGFR and ERK1/2, correlating 
with their effects on ERa phosphorylation at serine 118 (Figure 3.29). Thus 
EGF significantly increased ERE activity in TAM-R cells (P < 0.05, n=3), 
while basal ERE activity was inhibited by both gefitinib (P < 0.05, n=3) and 
PD184352 (P < 0.05, n=3) in this cell line. Similarly, ERE activity in TAM-R 
cells was also shown to be under the regulation of the IGF-IR signalling
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pathway (Figure 3.30), with IGF-II, but not IGF-I, significantly increasing ERE 
activity in the TAM-R cells (P < 0.05, n=3). Interestingly, TAM-R cells treated 
with AG1024 for 24 hours at 20pM demonstrated an approximate 25 % 
reduction in basal ERE activity although this did not reach statistical 
significance.
Pharmacological modulation of ERE activity in WT cells.
As previously observed by Hutcheson et al 2003 ERE activity in WT cells was 
regulated by ERa, with oestradiol significantly increasing ERE activity (P < 
0.05, n=3) and basal ERE activity being reduced by approximately 30% 
following treatment of this cell line with fulvestrant. Correlating with ERa 
phosphorylation at serine 118, inhibition of the EGFR/ERK1/2 signalling 
pathway had no effect on ERE activity, whilst EGF significantly enhanced 
ERE activity in the WT cell line (P < 0.05, n=3; Figure 3.32). Further 
correlations between ERa phosphorylation at serine 118 and ERE activity were 
also observed following regulation of IGF-IR signalling in WT cells. IGF-I and 
IGF-II significantly increased ERE activity (P < 0.001, n=3 for both ligands), 
whilst AG1024 significantly reduced basal ERE activity in WT cells (P < 
0.001, n=3; Figure 3.33).
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Figure 3.26. ft-Galactosidase cell staining assay to measure
transfection efficiency in WT and TAM-R cells
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Figure 3.27. Luciferase reporter gene assay to measure
ERE activity in WT and TAM-R cells.
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Mean (± SEM) ERE activity in TAM-R cells relative to WT cells prior to (a) 
and following (b) normalisation to relative transfection efficiency. This data 
is representative of 3 separate experiments. * P<0.05 compared to control.
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Figure 3.28. Effects of ER ligands on ER transcriptional
activity in TAM-R cells.
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Mean (± SEM) ERE activity in TAM-R cells in the absence and presence of 
either 100 nM Fulvestrant or 1 nM oestradiol for 24 hours (n=3). The data 
was normalised to the control ERE activity. * P<0.05 compared to control.
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Figure 3.29. Effect of EGFR ligands on ER
transcriptional activity in TAM-R cells
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either lpM gefitinib 24hrs (TAM-R GEF), 10pM PD 184352 24hrs (TAM-R 
PD) or lOng/ml EGF for 6hrs (TAM-R EGF) (n=3). The data was normalised 
to the control ERE activity. * P<0.05 compared to control.
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Figure 3.30. Effect of IGF-IR ligands on ER transcriptional activity
in TAM-R cells
200
180
TAM-R TAM-R TAM-R TAM-R
C AG IGF-I IGF-n
(20fiM) (30ng/ml) (30ng/ml)
Mean (± SEM) ERE activity in the absence and presence of either 20 pM 
AG1024 for 24 hrs or 30ng/ml IGF-I/IGF-II for 6hrs. The data was 
normalised to the control ERE activity. * P<0.05 compared to control.
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Figure 3.31. Effects of ER ligands on ER transcriptional
activity in WT cells
coou-iO
<L>
f
C
2V
O h
OS
c<3
>
1
Mean (± SEM) ERE activity in WT cells in the absence and presence of 
either 100 nM Fulvestrant (WT FUL) or 1 nM oestradiol for 24 hrs (TAM-R 
E2) (n=3). The data was normalised to the control ERE activity. * P<0.05 
compared to control.
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Figure 3.32. Effects of EGFR ligands on ER transcriptional activity
in WT cells
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Mean (± SEM) ERE activity in WT cells in the absence and presence of 
either lpM gefitinib for 24hrs, lOpM PD184352 for 24 hrs or lOng/ml EGF 
for 6hrs (n=3). The data was normalised to the control ERE activity. * P < 
0.05 compared to control.
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Figure 3.33. Effects of the IGF-IR ligands on ER transcriptional
activity in WT cells
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Mean (± SEM) ERE activity in WT cells in the absence and presence of 
either 20pM AG1024 for 24 hrs, or 30ng/ml IGF-I/IGF-II for 6hrs (n=3). 
The data was normalised to the control ERE activity. ** P 0 .0 0 1  compared 
to control.
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3.12 Pharmacological modulation of response elements other than ERE in
transfected TAM-R and WT cells
Aims
ER is known to interact with an array of additional transcription factors bound 
to their respective response elements (Kushner et al 2000). This is termed non- 
classical ER transcription and in part explains how ER can influence the 
expression genes deficient of EREs in their promoter region. The aim of this 
section therefore was to identify whether any potential non-classical ER 
transcriptional events occur in TAM-R cells and WT cell lines and whether 
ERa phosphorylation at serine 118 plays a role in such events.
Results
Level of transcriptional activity at the API dependent luciferase reporter gene 
in TAM-R and WT cells
The data shown in figure 3.34a illustrates that, after normalisation to the 
relative transfection efficiency of the cells, basal API-dependent luciferase 
activity was almost doubled in the TAM-R cells compared to the WT cell line.
Effect of EGFR activity modulators on API activity in TAM-R and WT cells 
AP-1 activity in TAM-R and WT cells showed some correlations with ERa 
phosphorylation at serine 118. Figure 3.34b and c shows that EGF was a potent 
stimulator of AP-1 activity in TAM-R and WT cells and while gefitinib and 
PD184352 lacked inhibitory effects in WT cells, gefitinib showed some 
inhibitory activity in TAM-R cells consistent with the high levels of EGFR
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signalling in this cell type. The 12-0-tetradecanoyl-phorbol 13-acetate (TPA) 
positive control was less effective than EGF at increasing API dependent 
transcription. Interestingly however, EGFR modulation of AP-1 activity 
appears independent of non-classical ER events and hence ERa 
phosphorylation, as fulvestrant showed no inhibitory effects on AP-1 activity 
in TAM-R or WT cells in the presence or absence of EGF (Figure 3.34 b/c).
Level of transcriptional activity at the SRE dependent luciferase reporter gene 
in TAM-R and WT cells
Figure 3.35a revealed that, after normalisation to the relative transfection 
efficiency of the cells, basal SRE-dependent luciferase activity was 
approximately 6 times greater in TAM-R cells than it was in the WT cell line.
Effect of EGFR activity modulators on SRE activity in TAM-R and WT cells 
Figure 3.35 shows that EGFR signalling is a modulator of SRE activity in 
TAM-R cells. Thus EGF stimulates, while gefitinib and PD184352 inhibits 
SRE activity in this cell type. The results contrast with those obtained in WT 
cells where EGF, gefitinib and PD184352 are largely without effect. 
Importantly, as with the AP-1 response element, fulvestrant was unable to 
reduce SRE activity in TAM-R cells in the presence or absence of EGF (Figure 
3.35).
The importance of non-classical ERa transcriptional activity in TAM-R cells 
on a variety of other reporter gene constructs containing response elements to 
heat shock (HSE), NFkB, Glucocorticoid (GRE) and cAMP (CRE) were also
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investigated. Again however, fulvestrant had no effect on the basal activity of 
these response elements (not illustrated). Clearly ERa and hence ERa 
phosphorylation at serine 118 appears less significant to the transcriptional 
activity of these additional response elements. The remaining studies therefore 
focussed on ERE containing genes.
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Figure 3.34. Effects of EGFR activity modulators on AP-1
activity in TAM-R and WT cells
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a. API activity in TAM-R cells relative to WT cells following their normalisation 
with transfection efficiency. Level of API activity in b) WT and c) TAM-R cells 
following treatment with either 100 nM Fulvestrant, 10 ng/ml EGF, 1 pM Gefitinib, 
10 |iM PD 184352 or 1 pM TP A. The data was normalised to the control ERE 
activity (n=l).
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Figure 3.35. Effects of EGFR activity modulators on SRE activity in
TAM-R and WT cells
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a. SRE activity in TAM-R cells relative to WT cells following their 
normalisation with transfection efficiency. Level of SRE activity in b) WT 
and c) TAM-R cells following treatment with either 100 nM Fulvestrant, 10 
ng/ml EGF, 1 gM Gefitinib, 10 gM PD184352 or 5% FCS. The data was 
normalised to the control ERE activity (n=l).
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3.13 ERg and protein-protein interactions with nuclear receptor co-
regulators in the WT and TAM-R MCF-7 cell lines.
Aim
The aim of this section was to develop an immunoprecipitation (IP) assay 
capable of detecting protein-protein interactions between ERa and co- 
regulators. Such an assay can therefore potentially elucidate whether 
EGFR/ERK1/2 modulation over ERE activity in TAM-R cells was directly 
related to co-regulator recruitment.
Results
WT cells were initially used for assay development due to sample availability. 
A host of co-regulators were shown to co-immunoprecipitate with ERa in the 
WT cell line including p68 RNA helicase, SRC1, SRC3, CBP and RNA 
polymerase II (Figure 3.37). These proteins also co-immunoprecipitated with 
total ERa and ERa phosphorylated at serine 118 in the TAM-R cells. More 
extensive studies in the TAM-R cell line demonstrated that further proteins 
including SRC2, NCoR and SMRT co-immunoprecipitated with total and 
phospho-ERa in these cells. ERa and p68 were not co-immunoprecipitated 
from the ER negative DU145 cell line (Figure 3.37).
Optimisation of the IP assay allowed investigations to demonstrate that total 
ERK1/2 and ERa interacted directly in TAM-R cells and this interaction was 
inhibited in the presence of PD184352 (Figure 3.38).
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Figure 3.36. Immunoprecipitation studies demonstrate that
ERa interacts with several co-regulator proteins in the WT
cell line.
WT cell lysate immimoprecipitated for; ERa, p68 RNA helicase, SRC1, SRC3, 
CBP, RNA pol n. Each immunoprecipitate run on gel in separate lanes and blot 
incubated in total ERa primary antibody.
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Figure 3.37. Immunoprecipitation studies demonstrate that ERa
interacts with several co-regulator proteins in the TAM-R cell line.
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TAM-R cell lysate immunopreciptated for, ERa, p68 RNA helicase, SRC1, 
SRC2, SRC3, CBP, RNA pol II, NCoR or SMRT. DU-145 cell lysate 
immimoprecipitated for ERa or p68 RNA helicase. Each immunoprecipitate 
run on gel in separate lanes. Western blots incubated in either total ERa or 
pERaSERl 18 primary antibody.
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Figure 3.38. Immunoprecipitation studies demonstrate that the
interaction between ERK1/2 and ERa is dependent on ERK1/2
activity in the TAM-R cell line.
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a: Western blot analysis and b: Densitometry values (expressed as mean ± 
SEM) of total ERK1/2 expression following immunoprecipitation with total 
ERa in TAM-R cells treated with either PD184352 (lOpM) or appropriate 
vehicle control for 1 hour (n=2). Densitometry values were normalised to 
Ponceau S staining of IP antibody to account for possible errors in sample 
loading.
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3.14 ERa phosphorylation at serine 118 and recruitment of nuclear
receptor co-activators in TAM-R MCF-7 cell lines
Aims
ER phosphorylation has been directly linked with the recruitment of nuclear 
receptor co-activators including p68 RNA helicase and the SRC family 
members, resulting in enhanced transcriptional activity of the receptor (Endoh 
et al 1999; Tremblay et al 1999; Dutertre and Smith 2003; Watanabe et al 
2003). Others however, have shown that nuclear receptor interactions with co- 
regulators are dependent on phosphorylation of the co-regulators themselves at 
specific serine residues (Rowan et al 2000; Wu et al 2004). The aim of this 
section is to determine whether some of the protein-protein interactions 
between ERa and co-regulators in the TAM-R cells were dependent on EGFR 
signalling activity and if so whether ER phosphorylation or co-regulator 
phosphorylation were responsible. Such studies may explain how EGFR 
mediates ERE activity in the TAM-R cells.
Results
The nuclear receptor co-activator p68 RNA helicase associates with ERa in an 
AF-1 dependent/AF-2 independent manner (Endoh et al 1999). In support of 
these findings and correlating with ERa phosphorylation at serine 118, 
modulation of EGFR in the TAM-R cells directly influenced recruitment of 
p68 to ERa, as gefitinib strongly decreased, while EGF strongly increased the 
ERa-p68 RNA helicase interaction (Figure 3.39). Interestingly the level of
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phosphorylation at the serine residues of p68 RNA helicase were unchanged 
between treatment arms. Gel loading was equal as shown by the level of 
ponceau S stained antibody (Figure 3.39).
The interaction between ERa and SRC1 was also dependent on EGFR activity 
in TAM-R cells as gefitinib strongly decreased, while EGF strongly increased 
the ERa-SRCl interaction (Figure 3.40). The level of phosphorylation at the 
serine residues of SRC1, however, again remained unchanged by EGFR 
signalling activity modulation. Ponceau S staining of the blot demonstrated 
equal sample loading (Figure 3.40)
The interaction between ERa and SRC3 was not as dependent on the EGFR 
activity in the TAM-R cell line as the interaction between ERa and p68 or 
SRC1. Gefitinib decreased the interaction between these proteins in TAM-R 
cells by approximately 20%, whilst EGF showed no effect. Interestingly the 
level of phosphorylation on the serine residues of SRC3 decreased dramatically 
in TAM-R cells treated with gefitinib, while EGF clearly increased SRC3 
serine phosphorylation. Gel loading was equal as shown by the level of 
ponceau S staining of the blot (Figure 3.41).
Growth factor signalling pathways are also reported to mediate the interaction 
between co-repressors and ERa in tamoxifen treated breast cancer cells 
(Carroll et al 2003), therefore, regulation of SMRT/ERa interactions by EGFR 
signalling activity was also investigated in TAM-R cells. Gefitinib and EGF 
had no effect on SMRT association with ERa (Figure 3.42), furthermore, the
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level of phosphorylation on the serine residues of SMRT were unchanged 
following treatment with these agents. Gel loading was equal as shown by the 
level of ponceau S staining of the blot (Figure 3.42).
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Figure 3 .39. EGF-R signalling regulates the level of interaction 
between ERa and the transcriptional coregulator p68 RNA
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a: Western blot analysis and of total ERa and phospho-serine expression 
following immunoprecipitation with p68 RNA helicase in TAM-R cells 
treated with either gefitinb (1 pM), EGF (10 ng/ml) or ethanol control, b: 
Densitometry values (expressed as mean ± SEM) of total ERa expression 
following immunoprecipitation with p68 RNA helicase in TAM-R cells 
treated with either gefitinb, EGF or ethanol control (n=2). Values were 
normalised to Ponceau S staining of IP antibody to account for possible 
errors in sample loading.
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Figure 3.40. EGF-R signalling regulates the level of interaction
between ER and the transcriptional coregulator SRC 1
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a: Western blot analysis and o f total ERa and phospho-serine expression 
following immunoprecipitation with SRC1 in TAM-R cells treated with 
either gefitinb (1 pM), EGF (10 ng/ml) or ethanol control, b: Densitometry 
values (expressed as mean ± SEM) o f total ERa expression following  
immunoprecipitation with SRC1 in TAM-R cells treated with either gefitinb, 
EGF or ethanol control (n=2). Values were normalised to Ponceau S staining 
o f  IP antibody to account for possible errors in sample loading
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Figure 3.41. Effect of EGF-R signalling on the interaction
between ERa and the transcriptional co-regulator SRC3
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a: Western blot analysis and of total ERa and phospho-serine expression 
following immunoprecipitation with SRC3 in TAM-R cells treated with 
either gefitinb (1 pM), EGF (10 ng/ml) or ethanol control, b: Densitometry 
values (expressed as mean ± SEM) of total ERa expression following 
immunoprecipitation with SRC3 in TAM-R cells treated with either gefitinb, 
EGF or ethanol control (n=2). Values were normalised to Ponceau S staining 
o f IP antibody to account for possible errors in sample loading
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Figure 3.42. EGF-R signalling does not regulate the level of
interaction between ER and the transcriptional coregulator SMRT
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a: Western blot analysis and of total ERa and phospho-serine expression 
following immunoprecipitation with SMRT in TAM-R cells treated with 
either gefitinb (1 pM), EGF (10 ng/ml) or ethanol control, b: Densitometry 
values (expressed as mean ± SEM) of total ERa expression following 
immunoprecipitation with SMRT in TAM-R cells treated with either 
gefitinb, EGF or ethanol control (n=2). Values were normalised to Ponceau S 
staining of IP antibody to account for possible errors in sample loading.
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3.15: ERa phosphorylation at serine 118 and effects on transcriptional 
regulation of endogenous oestrogen dependent genes in TAM-R and WT 
MCF-7 cell lines
Aim
The aim of this section was to parallel the Luciferase assay findings and 
investigate whether transcriptional activity at the endogenous oestrogen/ERE 
dependent gene, pS2, correlated with ERa phosphorylation at serine 118 in the 
TAM-R and WT cells following modulation of EGFR/ERK1/2 signalling 
activity.
Results
pS2 mRNA levels were approximately equal in WT and TAM-R cells under 
basal conditions (Figure 3.43a/b). In agreement with the ERE luciferase assay 
findings ER functionality continued in the TAM-R cells as oestradiol 
significantly increased (P < 0.001, n=3; figure 3.43c/d), whilst fulvestrant 
significantly decreased (P < 0.005, n=3; figure 3.43c/d) pS2 mRNA in both cell 
lines.
EGF induced significant increases (P < 0.05, n=3; Figure 3.44) in pS2 mRNA 
in TAM-R and WT MCF-7 cells correlating with ERE activity and ERa 
phosphorylation at serine 118. Furthermore, Fulvestrant was shown to 
significantly inhibit these EGF-induced increases in pS2 mRNA (P < 0.05, 
n=3; figure 3.44). Gefitinib and PD184352 significantly reduced pS2 mRNA 
levels in the TAM-R cells (P < 0.05, n=3 for both; figure 3.45c) whilst having
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no significant effects in the WT cells (figure 3.45b), again correlating with 
ERa phosphorylation at serine 118 and ERE luciferase transcriptional activity 
in these cell lines.
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Figure 3.43. Modulation of pS2 mRNA levels in WT and
TAM-R MCF-7 cells
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a. pS2 mRNA expression levels in WT and TAM-R cells in the absence and 
presence of either 100 nM Fulvestrant or 1 nM oestradiol. P-actin was used 
as an internal control. Densitimetry values for pS2 mRNA levels in WT vs 
TAM-R cells either b. under basal growth conditions or a  in the absence 
and presence of either 100 nM fulvestrant or 1 nM oestradiol following 
normalisation to P-actin levels (n=3). * P<0.05 compared to control. ** 
P<0.01 compared to control.
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Figure 3.44. Modulation of pS2 mRNA levels in WT and TAM-
R MCF-7 cells
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a. RT-PCR analysis and tx Densitometry values o f pS2 mRNA expression 
levels in WT and TAM-R cells in the absence and presence of either 100 nM 
fulvestrant (FUL), 10 ng/ml EGF or a combination of the two agents. P-actin 
was used as an internal control, b. Densitimetry values were normalised to (3- 
actin levels (n=3). * P<0.05 compared to control, f  P<0.05 compared to 
EGF.
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Figure 3.45. Modulation of PS2 mRNA levels in WT and TAM-R
MCF-7 cells
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a. RT-PCR analysis and Densitometry values of pS2 mRNA expression 
levels in WT and TAM-R cells in the absence and presence of either 1 gM 
gefitinib for 1 hour (GEF) or lOpM PD184352 (PD184). p-actin was used 
as an internal control, b. Densitimetry values were normalised to p-actin 
levels (n=3). * P<0.05 compared to control.
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3.16 ER regulation of EGFR ligands in TAM-R and WT cell lines
Aim
EGFR signalling activity is dependent on a functional ER in TAM-R cells 
under basal conditions as fulvestrant significantly inhibits EGFR/ERK1/2 
phosphorylation (Hutcheson et al 2003). Early findings showed that TGFa 
expression levels were also decreased by fulvestrant, whilst total 
EGFR/ERK1/2 expression levels remained unchanged, suggesting that ER 
regulation of EGFR activity was mediated through transcriptional regulation of 
EGFR ligands (Hutcheson et al 2003). The aim of this section was to 
investigate the effects of fulvestrant on EGFR ligands in TAM-R cells more 
extensively and study whether EGFR/ERK1/2 dependent phosphorylation at 
serine 118 influences ER-mediated transcription of these ligands.
Results
Of the EGFR ligands examined only epiregulin and amphiregulin (AR) 
appeared to be under obvious ER regulation. Epiregulin mRNA levels were 
significantly reduced by fulvestrant in TAM-R (P < 0.05, n=3) and WT cells (P 
< 0.05, n=3; Figure 3.46). Fulvestrant also significantly reduced AR mRNA 
levels in the two cell lines (P < 0.05, n=3 for both cell lines; Figure 3.47). 
TGFa levels appeared to be modulated in WT and TAM-R cells, albeity 
weakly, by fulvestrant however this was not found to be significant. 
Significance may be reached with further repeat experiments to increase the n 
value that used in the Hutcheson et al study (n=7). Similarly there was no
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significant effect of fulvestrant on either EGF, HB-EGF or (3-cellulin mRNA 
expression in the two cell lines (Figure 3.46). Only amphiregulin showed 
significantly raised levels of mRNA in the TAM-R compared to WT cells (P < 
0.05, n=3; Figure 3.47), correlating with the elevated EGFR/ERK1/2 signalling 
activity observed previously in this cell line. Oestradiol also significantly 
increased amphiregulin transcription in the TAM-R and WT cell lines (P < 
0.05, n=3 for both cell lines; figure 3.47) confirming ER-dependent 
transcription of this gene.
EGF induced significant increases in amphiregulin mRNA in the TAM-R and 
WT cell lines (P < 0.05, n=3 for both cell lines; Figure 3.48) correlating with 
ERE activity and ERa phosphorylation at serine 118. Furthermore fulvestrant 
significantly inhibited the EGF induced increases in both cell lines (P < 0.05, 
n=3; Figure 3.48).
Gefitinib (P < 0.05, n=3; figure 3.49) and PD184352 (P < 0.05, n=3; figure 
3.49) significantly reduced basal amphiregulin mRNA levels in the TAM-R 
cells, whilst showing no effect in the WT cells, again correlating with ERE 
activity and ERa phosphorylation at serine 118 in these two cell lines (Britton 
et al 2005). AG1024 also induced a reduction in basal amphiregulin mRNA 
expression in TAM-R cells, however, this was not found to be statistically 
significant (Figure 3.49). Interestingly, AG1024 showed no significant effects 
on amphiregulin mRNA levels in the WT cells (figure 3.49).
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Figure 3 .46. ERa regulation of EGFR ligand mRNA levels in WT
and TAM-R MCF-7 cells
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a  RT-PCR analysis and b. Densitometry values for epiregulin, EGF, TGFa, 
HB-EGF and P-cellulin mRNA expression in WT and TAM-R cells either in 
the absence or presence of 100 nM fulvestrant for 7 days (n=3). p-actin was 
used as an internal control in RT-PCR studies and densitometry values were 
normalised to P-actin levels to take account of any errors in sample loading. 
* P<0.05 compared to control.
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Figure 3 .47. Modulation of Amphiregulin mRNA levels in WT and
TAM-R MCF-7 cells
WT WT WT TAM-R TAM-R TAM-R
C FUL E, C FUL E,
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P-actin
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a, RT-PCR analysis o f amphiregulin mRNA expression in WT and TAM-R 
cells in the absence and presence of either 100 nM fulvestrant or 1 nM 
oestradiol for 7 days, p-actin was used as an internal control, b. 
Densitometry values for amphiregulin mRNA expression under basal growth 
conditions in WT and TAM-R cells, c. Densitometry values for 
amphiregulin mRNA expression in WT and TAM-R cells in the absence and 
presence of either 100 nM fulvestrant or 1 nM oestradiol for 7 days (n=3). 
All densitometry values were normalised to P-actin levels to take account of 
any errors in sample loading. * P<0.05 compared to control.
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Figure 3 .48. Modulation of Amphiregulin mRNA levels in WT
and TAM-R MCF-7 cells
WT TAM-R TAM R TAM R TAM-R 
EGF/ C FUL EGF EGF/ 
FUL FUL
Amphiregulin
p-actin
TAM-R TAM-R TAM-R TAM-R 
C FUL EGF EGF/ 
FUL
WT
EGF/
FUL
RT-PCR analysis and b. Densitometry values for amphiregulin mRNA 
expression in WT and TAM-R cells in the absence and presence of either 
100 nM fulvestrant (FUL), 10 ng/ml EGF or a combination of the two agents 
for 7 days (n=3). P-actin was used as an internal control in RT-PCR studies 
and densitometry values were normalised to p-actin levels to take account of 
any errors in sample loading. * P<0.05 compared to control.
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Figure 3 .49. Modulation of Amphiregulin mRNA levels in WT and
TAM-R MCF-7 cells
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a, RT-PCR analysis and b. Densitometry values for amphiregulin mRNA 
expression in WT and TAM-R cells in the absence and presence of either (i) 
lpM  gefitinib (GEF) for 1 hour, (ii) 10 pM PD184352 (PD184) for 4 hours 
or (iii) 20 pM AG1024 for 24 hours (n=3). P-actin was used as an internal 
control in RT-PCR studies and densitometry values were normalised to P- 
actin levels to take account of any errors in sample loading. * PO .05  
compared to control.
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3.17 Interaction between ERa and the Amphiregulin promoter in TAM-R
cells
Aims
The data suggests that EGFR/ERK1/2 signal transduction pathway may 
regulate amphiregulin transcription in TAM-R cells by modulating ERa 
phosphorylation at serine 118 and therefore transcriptional activity at ERE 
dependent genes. The aim of this section was to use the Chromatin 
Immunoprecipitation (ChIP) technique to examine whether ERa interacts with 
potential EREs identified within the putative amphiregulin promoter, thereby 
providing supporting evidence that amphiregulin transcription in the TAM-R 
cells may depend on this cross talk between the EGFR and ERa signalling 
pathways.
CHIP assay development
The Active Motif ChlP-IT kit used in this procedure contained an internal 
control test ensuring low background staining and high specificity. Low 
background was demonstrated following ChIP using antibodies to ERa and 
TFEOB with signals of similar intensity to the negative control being generated 
following PCR with the negative control primer (Figure 3.50a). As expected 
the negative control primer produced a strong signal in the presence of total 
DNA following PCR (Figure 3.50a). High specificity of the assay was 
demonstrated as ChIP using the TFITB antibody produced a signal of greater 
intensity than ChIP with ERa or negative control antibodies following PCR in
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the presence of a GAPDH primer (Figure 3.50b). Once again, as expected, the 
GAPDH primer produced a strong signal in the presence of total DNA 
following PCR.
The Alibaba 2.1 transcription factor binding software identified 5 potential 
ERE’s within a 600bp region (Accession number: AY442340 or Gene 
identifier: gi|37953278, nucleotides 671 to 1270) of the amphiregulin gene 
promoter. Three primer pairs were designed by the Primer 3 design software to 
encompass this ERE rich region then run on the NCBI nucleotide-nucleotide 
blast programme to confirm their specificity to the amphiregulin gene promoter 
region. Initially the ability of each primer pair to bind efficiency to total DNA 
was assessed. Only primer pairs 2 and 3 produced signals, therefore primer 1 
was excluded from further studies (Figure 3.50c).
Efficiency of the primers to associate to DNA ChlP’ed with the total ERa 
antibody was then tested. Primer 3 was found to be incapable of producing a 
band with ER ChlP’ed DNA in both WT and TAM-R cells and so was also 
excluded from future studies (Figure 3.50d).
Results
Primer 2 produced a signal, following a PCR reaction, in the presence of DNA 
ChlP’ed using the ERa antibody in both oestradiol treated WT cells and 
control TAM-R cells, suggesting that ERa may associate to this region of the 
amphiregulin gene promoter in these two cell lines under these conditions 
(Figure 3.51a and b). The data in control (untreated) WT cells suggests that ER 
association with this putative ERE within the AR promoter is non-specific in
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untreated WT cells but specific in the WT cells treated with oestradiol as there 
is a clear difference in the intensity of the signal between ER ChIP and -ve 
control in the oestradiol treated WT cells, which was not so evident in the 
untreated WT cells. The high signal from the negative control in the untreated 
WT cells suggests high non-specific binding between the primer and ChlP’ed 
DNA from the ER ChIP sample.
TAM-R cells showed a significant difference in intensity of the primer 2 band 
between the -ve control sample and the ER ChIP sample, suggesting that ERa 
has a highly specific affinity for this ERE rich region of the amphiregulin 
promoter in TAM-R cells (P < 0.001, n=6; figure 3.51a/b).
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Figure 3.50. ChIP assay development
+ ve -ve ER TFIIB
control control ChDP ChIP
-ve pnmer
+ ve -ve ER
control control ChIP
■ GAPDH primer
Primer 1 Primer 2 Primer 3
+ve control 
(TAM-R)
Primer 3
+ ve - ve ER + ve - ve ER 
control control ChIP control control ChIP
Primer 3
+ ve - ve ER 
control control ChIP
WT (- E,)
V -------------
WT (+ E,) TAM-R (- E?)
a. Negative control primers flank region of genomic DNA containing no 
binding sites for transcription factors. PCR product is 174 bp long, b, 
GAPDH primers flank the TFIIB site (positive control) of the constitutively 
active GAPDH promoter. Samples in a. and b. include total DNA (+ve 
control), IgG antibody ChIP (-ve control), ERa antibody ChIP and the TFIIB 
antibody ChIP. c. Binding efficiencies of primers 1, 2 and 3 to total DNA 
(+ve control), d  Binding efficiency o f primer 3; in +ve control, -ve control 
and DNA ChlP’ed using ER Ab (ER ChIP). Samples were obtained from 
WT and TAM-R control cells in the absence of oestradiol (-E2), or WT cells 
in the presence of oestradiol (+E2).
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Figure 3.51. ERa binds to the promoter region of the
Amphiregulin gene in TAM-R and WT cells
Primer 2 Primer 2
+ ve - ve ER + ve - ve ER + ve - ve ER
control control ChIP control control ChIP control control ChIP
WT (- E2) WT (+ E^ TAM-R (- E2)
b: Primer 2 
* *
+ ve - ve ER 
control control ChIP
Binding efficiency of primer 2; in +ve control, -ve control and ER ChIP. 
Samples were obtained from WT and TAM-R cells in the absence of 
oestradiol (-E2) or WT cells in the presence of oestradiol (+E2). fr Level o f  
interaction between primer 2 and the +ve control, -ve control and DNA 
ChlP’ed with ER Ab from TAM-R cells. * = P<0.005 compared to ER chip 
sample. ** = P<0.001 compared to ER chip sample
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3.18 Effect of Amphiregulin on EGFR/ERK1/2 activity and ERa
phosphorylation at serine 118 in TAM-R cells.
Aim
The data suggests that ER regulation over EGFR signalling activity in TAM-R 
cells, as observed previously by Hutcheson et al 2003, was a consequence of 
ER-dependent transcription at the amphiregulin gene. Neutralising antibodies 
to several EGFR ligands which sequester the target growth factor were used to 
confirm the role of amphiregulin.
Results
Amphiregulin neutralising antibodies clearly reduced levels of phosphorylated 
EGFR, ERK1/2 and ERa at serine 118 in TAM-R cells in a concentration- 
dependent manner (n=2; Figure 3.52). There was no effect of amphiregulin 
neutralising antibodies on total EGFR, ERK1/2 and ERa protein expression 
levels. Unlike the amphiregulin neutralising antibody, TGFa, EGF and HB- 
EGF neutralising antibodies were ineffective at reducing the level of EGFR 
phosphorylation on two separate occasions.
Further confirmation of the effects of amphiregulin on TAM-R cells were 
demonstrated in figure 3.53 as amphiregulin greatly increased the level of 
phosphorylated EGFR, ERK1/2 and ERa at serine 118 in a concentration- 
dependent manner. There was again no effect of amphiregulin treatment on 
total EGFR, ERK1/2 and ERa expression.
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Figure 3.52. Amphiregulin neutralising antibody reduces ERa 
phosphorylation at serine 118 in the TAM-R cell line
p-ERa 
SERI 18
TAM-R TAM-R TAM-R 
C Amph Ab Amph Ab 
10ug/ml 20ug/ml
<
Total ERa
Phospho-
ERK1/2
Total ERK1/2
Phosph-
EGFR
Total EGFR
Phospho-
EGFR
TAM-R TAM-R TAM-R TAM-R 
C TGFa Ab TGFa Ab TGFa Ab 
lpg/ml 2.5pg/ml 5fig/ml
Total EGFR
Phospho-
EGFR
Total EGFR
TAM-R TAM-R 
C EGF Ab
lpg/ml
TAM-R TAM-R 
EGF Ab EGF Ab 
lOpg/ml
Phospho-
EGFR
TAM-R TAM-R TAM-R TAM-R TAM-R
C HB-EGF HB-EGF HB-EGF HB-EGF
Ab Ab Ab Ab
lpg/ml lOpg/ml 20pg/ml 30pg/ml
Total EGFR
Western analysis o f a  EGFR/ERK1/2 phosphorylation and ERa 
phosphorylation at serine 118 in TAM-R cells either in the absence or 
presence o f increasing concentrations of amphiregulin neutralising antibody 
for 1 hour (n=2), and b. c. d. EGFR phosphorylation in TAM-R cells in the 
absence or presence of increasing concentrations of either TGFa, EGF or 
HB-EGF neutralising antibodies for 1 hour (n=2).
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Figure 3.53. Amphiregulin increases the level of ER phosphorylation
at serine 118 in TAM-R cells
p-ERa 
SERI 18
Total ERa
Phospho-
ERK1/2
Total ERK1/2
TAM-R
C
TAM-R
AMPH
lOng/ml
TAM-R
AMPH
lOOng/ml
Phosho-
EGFR
Total EGFR
Western analysis o f EGFR/ERK1/2 phosphorylation and ERa 
phosphorylation at serine 118 in TAM-R cells in the absence and presence of 
either lOng/ml or lOOng/ml amphiregulin for 10 minutes. Figure is 
representative of two separate experiments.
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3.19 Short term 4-OH-tamoxifen treatment in WT MCF-7 cells and the
effects on ERa phosphorylation at serine 118
Aims
In addition to oestrogen, protein kinase activators and growth factors; anti- 
oestrogens are also known to increase phosphorylation of ERa at a number of 
residues including serine 118 (Ali et al 1993; Katzenellenbogen et al 1995; 
Lahooti et al 1994). This section investigated the short term effects of 
tamoxifen in WT MCF-7 cells to assess the contribution of this antioestrogen 
to the increased ERa phosphorylation at serine 118 observed in TAM-R cells. 
Results
Figure 3.54 demonstrates that 4-OH-tamoxifen significantly increased the level 
of phosphorylation at serine 118 in WT MCF-7 cells after only 10 minutes 
treatment and this level was sustained for four hours. Significantly, however, 
these increases in ERa phosphorylation were not as great as those observed 
earlier between the WT and the TAM-R MCF-7 cell lines under basal growth 
conditions.
ERK1/2 phosphorylation increased but not significantly, whilst AKT 
phosphorylation was unchanged, in WT cells treated with 4-OH-tamoxifen 
(Figure 3.55). Furthermore, neither gefitinib nor PD184352, had any effect on 
the 4-OH-tamoxifen induced increase in ERa phosphorylation at serine 118 
despite significantly inhibiting ERK1/2 phosphorylation (P < 0.05, n=3, Figure
3.55).
Interestingly, the pure anti-oestrogen Fulvestrant, after one hour treatment of 
WT cells, also induced an increase in the level of ERa phosphorylation
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compared to the control. This increase in serine 118 ERa phosphorylation was 
significantly greater than that observed with 4-OH-tamoxifen treatment (P < 
0.001, n=3) despite fulvestrant substantially reducing total ERa levels (Figure
3.55).
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Figure 3.54. Short term Tamoxifen (TAM) effects in WT MCF-7
cells
10 mms 
A
p ERa ser 118
Phospho-
ERK1/2
1 hr
_ A _
4 hrs
Ar ^  r  ^ r \
WT WT WT WT WT WT
C TAM C TAM C TAM
p actin
b
■ c
lOnin lhr 4hr
a; Western blot analysis and Mean densitometry readings (± SEM) of 
western blots demonstrating expression of phosphorylated ERK1/2 and ERa 
at serine 118 in WT MCF-7 cells either in the absence or presence of 
tamoxifen (lOOnM) for 10 mins, lhr and 4hrs (n=3). Equal loading was 
confirmed by consistent expression levels of 3-actin. Densitometry values 
were normalised using the p-actin expression levels. * P<0.05 compared to 
control.
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Figure 3.55. Short term Tamoxifen (TAM) and Fulvestrant (FUL) 
effects in WT MCF-7 cells
WT
TAM
WT WT 
FUL FUL 
TAM
p ERa ■ 
ser 118
Total ERa
Phospho-
AKT
Phospho-
ERK1/2
P-Actin
TAM
i i
TAM PD PDTAM GEF GEF/TAM FUL FUL/TAM
a: Western blot analysis and b. Mean densitometiy readings (± SEM) of 
western blots demonstrating expression of phosphorylated ERK1/2, AKT and 
ERa at serine 118 in WT MCF-7 cells in the absence and presence of either 4- 
OH-tamoxifen (lOOnM, lOminutes, TAM), fulvestrant (lOOnM, 1 hour, FUL), 
gefitinib (I pM, 10 minutes, GEF), PD184352 (10 mM, 1 hour, PD184), a 
combination of either gefitinib or PD 184352 and 4-OH-tamoxifen or a 
combination of fulvestrant and tamoxifen (lOminutes) (n=3). Equal loading 
was confirmed by consistent expression levels o f P-actin. Densitometry values 
were normalised using the P-actin expression levels. * P<0.05 compared to 
control. ** P<0.001 compared to control
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3.20 Long term 4-OH-tamoxifen treatment in WT MCF-7 cells and the
effects on ERa phosphorylation at serine 118 
Aim
As shown above, 4-OH-tamoxifen induced increases in ERa phosphorylation 
within minutes of treatment and this increase was sustained for up to 4 hours. 
Gee et al (2003) demonstrated that no significant decreases in the rate of 
growth of the WT MCF-7 cells were observed in the presence of 4-OH- 
tamoxifen until day seven of treatment and at day 15 the growth curve begins 
to decline. The aim of this section was to study WT cells treated with 4-OH- 
tamoxifen for these longer durations to elucidate the significance of ERa 
phosphorylation at serine 118 in response to 4-OH-tamoxifen on cell growth.
Results
At five days 4-OH-tamoxifen treated MCF-7 cells continued to grow steadily, 
although at a slower rate than the untreated MCF-7 cells (Figure 3.56a). During 
this time the level of ERa phosphorylation at serine 118 remained elevated 
over the untreated cells, whilst ERK1/2 increased only slightly (Figure 3.56b). 
After 14 days there was no further net growth of the 4-OH-tamoxifen-treated 
cells resulting in a significant difference in cell number compared to the control 
cells (P < 0.001, n=3). The decrease in growth rate was accompanied by a 
dramatic drop in ERa and ERK1/2 phosphorylation to almost undetectable 
levels, compared to the 14 day control (n=l).
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Figure 3.56. Long-term Tamoxifen treatments in WT cells
1o
<o
I
3
M
MCF-7 control79
SO
MCF-7 + 
4-OH-TAM
10
« 5 IS IS M 350 10 40
pERa  
SER 118 
Phospho- 
ERK1/2
P-Actin
p ERa 
SER 118 
Phospho- 
ERK1/2
P-Actin
WT
C
V 5
Day
s
► 14
Day
s
Days
■ WT C
a WT TAM 5 days 
D WT TAM 14 days
p ERa Phospho-
SE R 118 ERK1/2
a; Growth responses of WT MCF-7 cells after 7 days in phenol red-free RPMI 
medium containing 5% charcoal-stripped serum in the absence (CON;*) and 
presence of 4-OH-tamoxifen (0.1 pM, A). Results are expressed as mean (± 
SD) of triplicate cell counts (Adapted from Gee et al 2003). b; Western blot 
analysis and a  Mean densitometry readings (± SEM) of phosphorylated 
ERK1/2 and ERa at serine 118 in WT MCF-7 cells in the absence and presence 
of 4-OH-tamoxifen (lOOnM) after 5 or 14 days (n=l). Equal loading was 
confirmed by consistent expression levels of P-actin. Densitometry values were 
normalised to p-actin expression levels. * P<0.001 compared to control
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3.21 Development of Western blot assay measuring ERa phosphorylation
at serine 167
Aim
EGF-induced activation of ERK1/2 reportedly increased ERa phosphorylation 
at serine 167 via ERK1/2 and p90 ribosomal S6 kinase (Lannigan 2003). The 
aim of this section was to investigate whether elevated EGFR/ERK1/2 
signalling in TAM-R cells increases ERa phosphorylation at serine 167 as well 
as at serine 118.
Results
Figure 3.57a demonstrates that the Abeam antibody to ERa phosphorylated at 
serine 167 produced many bands at approximately 67 KDa. The band which 
was positioned closest to 67 KDa was not the strongest of these bands casting 
doubt as to whether the 67KDa band was specific. The remaining experiments 
were used to confirm which band corresponded to ERa. To aid identification of 
the specific band a sample containing protein from TAM-R cells 
immunoprecipitated with the total ERa 1D5 antibody was run along side the 
other samples. The immunoprecipitated sample contained only one band 
around the 67 KDa region but this was slightly up shifted from the band in the 
non-immunoprecipitated samples positioned at exactly 67KDa (Figure 3.57b). 
The same upshift with immunoprecipitated proteins was observed in blots 
probed for ERa phosphorylated at serine 118 and total ERa (Figure 3.58a). 
These blots were used to demonstrate that proteins from immunoprecipitated
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samples are prone to up shift suggesting that the band labelled 67KDa in figure 
3.57b is in fact ERa, despite the immunoprecipitated/non-immunoprecipitated 
bands not being aligned precisely.
Figure 3.58b provides additional evidence that the band labelled 67KDa in 
figure 3.57b is ERa. The samples were all run along side each other in a gel 
and transferred to a nitrocellulose membrane, stained with ponceau S and cut 
down the side of the well containing TAM-R T47D cells. The two membrane 
sections were then probed in antibody to either ERa phosphorylated at serine 
167 or ERa phosphorylated at serine 118. Once reassembled in exactly the 
same position as prior to cutting it became evident that a band was located on 
the ERa serine 167 blot at exactly the same position as the band for ERa 
phosphorylated at serine 118. With closer inspection of the serine 167 blot one 
can see that this band corresponds to the 67KDa band identified earlier on 
figure 3.57b.
Once the band for ERa phosphorylated at serine 167 had been identified it was 
clear that there was no clear difference in the expression of this phosphorylated 
form of the protein between the WT and TAM-R cell line (adding to the reason 
for continuing the more extensive investigations on ERa phosphorylation at 
serine 118 rather than serine 167). The same level of expression of ERa 
phosphorylated at serine 167 was also observed in the MCF-7 cells resistant to 
4-OH-tamoxifen and Gefitinib (TAM/GEF-R MCF-7), yet expression was 
reduced dramatically in the MCF-7 cells resistant to Tamoxifen and Herceptin 
(TAM/HER-R MCF-7). Interestingly, serine 167 phosphorylation was 
detectable in the Fulvestrant resistant MCF-7 cell line (FUL-R MCF-7), but
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was less apparent in the MCF-7 cells resistant to both Fulvestrant and Gefitinib 
(FUL/GEF-R MCF-7). The cells resistant to oestrogen deprivation MCF-7 X) 
showed the greatest level of serine 167 phosphorylation of ERa and high levels 
of this phosphorylated form of ERa was also observed in the WT T47D breast 
cancer cell line. The TAM-R T47D cells showed detectable levels of 
phosphorylation at serine 167 but to a much lesser extent than that observed in 
the WT T47D cells.
Expression levels of ERa phosphorylation at serine 118 across these cell lines 
followed a different pattern to that observed with serine 167 phosphorylation 
levels. Firstly, TAM-R cells expressed considerably greater levels of ERa 
phosphorylated at serine 118 compared to the WT cell line, confirming earlier 
findings. MCF-7 cells resistant to both Tamoxifen and Gefitinib (TAM/GEF-R 
MCF-7) or Tamoxifen and Herceptin (TAM/HER-R MCF-7) or MCF-7 cells 
that have become resistant to oestrogen deprivation (MCF-7 X), showed 
similar levels as the TAM-R cells. The fulvestrant-resistant cell line did not 
express ERa phosphorylated at serine 118, yet interestingly, the MCF-7 cells 
resistant to Fulvestrant and Gefitinib (FUL/GEF-R MCF-7) expressed weak 
levels of phosphorylated serine 118. Expression of ERa phosphorylated at 
serine 118 in the WT and TAM-R T47D cell lines followed the same pattern as 
the WT and TAM-R MCF-7 cells yet this may be attributed to the expression 
level of total ERa as the TAM-R T47 D cells express greater levels of total 
ERa than the WT T47D cell line.
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Figure 3 .57 Development of western blot assay measuring
ERa phosphorylation at serine 167
67KDa
a: ERa phospho-SER 118 and total ERa blots containing protein from EGF 
treated TAM-R cells that were Immunoprecipitated for total ERa Also 
contains protein samples from several different cell lines (as labelled) under 
basal conditions, that were not immuno-precipitated. fr ERa phospho-SER 
167 blot containing protein from EGF treated TAM-R cells that were 
Immunoprecipitated for total ERa Also contains protein samples from 
several different cell lines (as labelled) under basal conditions, that were not 
immuno-precipitated
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3.58 Development of western blot assay measuring ERa
phosphorylation at serine 167
67KDa
67KDa
a; ERa phospho-SER 167 blot containing protein from several different cell lines (as labelled) 
under basal conditions (repeat experiment of figure 28b). h  Western blot cut as indicated. Left 
side of blot contains samples from several different cell lines (as labelled) and incubated in ERa 
phospho-SER 167 antibody. Right side of blot contained TAM-R C sample and was incubated 
in pERaSERl 18 antibody.
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3.22 Two-dimensional gel electrophoresis and MALDI/TOF MS
Aim
This study has utilised the western blot and ICC techniques to investigate the 
phosphorylation status of ERa at the serine 118 residue and ER interacting 
proteins. Such investigations have been time consuming and depended on the 
specificity of all the antibodies used. This post-genomic age provides 
technologies, such as 2D electrophoresis, chromatography and mass 
spectrometry, capable of analysing all potential phosphorylation sites on ER, 
identifying the array of different proteins associated with ER, and the means to 
identify the many splice variants of ER within clinical samples and various cell 
lines under specific growth conditions. The aim of this section was to 
immunoprecipitate ER from TAM-R cells using the 1D5 antibody and carry 
out proteomic techniques to elucidate the full phosphorylation status of ER in 
the TAM-R cells under basal conditions and identify all and potentially novel 
ER interacting proteins.
Results
The coomassie blue stained gel in figure 3.59 illustrates the first attempt of 2D 
gel electrophoresis. Each spot on the gel represents coomassie blue stained 
proteins immunoprecipitated, using the ERa 1D5 antibody (lpg), from TAM-R 
cell lysate (total protein content = lmg). Each numbered spot was excised 
using a sterile scalpel, subjected to in gel digestion, then analysed using a 
Bruker Reflex m  MALDI-TOF mass spectrometer in the reflection mode. The
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Mass spectrometer data were entered into the Mascot search to produce a 
probability based mowse score, which predicts the likelyhood that the analysed 
peptides belong to a specific protein. Results are displayed in Table la and lb. 
The coomassie blue stained gel in figure 3.60 illustrated the second attempt of 
2D gel electrophoresis. Each spot on the gel represented coomassie blue 
stained proteins immunoprecipitated, using the ERa 1D5 antibody (10pg), 
from TAM-R cell lysate (total protein content = lOmg). The gel was re-stained 
with silver stain (figure 3.61) to reveal protein spots lower than lng. Each 
numbered spot was analysed as above. The results are displayed in table 2a and 
2b.
196
Figure 3.59. Coomasie blue stained 2 Dimensional gel containing 
proteins immunoprecipitated. using ERa specific antibody, from
TAM-R cells.
Coomasie blue stained 2D gel containing proteins 
immunoprecipitated, using the ERa 1D5 antibody (lpg), from 
TAM-R cell lysate (total protein content=lmg). Each numbered 
spot represents a protein that has been excised from the gel and 
analysed using MALDI/TOF MS.
/
H |  ' * *
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Table la. Mascot search results from MALDI/TOF mass
spectrometry data, of samples cut from the coomasie stained gel in
figure 3.59
Spot
No.
from
fig
3.59
Protein Accession
number
Mass Protein
Score
Protein
scores
>X
are
significa
nt
1.
2. Olfactory
marker
protein
OMP HUM 
AN
18794 56 X=59
3. T-Cell 
receptor 
delta chain
CAB38241 2190 43 X=59
4. Ras-related
protein
RAB-14
Q9UI11 24110 59 X=59
5. Cytokeratin
8
K2C8 HU 
MAN
53510 236 X=59
6. Cytokeratin
8
K2C8HU
MAN
53510 130 X=59
7. Cytokeratin
8
K2C8 HU 
MAN
53510 183 X=59
8. Cytokeratin
8
K2C8 HU 
MAN
53510 152 X=59
9. Cytokeratin
8
K2C8 HU 
MAN
53510 99 X=59
10. Cytokeratin
18
K1CR HU 
MAN
47897 192 X=59
Identity of proteins excised from the gel (numbered spots 1-10, Figure 3.59) 
and analysed by MALDI/TOF mass spectrometry. The protein score is - 
10*Log(P), where P is the probability that the observed match is a 
random event.
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Table lb. Mascot search results from MAT DT/TQF mass
spectrometry data, of samples cut from the coomasie stained gel
in figure 3.59
Spot
No.
from 
fig 3.59
Protein Accession
number
Mass Protein
Score
Protein 
scores >X 
are
significant
11. Cytokeratin
18
K 1CRJI
UMAN
4789
7
165 X=59
12. Keratin 10 KRHUO 5972
0
110 X=59
13. Cytokeratin
18
K1CR H 
UMAN
4789
7
126 X=59
14. Keratin 19 KRHU9 4407
9
150 X=59
15. Keratin 19 KRHU9 4407
9
188 X=59
16. Keratin 19 KRHU9 4407
9
156 X=59
17. Keratin 19 KRHU9 4407
9
163 X=59
18. Keratin 19 KRHU9 4407
9
112 X=59
19. Keratin 10 KRHUO 5972
0
78 X=59
20. Cytokeratin
8
K2C8_HU
MAN
5351
0
173 X=59
Identity of proteins excised from the gel (numbered spots 11-20, Figure 3.59) 
and analysed by MALDI/TOF mass spectrometry. The protein score is - 
10*Log(P), where P is the probability that the observed match is a 
random event.
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Figure 3.60. Repeat coomasie blue stained 2 Dimensional gel 
containing proteins immunoprecipitated. using ERa specific 
antibody, from TAM-R cells.
4O a
©2©1
a *  66
✓  '4
Repeat coomasie blue stained 2D gel containing proteins 
immunoprecipitated, using the ERa 1D5 antibody (lOpg), from 
TAM-R cell lysate (total protein content=10mg). Each 
numbered spot represents a protein that has been excised from 
the gel and analysed using MALDI/TOF MS.
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Figure 3.61. Silver stained 2 Dimensional gel containing proteins 
immunoprecipitated. using ERa specific antibody, from TAM-R cells
Same gel as in figure 3.60, but re-stained using the silver 
staining technique. Each numbered spot represents a protein 
that has been excised from the gel and analysed using 
MALDI/TOF MS.
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Table 2a. Mascot search results from MALDI/TOF mass spectrometry
data, of samples cut from the silver stained gel in figure 3.61
Spot
No.
Protein Accession
number
Mass Protein
Score
Expect
1. Keratin 10 gi:40354192 59020 73 0.0058
2. Chain L, 
IgglFab 
Fragment
gi:4558340 23693 88 0.0033
3. Keratin 10 gi:40354192 92
4. Keratin 9 gi:4557705 62178 98 1.8e-0.5
5. FKSG14 gi: 11141855 31677 44 5.6
6. Mixture of 
cytokeratin land 
9
gi:55956899 
+1346343
62255+
66149
143 6.4e-10
7. Keratin 6 gi:27465517 60472 63 0.06
8. CRDP 12 gi:13899173 117341 57 0.26
9. Cytokeratin 2 gi: 181402 66110 99 1.6e-05
10. IgG heavy chain gi:49523848 13533 36
11. Zinc finger 
protein
gi:7019591 84893 52 0.89
12. PPIL3b gi: 14043400 18385 51 0.93
13. Unnamed protein gi: 16552024 41878 47 2.6
14. Pleckstrin and 
sec7
gi:14150035 85292 54 0.47
15. Unnamed protein gi: 10438010 24432 48 1.9
Identity of proteins excised from the gel (numbered spots 1-15, Figure 3.61) and 
analysed by MALDI/TOF mass spectrometry. The protein score is -10*Log(P), 
where P is the probability that the observed match is a random event. Expect is 
the probability that the match is a random event.
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Table 2b. Mascot search results from MALDI/TOF mass spectrometry
data, of samples cut from the silver stained gel in figure 3.61
Spot
No.
Protein Accession
number
Mass Score Protein 
score >X 
significant
16. Protein XP gi:51466965 28654 64 0.054
17. Keratin 10 gi:40354192 59020 69 0.015
18. Mix of Keratin 
10
and Cytokeratin 
9
gi:307086
gi:435476
46473
62320
159 1.5e-ll
19. Keratin 2a gi:4713260 65678 77 0.0026
20. Keratin 1 gi: 17318569 66198 51 0.99
21. Keratin 10 gi:40354192 59020 95 3.7e-5
22. Mix of Keratin 
10
and Keratin 2a
gi:40354192 
gi:47132620
59020
65678
194 4.9e-15
23. Keratin 6a gi:46812692 60323 78 0.002
24. Mix of Keratin 
10
and keratin 2a
gi:40354192 
gi:47132620
59020
65678
187 2.4e-14
25. Cytokeratin 1 gi: 1346343 66149 74 0.0055
26. Keratin 6a gi;46812692 60323 76 0.0034
27. Mixture of 
Cytokeratin land 
9
gi:435476 
gi: 1346343
62320
66149
174 4.9e-13
Identity of proteins excised from the gel (numbered spots 16-27, Figure 3.61) and 
analysed by MALDI/TOF mass spectrometry. The protein score is -10*Log(P), 
where P is the probability that the observed match is a random event. Expect is 
the probability that the match is a random event.
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4.0 DISCUSSION
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Tamoxifen resistant breast cancers appear to stably express ERa both in the 
clinical setting and in preclinical cell models (Robertson, 1996, Brunner et al.,
1993, Lykkesfeldt et al., 1994, Encamacion et al., 1993; Hutcheson et al 2003). 
Furthermore, a number of reports have indicated that down regulation of the 
ER with the pure anti-oestrogen, fulvestrant, inhibits tamoxifen-resistant 
growth in the clinic and in vitro suggesting that the ER has a continued role in 
growth regulation in this condition (Brunner et al., 1993, Lykkesfeldt et al.,
1994, Coopman et al., 1994, Hu et al., 1993, Howell & Robertson, 1995, 
Howell et al., 1996, 2002). Similarly, the Tenovus laboratory has shown that 
growth of a tamoxifen resistant MCF-7 breast cancer cell line is sensitive to the 
growth inhibitory actions of fulvestrant (Knowlden JM et al, 2003, Hutcheson 
et al 2003). In support of these findings the current study has confirmed that 
ERa expression levels are comparable in the tamoxifen-resistant (TAM-R) and 
WT MCF-7 cell lines and that fulvestrant induced down regulation of ERa and 
consequently reduced growth in these two cell lines. The primary aim of the 
current study, therefore, was to elucidate a potential mechanism, utilised by the 
tamoxifen resistant MCF-7 breast cancer cell line, to maintain ER functionality 
despite the continued presence of tamoxifen. Identification of such a 
mechanism may lead to the development of a more effective therapy for the 
treatment of acquired tamoxifen resistant breast cancer.
In addition to ER playing a continued role in the growth of tamoxifen resistant 
breast cancer, this condition has also been associated with a dependence on 
growth factors, their respective receptors and constituents of the growth factor 
receptor signalling pathway (Clarke et al 2001; Nicholson et al 2005). In
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clinical breast cancer it has been demonstrated that lack of response to 
endocrine therapy, together with increased metastasis and poor survival, can be 
associated with over expression of the epidermal growth factor receptor EGFR 
and c-erbB2 (Write et al 1992; Nicholson et al 1993; Nicholson et al 1994). In 
vitro models of acquired tamoxifen resistance have further demonstrated that 
raised levels of EGFR may contribute to increased proliferative activity (Long 
et al 1992; El-Zarruk et al 1999, Knowlden et al 2003; Hutcheson et al 2003) 
and transfection of either EGFR or c-erbB2 into hormone-dependent breast 
tumour cells resulted in hormone-independent cell proliferation and tamoxifen 
resistance respectively (van Aguthen et al 1992; Benz et al 1992; Miller et al 
1994; Kurokawa et al 2000; Hutcheson et al 2003, Osbome K 2005). 
Experimental evidence has suggested that IGF-IR signalling may also play an 
important role in the development and growth of tamoxifen resistant cell lines 
(Knowlden et al 2005; Parisot et al 1999; Wiseman et al 1993). Over­
expression of IGF-H, IGF-IR and IRS-1 has been shown to reduce sensitivity 
of MCF-7 and T47-D breast cancer cell lines to tamoxifen treatment (Daly et 
al., 1991, Surmacz & Burgaud, 1995, Abdul-Wahab et al., 1999) and 
tamoxifen-resistant MCF-7 cells demonstrate increased sensitivity to both the 
proliferative effects of IGF-I/n and the growth inhibitory actions of the 
selective IGF-IR tyrosine kinase inhibitor AG1024 and the IGF-IR 
monoclonal antibody aIR-3 (Knowlden et al 2005; Parisot et al 1999; Wiseman 
et al 1993). Interestingly, the increased reliance on IGF-IR signalling is 
observed in tamoxifen-resistant cell lines despite expression levels of IGF-IR 
being lower in these cells compared to their parental, tamoxifen-sensitive, cell
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lines (Brockdorff et al 2003; van den Berg et al 1996; McCotter et al 1996; 
Knowlden et al 2003).
Both EGFR and IGF-IR regulate cell proliferation through activation of 
downstream signal transduction cascades, in particular the mitogen-activated 
protein kinase (MAPK) pathway. Increased activity of MAPK (or extracellular 
signal-regulated kinase [ERK]) has been associated with reduced quality and 
duration of response to tamoxifen and shortened disease free survival in ER- 
positive breast cancer patients (Mueller et al 2000; Gee et al 2001). 
Furthermore, constitutive activation of ERK1/2 has also been shown to 
contribute to anti-oestrogen resistance in MCF-7 breast cancer cell lines 
(Kurokawa et al 2000; El-Ashry et al 1997; Donovan et al 1997). The current 
study supports the above findings as blockade of EGFR, IGF-IR and ERK1/2 
signalling activity using gefitinib (selective EGFR tyrosine kinase inhibitor), 
AG1024 (selective IGF-IR tyrosine kinase inhibitor) and PD184352 (selective 
MEK1/2 inhibitor), respectively, induced significant reductions in TAM-R cell 
growth, in agreement with previous Tenovus findings (Knowlden et al 2003, 
Jones et al., 2005, Knowlden et al., 2005).
Interestingly, evidence exists to suggest that in addition to direct stimulatory 
effects on cell growth, EGFR and IGF-IR signalling can also target and 
phosphorylate key serine residues within the AF-1 domain of ERa in endocrine 
responsive breast cancer cells (Bunone et al 1996; Kato at al 1995, Joel et al., 
1998, Lannigan, 2003). Phosphorylation of these residues, in particular serine 
118 which has been suggested as a target for ERK1/2 MAPK, promotes co­
activator recruitment and activation of ERa transcriptional activity (Bunone et
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al 1996; Kato at al 1995; Joel et al 1998; Endoh et al 1999; Deblois et al 2003). 
It is possible that such ligand-independent activation of ERa may play a role in 
endocrine resistance as increased levels of serine 118 and serine 167 
phosphorylated ERa have been reported in breast cancer cell lines resistant to 
both tamoxifen and long-term oestrogen deprivation (Campbell et al 2001; 
Chan et al 2002; Martin et al 2003; Shou et al 2004; Vendrell et al 2005). 
Based on these findings and the knowledge that the EGFR and IGF-IR 
signalling pathways are active in the TAM-R cell line, we hypothesised that 
cross talk between these signalling pathways and ERa, via ERKl/2-mediated 
phosphorylation of ERa at serine 118, may provide a mechanism to maintain 
ER transcriptional functionality in these cells despite the presence of 
tamoxifen.
Early evidence to suggest that this may in fact be the case was provided by the 
western blotting assay developed in this study which revealed that there was a 
significant increase in the level of basal ERa phosphorylation at serine 118 in 
the TAM-R compared to the WT MCF-7 cell line. Furthermore, this increased 
level of serine 118 phosphorylated ERa in TAM-R cells correlated with the 
elevated EGFR/ERK1/2 signalling activity observed in this cell line. These 
findings were confirmed by a developed ICC assay, which indicated that serine 
118 phosphorylated ERa was localised predominantly within the nuclei of the 
TAM-R cells. This is consistent with reports from other groups who have 
shown enhanced ERK1/2 activity in association with increased ERa 
phosphorylation at serine 118 in other MCF-7 breast cancer cell lines resistant 
to tamoxifen (Vendrell et al 2005; Shou et al 2004). The higher levels of ERa
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phosphorylation was not a result of changes in total ERa expression as levels 
of this receptor were equivalent in the two cell lines as previously reported and 
confirmed above (Hutcheson et al 2003).
Conformational changes in ERa induced by ligand interactions have also been 
reported to induce phosphorylation of serine 118 (Chen et al 2000; Joel et al 
1998; Shou et al 2004). However, this study shows that, although tamoxifen 
clearly induced significant increases in ERa phosphorylation at serine 118 in 
the WT MCF-7 cells, as early as 10 minutes post treatment and lasting up to 
five days, after 14 days treatment ERa phosphorylation levels had reduced to 
well below basal WT values. Interestingly, ERa phosphorylation levels closely 
correlated with cell growth following tamoxifen treatment in WT cells, with 
cells continuing to proliferate whilst levels of ERa phosphorylation were 
evident during the first week of tamoxifen treatment but being growth inhibited 
at day 14 when levels of ERa phosphorylation were substantially reduced. It 
should also be noted that phosphorylation of ERa at serine 118 in TAM-R cells 
was significantly greater than the tamoxifen-induced increases in ERa 
phosphorylation observed in WT cells suggesting that additional factors 
alongside tamoxifen binding, such as EGFR/MAPK signalling, were required 
to generate the levels observed in TAM-R cells.
Confirmation that the EGFR/ERK1/2 signalling pathway was indeed 
responsible for much of the ERa phosphorylation at serine 118 in TAM-R cells 
was provided by treating the cells with EGF, which significantly up-regulated 
activation of EGFR/ERK1/2 signalling and ERa phosphorylation, whilst the 
selective inhibitors of EGFR and MEK1/2, gefitinib and PD184352,
209
significantly reduced ERa phosphorylation. This regulation of ERa 
phosphorylation at serine 118 by EGFR driven ERK1/2 activity was 
emphasised by the finding that ERK1/2 was physically associated with ERa in 
the TAM-R cells and this association could be blocked using PD184352. These 
findings are again consistent with the Shou et al (2005) report which also 
demonstrated EGFR dependent regulation of ERa phosphorylation at serine 
118 in their HER2 over-expressing MCF-7 breast cancer cell line in the 
presence of tamoxifen.
Modulation of IGF-IR signalling was also found to influence ERa 
phosphorylation at serine 118 in the TAM-R cell line. Stimulation of IGF-IR 
signalling with IGF-II promoted ERK1/2 activation and increased serine 118 
phosphorylation in the tamoxifen-resistant cells. Furthermore, inhibition of 
IGF-IR activity using AG1024 reduced both ERK1/2 and ERa 
phosphorylation levels in this cell line. Recently, it has been reported that, in 
addition to direct activation of ERK1/2 via the Shc/Ras/Raf/MEKl/2 pathway, 
IGF-IR signalling can promote ERK1/2 activation indirectly through 
transactivation of EGFR via a c-src-dependent mechanism in the TAM-R cell 
line (Knowlden et al 2005). It is likely that IGF-IR regulates serine 118 
phosphorylation of ERa via EGFR in TAM-R cells as blockade of IGF-IR 
signalling with AG1024 provided no additive inhibitory effect on ERa 
phosphorylation at serine 118 when given in combination with gefitinib in 
these cells.
Growth factor signal transduction pathways clearly played a role in regulating 
the phosphorylation of ERa in TAM-R cells, therefore, investigations were
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carried out to elucidate whether the same pathways still played a role in 
maintaining the low but measurable levels of ERa phosphorylation at serine 
118 in the parent WT MCF-7 cell line or whether this phosphorylation was 
dependent on other factors such as background oestrogen levels found in the 
charcoal stripped serum (Chen et al 2002; Joel et al 1998). Early results 
showed that EGF and IGF-II both significantly increased ERa phosphorylation 
at serine 118 in the WT cells, as previously reported by Joel et al (1998). Under 
basal conditions, however, ERa phosphorylation was not reduced by either 
EGFR or ERK1/2 inhibition using gefitinib and PD184352 respectively, but 
was significantly reduced by AG1024 inhibition of IGF-IR. These results 
compliment growth studies in WT MCF-7 cells where gefitinib and PD184352 
were less effective than AG1024 at reducing growth, probably due to the 
relatively low expression and phosphorylation levels of EGFR/ERK1/2. Thus, 
although priming of the EGFR signalling pathway with EGF demonstrated that 
EGFR dependent phosphorylation of ERa at serine 118 via ERK1/2 can take 
place, under basal growth conditions IGF-IR appears the dominant mediator of 
ERa phosphorylation at serine 118 through an ERKl/2-independent pathway. 
To further examine the regulatory role of IGF-IR in the WT cells the 
PI3K/AKT signalling pathway, another down stream IGF-IR signalling 
pathway independent of the Ras/Raf/ERKl/2, was inhibited using the PI3K 
inhibitor LY294002. Although LY294002 significantly reduced ERa 
phosphorylation at serine 118 in these cells, total ERa levels were also reduced 
in the presence of this agent. This observation may relate to the findings by 
Pasapera Limon et al (2003) who demonstrated that LY294002 could act as a
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direct competitive antagonist of ERa and as a consequence accelerate protease 
degradation of the receptor, possibly in a similar fashion to fulvestrant (Carlson 
et al 2005; McClelland et al 1995). Interestingly, in the current study 
fulvestrant treatment of WT cells induced an enormous increase in ERa 
phosphorylation at serine 118 after one hour despite significantly down 
regulating total ERa levels. These data suggest that differences exist between 
the LY294002- and fulvestrant-induced degradation of ERa in the WT cells. 
Overall, the findings suggest that a growth factor signalling pathway 
independent of that found to regulate ERa phosphorylation at serine 118 in 
TAM-R cells exists in WT cells. In support of the findings that IGF-IR 
possibly via PI3K/AKT regulated ERa phosphorylation at serine 118 in the 
WT cells, Martin et al (2000) have previously demonstrated that AKT 
dependent phosphorylation of serine 118 and other N-terminal serine residues 
such as 104, 106 and 167 appear to play a role in the activation of ERa in 
COS1 cells. They also demonstrated that in MCF-7 cells AKT activation was 
blocked by inhibitors of PI3K such as wortmannin which, unlike LY294002, 
have no affinity for ERa. Moreover, stable transfection of the MCF-7 cells 
with a dominant negative AKT mutant blocked the effects of EGF and IGF-I 
on ER-alpha expression and activity, whereas stable transfection of cells with a 
constitutively active AKT mutant mimicked the effects of EGF and IGF-I 
(Martin et al 2000).
Prior to discovering that IGF-IR provides a level of regulation over ERa 
phosphorylation at serine 118 in WT cells under basal conditions, probably 
through a PI3K/AKT dependent mechanism, this study demonstrated that
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tamoxifen induced increases in ERa phosphorylation at serine 118 were 
independent of the EGFR/ERK1/2 signalling pathway as gefitinib and 
PD184352 were ineffective at inhibiting such increases. Based on these 
observations it appears necessary to carryout a study to investigate whether the 
IGF-1R/PI3K/AKT pathway mediates the tamoxifen induced increase in ERa 
phosphorylation at serine 118 in the WT cells.
Interestingly, within both the TAM-R and WT cell lines the growth factor 
inhibitors used in this study to reduce ERa phosphorylation at serine 118, were 
not fully effective. For example, although gefitinib, AG1024 and PD184352 
lowered ERa phosphorylation at serine 118 in TAM-R cells, either alone or in 
combination, it is clear that a measurable level of ERa phosphorylation 
remained under conditions where EGFR, IGF-IR and ERK1/2 appeared 
completely blocked by the inhibitors. Similarly, when gefitinib or PD184352 
were used in combination with EGF in the TAM-R cells it is clear that while 
the inhibitors prevented the EGF induced increase in ERa phosphorylation at 
serine 118 and in the case of gefitinib even reduced ERa phosphorylation 
below the control, once again residual ERa phosphorylation at serine 118 
remained despite relatively complete inhibition of EGFR and ERK1/2. There 
are several possible explanations for these observations. Firstly, the western 
blotting assay may not be sensitive enough to detect any residual low levels of 
phosphorylated EGFR, IGF-IR or ERK1/2 following exposure of cells to the 
inhibitors, where such residual signalling may be sufficient to induce some 
ERa phosphorylation. Alternatively, other kinases may come into play, 
including CDK-7, which has been previously implicated in ERa
213
phosphorylation at serine 118 (Chen et al 2000; Chen et al 2002; Ito et al 
2004). Importantly however, CDK-7-induced ERa phosphorylation has been 
suggested to be dependent on oestradiol induced recruitment of TF11H to the 
AF-2 domain, an event unlikely to occur in the presence of tamoxifen due to 
the altered position of helix 12 (Chen et al 2000). The findings that ERK1/2, 
AKT and CDK7 have all been implicated in phosphorylation of ERa at serine 
118 does in fact highlight that a level of redundancy exists within the 
mechanisms phosphorylating ERa at serine 118 and such pathways may either 
function alongside one another or take over from the dominant phosphorylating 
pathway immediately after inhibition, due to their increased access to the 
phosphorylation domain.
A further example suggesting redundancy in the kinases responsible for 
phosphorylating ERa at serine 118 has been provided by examining ERa 
phosphorylation status across a number of our MCF-7 resistant cells lines. 
These studies have clearly shown that cells doubly resistant to tamoxifen and 
inhibitors of two of the principle proteins implicated in phosphorylation of ERa 
at serine 118, namely EGFR and HER2 (TAM/TKI-R and TAM/HER-R MCF- 
7 respectively), have very high levels of phosphorylated ERa at serine 118. 
Indeed, their ERa phosphorylation levels are actually greater than the parent 
TAM-R cells. Thus, after an initial inhibition of ERa phosphorylation at serine 
118 and blockade of cell growth promoted by gefitinib and herceptin, the cells 
eventually find mechanisms to re-establish elevated ERa phosphorylation at 
serine 118. Early studies by Dr Helen Jones (personal communication) within 
the Tenovus laboratories have shown that TAM7TKI-R cells are dependent on
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IGF-IR and PKC signalling to mediate growth and ERa phosphorylation at 
serine 118, implicating an additional kinase capable of phosphorylating ERa. 
These suggestions of redundancy within the system regulating ERa 
phosphorylation at serine 118 potentially highlight the need to carry out large 
scale in vitro kinase assays and kinase library screening assays within a range 
of breast cancer cell lines to evaluate other potential kinases responsible for 
serine 118 phosphorylation. Alternatively it may be possible to design 
antagonistic compounds or peptides to inhibit AF-1 phosphorylation by direct 
interaction with ERa rather than targeting single kinases.
It should be noted at this point that although ERa phosphorylation at serine 118 
may play a role in the growth of acquired resistant breast cancer cell models 
clinical studies by Murphy LC et al 2004 have strongly suggested that such a 
phosphorylation event appears to play no role in de novo tamoxifen resistance. 
In fact their studies show that along with ERa and progesterone positive status, 
ERa phosphorylation at serine 118 corresponds to longer disease free survival 
in node-negative patients who were subsequently treated with adjuvant 
tamoxifen. Such discrepancies between the role of ERa phosphorylation at 
serine 118 in de novo and acquired resistance may relate to the observations 
that the ligand dependent mechanism may be prominent in the clinical tumour 
samples, whereas the current study suggests that ligand independent 
phosphorylation of ERa plays a much stronger role in the acquired tamoxifen 
resistant MCF-7 cell line.
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To better understand the biological significance of the EGFR/ERK1/2 
dependent phosphorylation of ERa at serine 118 in TAM-R cells, the 
recruitment of nuclear receptor co-regulators to ERa was next investigated. 
Binding of tamoxifen to ERa is believed to cause a conformational change in 
the receptor allowing recruitment of co-repressors to the AF-2 domain whilst 
preventing association with co-activators (Lavinsky et al 1998; Levenson and 
Jordan 1999; Shiau et al 1998; Shang et al 2000; Shang & Brown 2002; Smith 
& O’Malley 2004). However, phosphorylation of serine 118 within the AF-1 
domain has been shown to promote co-activator recruitment to ERa in MCF-7 
cells and thus activate transcriptional activity of the receptor in the presence of 
tamoxifen, hence emphasising the potential importance of the AF-1 domain 
and it’s phosphorylation dependent activation in the TAM-R cells (Dutertre 
and Smith 2003; Endoh et al 1999; Lavinsky et al 1998). Immunoprecipitation 
and Western blotting studies were used in the current study to examine whether 
serine 118 phosphorylation of ERa influenced co-regulator recruitment. 
Significantly, in TAM-R cells both co-repressors (nuclear receptor corepressor 
(NCoR) and SMRT) and co-activators (SRC1, SRC3, CBP and p68 RNA 
Helicase) were found to be associated with ERa phosphorylated at serine 118. 
Similarly, Shou et al., 2004 have reported that tamoxifen treatment promotes 
recruitment of ERa and the co-activators SRC3, CBP and p300 to the ER- 
regulated pS2 gene promotor in a de novo tamoxifen-resistant MCF-7 cell line 
engineered to over-express HER2. However, in this model, association of co­
repressors to ERa was only observed following inhibition of EGFR signalling 
and thus reduction in serine 118 phosphorylated ERa levels.
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Interestingly in our TAM-R cell line recruitment of the co-activators p68 RNA 
helicase and SRC1 by ERa was regulated by EGFR/ERK1/2 signalling 
activity. In support of this, it has previously been reported that p68 RNA 
helicase preferentially binds ERa when phosphorylated at serine 118 by 
ERK1/2 (Endoh et al., 1999). It should be noted that direct, ERKl/2-mediated, 
serine phosphorylation of both co-activator and co-repressor proteins has also 
been shown to regulate their ability to associate with ERa (Font de Mora & 
Brown, 2000, Rowan et al., 2000, Lopez et al., 2001, Jonas & Privalsky, 2004) 
and thus ER-driven transcriptional activation may be a function of each of 
these serine phosphorylation steps. Interestingly, over expression of the co­
activator SRC3 has also been shown to correlate with resistance to tamoxifen 
in breast cancer patients and EGFR-dependent phosphorylation of this co­
activator has also been proposed to mediate tamoxifen resistance in HER2 over 
expressing MCF-7 cells (Shou et al., 2004). Although SRC3 was
phosphorylated on serine residues in our TAM-R cells, and this
phosphorylation was under EGFR/ERK1/2 regulation, no evidence was 
obtained that recruitment of the co-activator SRC3 to ERa was similarly under 
the regulation of this signalling pathway. Immunoprecipitation studies also
revealed no effect of either gefitinib or EGF treatment on serine
phosphorylation of SRC1, p68 RNA helicase and SMRT, suggesting that their 
recruitment to ERa is sufficient to promote transcriptional activity in TAM-R 
cells. As would be expected, immunoprecipitation studies carried out in the 
WT cell line showed strong associations between ERa, the co-activators p68 
RNA helicase, SRC1, SRC3, CBP and RNA polymerase n.
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The fact that both co-activators and co-repressors were found to associate with 
phosphorylated ERa in the TAM-R cells is counterintuitive. In the most 
simplistic of terms the. primary role of co-activators is to increase the 
accessibility of DNA to the pre-initiation complex, by principally weakening 
the interaction between DNA and histones either through ATP dependent 
mechanisms or through acetylation of the N-terminal tails of the histones 
(Klinge CM 2000). Conversely, the primary role of co-repressors is to promote 
chromatin condensation and inhibition of transcription predominantly through 
recruitment of histone deacetylases (Klinge CM 2000). Acetylation and 
deacetylation of nucleosomal histones by these coactivator and corepressor 
complexes, operating together with other covalent histone modifications such 
as methylation, phosphorylation and ubiquitination creates a ‘histone code’ and 
the prevalence or activity of either the coactivators or corepressors determines 
transcriptional activation or transcriptional repression respectively (Kraus and 
Wong 2002). However, in the present study both co-activators and co­
repressors associate with ERa in TAM-R cells, therefore it is possible that the 
positive effects of co-activators, associated to the AF-1 region of tamoxifen 
bound-ERa phosphorylated at serine 118, on transcriptional activity may be 
cancelled out by the inhibitory effects of co-repressors associated to the AF-2 
region of the same ERa. There are several possible scenarios that may occur to 
prevent this paradox. Firstly the balance of coactivators versus co-repressors 
bound to ERa may be un-equal, therefore, the co-regulator group with greater 
numbers will predominate. Secondly, it has been shown that the response 
elements of gene promoters themselves can influence the binding of co­
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regulators to a nuclear receptor (Klinge et al 2004). Natural and synthetic EREs 
with different nucleotide sequences were found to influence ER binding 
affinity, conformation, and transcriptional activity, through effects on ER 
interactions with coactivators and corepressors. For example, CHO-K1 cells 
transfected with ERa or ERp showed ERE sequence-dependent differences in 
the functional interaction of ERa and ERp with coactivators such as SRC-1, 
SRC-2, SRC-3, CBP and SRA, and corepressors such as NCoR and SMRT, as 
well as secondary coactivators such as CARM1 and PRMT1. These differences 
in co-regulator recruitment were observed in both the absence and presence of 
ligands such as oestradiol and 4-hydroxytamoxifen. This ability of ERE’s to 
influence co-regulator recruitment by ERa could be assessed in TAM-R cells 
by chromatin immunoprecipitation assays allowing comparison of co-regulator 
recruitment by ERa at promoters of ER-regulated genes that are either 
transcribed or not transcribed in TAM-R cells. Thirdly, the balance of co­
activator versus co-repressor may be equal but the activity of the co-regulator 
may potentially be regulated by post-translational modification. 
Phosphorylation and acetylation of the nuclear receptor co-regulators has been 
reported to influence the level of co-regulator activity (Klinge et al 2000). The 
phosphorylation events are regulated by signalling kinase pathways originating 
from the plasma membrane, however, acetylation and even methylation events 
have been reported to be regulated by other co-regulators (Rowen et al 2000; 
Wu et al 2004; Sterner and Berger 2000). For example co-Factor 
AcetylTransferases (FATs) such as p300/CBP and PCAF regulate the co­
activator SRC3 (ACTR) activity by acetylating a region adjacent to the
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LXXLL motif. The two other members of the p i60 family of nuclear receptor 
coactivators, SRC-1 and SRC-2 (TIF2), can also be efficiently acetylated by 
p300/CBP in vitro (Sterner and Berger 2000). It is therefore possible that, 
based on these reports, co-activators associated with AF-1 may repress the co­
repressors associated to the AF-2 domain of the tamoxifen bound-ERa 
allowing transcription of the gene in TAM-R cells. These discoveries indicate 
that further investigations are needed to elucidate all the possible 
posttranslational modifications that occur on co-regulator proteins and 
elucidate whether such modifications can be carried out by coactivators on 
corepressors and visa versa.
Significantly, the immunoprecipitation studies also revealed that RNA 
polymerase II was recruited to ERa phosphorylated at serine 118 in the TAM- 
R cells adding further weight to the concept that ERa was transcriptionally 
active. To examine this possibility in more detail we measured ERE-mediated 
gene transcription using a transiently-transfected reporter gene assay system. 
Initial evaluation revealed that TAM-R ERE levels were approximately 50% of 
those observed in WT cells, indicating a high level of basal ERa transcriptional 
activity despite the presence of tamoxifen. Further evaluation of basal ERE 
activity in the two cell lines revealed that pretreatment with fulvestrant, and 
thus downregulation of ERa, resulted in suppression of ERE activity in both 
cell lines. It should be noted that as well as activating gene transcription at 
classical ERE’s, ERa can also influence transcription at alternative response 
elements. For example, protein-protein interactions between the ERa and
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members of the AP-1 complex have been shown to enhance transcriptional 
activity of AP-1 responsive genes (Kushner et al 2000). Furthermore, it has 
been suggested that the partial oestrogenic activity of tamoxifen can be 
mediated by ER:AP-1 interactions (Webb et al 1995) and increased AP-1 
activity has been reported in tamoxifen-resistant clinical samples and breast 
cancer cells (Dumont et al 1996; Johnston et al 1999). This does not, however, 
appear significant in either our WT or TAM-R cells since fulvestrant had no 
inhibitory effect on AP-1 reporter gene activity in either cell line. Similarly, 
fulvestrant showed no inhibitory effect on the basal activity of reporter gene 
constructs containing serum response elements (SRE) in either WT or TAM-R 
cells and reporter gene constructs containing response elements to heat shock 
(HSE), NFkB, Glucocorticoid (GRE) and cAMP (CRE) were also insensitive 
to the inhibitory action of fulvestrant in TAM-R cells. These findings 
confirmed our previous investigations with respect to basal ERE activity in the 
TAM-R and WT cells (Hutcheson et al 2003) and would suggest that ERa 
exerts its action primarily through ERE’s in these cell lines. Interestingly a 
slight increase was observed in AP-1 and SRE activity in the WT and TAM-R 
cells in the presence of fulvestrant, which has also been reported by Wang et al 
(2004) in 293A cells. Wang et al (2004) did not believe that this was due to 
protein-protein interactions or sequestration of co-repressors away from the 
AP-1 complex but involved a nuclear shuttling event since Leptomycin B, 
which inhibits nuclear export shuttling of proteins from the nucleus to the 
cytoplasm, completely inhibited the fulvestrant induced activation of AP-1.
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The ERE luciferase assay also revealed that ERa transcriptional activity was 
regulated by the EGFR/IGF-1R/ERK1/2 signalling pathway, being increased 
by EGF and IGF-II and inhibited by gefitinib, AG1024 and PD184352, 
providing further indirect support for the involvement of EGFR/IGF- 
lR/ERKl/2-mediated serine 118 ERa phosphorylation in the regulation of ERa 
activity in TAM-R cells. Although the involvement of ERa serine 118 
phosphorylation in the regulation of ERa activity was further emphasised by 
the ability of the EGFR/IGF-1R/ERK1/2 signalling pathway to regulate ERE 
activity in these cells, it is important to note that the EGFR/IGF-1R signalling 
pathways can also mediate TAM-R cell growth directly through AP-1 and 
SREs (Whitmarsh and Davis 1996), as shown by the stimulatory effects of 
EGF, and inhibitory effects of gefitinib on AP-1 and SRE in the TAM-R cells. 
Thus, it is likely that ERa transcriptional activity is only one aspect of 
EGFR/IGF-1R signalling activity contributing to the proliferative response in 
these cells. Interestingly, in our studies PD184352 was inhibitory on SRE 
activity but not AP-1 activity in the TAM-R cells, suggesting that while 
EGFR/ERK1/2 may modulate SRE activity, the EGFR may mediate its effects 
on AP-1 activity through another signalling cascade, possibly Jun Kinase, JNK 
(Whitmarsh and Davis 1996).
Based on the findings that ER exerts its action primarily through ERE’s in WT 
cells, the ERE luciferase assay was used to elucidate whether ligand 
independent activation of ERa, possibly through phosphorylation of serine 118, 
has an effect on transcriptional activity. Interestingly there were strong
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correlations between ERE luciferase activity and ERa phosphorylation as EGF, 
IGF-I and IGF-II significantly increased, whilst AG1024 significantly inhibited 
ER transcriptional activity. Again correlating with ERa phosphorylation at 
serine 118 in WT cells, gefitinib and PD184352 were ineffective at reducing 
ER transcriptional activity at the ERE reporter gene. The ERE luciferase assay 
proved to be a convenient and reproducible technique to measure ER 
transcriptional activity, however the technique only assesses acute effects 
(within 24 hrs) and does not necessarily fully reflect ER dependent 
transcriptional events within the genome of the investigated cell lines. Reverse 
transcription (rt)-PCR, therefore, was used to measure the level of transcription 
at an endogenous oestrogen responsive gene. The pS2 gene was selected for 
investigation as its promoter contains a single imperfect ERE which confers 
oestrogen-responsiveness to this gene (Kim et al 2000), contrasting with the 
progesterone receptor which contains no classical full length ERE in its 
promoters (Flototto et al 2004; Petz et al 2004). The present study 
demonstrated that pS2 was still ERa-regulated in both WT and TAM-R cell 
lines being increased by oestradiol and reduced by fulvestrant treatment. In the 
present study, pS2 mRNA levels in WT and TAM-R MCF-7 cells were found 
to be comparable, whereas, a previous report by Hutcheson et al (2003) had 
demonstrated a 50% reduction in TAM-R pS2 mRNA levels compared to the 
WT cells. The reasons for this discrepancy are unclear but may simply reflect 
differences in experimental conditions used in the two studies.
Consistent with the previous findings concerning ER/ERE transcriptional 
activity and phosphorylation at serine 118, pS2 mRNA levels in TAM-R cells
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were increased significantly in the presence of EGF and significantly decreased 
in the presence of gefitinib and PD184352. In the WT cell line, however, only 
EGFR stimulation had any measurable effect on pS2 mRNA levels. 
Significantly, EGF induced increase in transcription of the pS2 gene in the 
TAM-R and WT cells was also found to be significantly inhibited by 
fulvestrant confirming the importance of the ER to the EGF-induced events. 
Interestingly, an ability of EGF to regulate pS2 gene transcription through ER- 
independent mechanisms has also been reported by other groups. In the ER 
negative HepG2 cell line ER independent activation of the pS2 gene via an 
ERKl/2-mediated activation of Fos and Jun at the AP-1 site has been 
demonstrated. However, in that study transcription of the pS2 gene was shown 
to be substantially greater in HepG2 cells transfected with wild type ERa 
(Barkhem et al 2002). Furthermore Shou et al (2004) demonstrated that in the 
presence of tamoxifen their de novo tamoxifen resistant MCF-7 cell line 
engineered to over-express HER2, maintained strong recruitment of ERa and 
the co-activators SRC3, CBP, p300 to the pS2 gene promoter as well as 
promoting increased acetylation of this promoter. The addition of gefitinib, 
however, inhibited acetylation of the pS2 promoter due to inhibition of the co­
activator recruitment and enhanced co-repressor recruitment to ERa.
Having established that EGFR/ERK1/2 signalling activity regulated ERa 
function in TAM-R cells, attention was focused on a potential bidirectional 
form of cross talk between ERa-EGFR/ERKl/2 signalling pathways described 
by Hutcheson et al (2003), who showed that fulvestrant induced reduction in
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TAM-R cell growth was a consequence of reduced EGFR/ERK1/2 signalling 
in these cells (Knowlden et al 2003; Hutcheson et al 2003). In this study, ERa 
was believed to modulate these effects on EGFR signalling through regulating 
the availability of EGFR ligands such as TGFa (Hutcheson et al 2003). 
However, the present Endings indicate that a role for TGFa is unlikely as 
fulvestrant only weakly reduced mRNA levels of this ligand in the TAM-R cell 
line and an anti-TGFa neutralizing antibody had no obvious effect on basal 
EGFR activity in these cells. In addition there were no inhibitory effects on 
TAM-R EGFR activity observed in the presence of neutralising antibodies to 
EGF and Hb-EGF. This study did, however, find that neutralizing antibodies to 
amphiregulin, another EGFR ligand which has also been shown to be ERa- 
regulated in a range of breast cancer cell lines, including MCF-7 (Martinez- 
Lacaci et al., 1995), reduced basal phosphorylation levels of EGFR/ERK1/2 
and ERa phosphorylation at serine 118 in TAM-R cells. In support of these 
findings, PCR studies showed that fulvestrant significantly inhibited the 
mRNA levels of amphiregulin in TAM-R cells, yet EGF, Hb-EGF and (3- 
cellulin mRNA levels were unaffected by fulvestrant. Interestingly another 
EGFR ligand in addition to amphiregulin was found to be ER dependent in the 
TAM-R cells as fulvestrant significantly inhibited the mRNA levels of 
Epiregulin. Unfortunately a neutralising antibody to Epiregulin was not 
available at the time of the study.
Consistent with ERa phosphorylation at serine 118, expression of amphiregulin 
mRNA was significantly higher in TAM-R compared to the parental WT cells 
and was also under the regulation of EGFR/ERK1/2 signalling being increased
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by EGF and reduced by gefitinib and PD184352 in the TAM-R cell line. 
Amphiregulin was also reduced by AG1024 however this was not found to be 
statistically significant, perhaps due to the inhibitors reduced ability to inhibit 
ERa phosphorylation at serine 118. Regulation of amphiregulin expression by 
both ERa and ERK1/2 signalling has also been reported in MCF-7 cells 
engineered to over-express constitutively active raf-1 (Weinstein-Oppenheimer 
et al., 2002). Additional support for ERa regulation of amphiregulin in TAM-R 
cells was provided by ChEP assays which demonstrated association of ERa 
with a putative ERE site within the region of 1531-1378bp from the start site of 
the amphiregulin promoter. Thus, although it is possible that EGFR/ERK1/2 
control over amphiregulin transcription is direct, the ChEP data and the ability 
of fulvestrant to reduce EGF-mediated amphiregulin mRNA expression implies 
ERa regulation, again implicating a role for serine 118 phosphorylation of the 
AF-1 domain in mediating this process.
Similar studies in the WT cells demonstrated that EGF also induced increased 
amphiregulin transcription, which appeared to depend on ER due to the 
significant reduction in the EGF-induced response following treatment with 
fulvestrant. Again consistent with ERa phosphorylation levels at serine 118, 
EGFR/ERK1/2 inhibition with gefitinib and PD184352 was ineffective at 
reducing amphiregulin mRNA levels, however, a discrepancy was observed in 
the WT cells following IGF-IR inhibition with AG1024. In fact, AG 1024 
almost doubled the level of amphiregulin transcription, despite previously 
showing clear reductions in the levels of ERE transcriptional activity and ERa 
phosphorylation at serine 118 in the WT cells. A possible explanation for this
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discrepancy may be linked with the observation from the ChIP studies that in 
WT cells ERa does not appear to interact strongly with the region of the 
amphiregulin promoter complementary to primer 2 unless oestradiol is present. 
The elevated ERa phosphorylation at serine 118 and the presence of tamoxifen 
in the ERa LBD may be required to allow this interaction to occur in TAM-R 
cells. As these factors are not present in WT cells a completely different 
mechanism may exist in the regulation of transcriptional activity at the 
amphiregulin promoter in WT cells compared to the TAM-R cells, hence the 
lack of dependence on ERa phosphorylation.
The EGFR/ERK1/2 signalling pathway clearly plays an important role in the 
phosphorylation of ERa at serine 118 in TAM-R cells however EGF-induced 
activation of EGFR is also reported to increase ERa phosphorylation at serine 
167 via ERK1/2 and p90 ribosomal S6 kinase (Lannigan 2003). Furthermore, 
Joel et al, Smith et al, and Clarke et al have all observed ERK1/2 dependent 
phosphorylation of ERa at serine 167, therefore this study investigated whether 
the elevated EGFR/ERK1/2 signalling in TAM-R cells also increases ERa 
phosphorylation at serine 167. Importantly, no real change in the level of ERa 
phosphorylation at serine 167 between the WT and TAM-R cell lines was 
observed. Interestingly, MCF-7 cells which have acquired resistance to growth 
conditions in the absence of oestrogen and serum growth factors displayed very 
high levels of serine 167 phosphorylation compared to both WT and TAM-R 
cells, an observation that correlates with increased ERE activity in transient 
transfection assays (Staka et al 2005). The WT T47D cells also displayed
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elevated serine 167 phosphorylation, despite expressing considerably lower 
levels of total ERa, however further studies are required to identify the 
relevance of such phosphorylation events in this cell line.
The current project has focused separately on individual ERa phosphorylation 
events and ER-coregulator interactions in order to gain an insight into the 
mechanisms that govern ERa functionality in the TAM-R cells continually 
exposed to tamoxifen. Although successful in answering many questions, other 
clear post-translational events and co-regulator interactions, may impact on 
ERa activation. In an attempt to answer some of these questions; such as the 
complete phosphorylation status of the ER in our MCF-7 cell lines and the 
identity of the many different ERa interacting proteins, proteomic technologies 
such as 2D gel electrophoresis and MALDI/TOF Mass spectrometry were 
used. These techniques have been used to study protein phosphorylation and 
the profile of protein-protein interactions in different pathological conditions 
and signalling pathways (Schilling et al 2005; Gibson BW 2005).
Although the MS analysis was possible through collaboration with Dr M 
Morton, University hospital of Wales; only a limited number of samples could 
be processed due to time restrictions. For this reason excision of the protein 
spots from the 2D gel was selective and only spots around the 66-68 KDa size 
range and 6.5-7.1 pi value were selected as the full length ERa has a molecular 
weight of approximately 67KDa and a pi of approximately 6.8, although other 
isoforms of ERa are detected at different KDa and pi (Puddefoot JR et al 
1993). Importantly however, full length ERa was not identified on the gels
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produced. An interesting theme throughout the results obtained from the 
proteomic experiments was the number of cytokeratins (numbers 1, 2, 6, 8, 9, 
10,18 and 19), that co-immunoprecipitated with ERa. There are three possible 
reasons for the presence of cytokeratins in the immunoprecipitates. Firstly, the 
cytokeratins may arise from contaminants, possibly hair and skin. This, 
however, is unlikely because the cytokeratins identified are commonly 
expressed in epithelial cells, rather than those from dermal origins. Secondly, 
the cytokeratins associated with the 1D5 antibody in a non-specific manner. 
Further studies are needed to examine this and would require preclearing with a 
non-specific monoclonal mouse antibody or washing the beads used in the 
immunoprecipitation under more stringent conditions. Thirdly, it is possible 
that ERa associates with cytokeratins within the cell in a biologically relevant 
manner, perhaps relating to the trafficking of the receptor from cytoplasm to 
nucleus. Indeed, cytokeratins 8 and 18, which were strongly co- 
immunoprecipitated with ERa, have previously been implicated in cell 
signalling events (Davezac et al 2004). If such an interaction is real, this study 
is the first to reveal a direct binding between ER and cytokeratins. In support of 
this Spencer et al 1998 showed that the interaction between nuclear DNA and 
the cytokeratins 8, 18 and 19 in hormone dependent ER positive T47D breast 
cancer cells was increased in the presence of oestrogens and decreased 
following oestrogen depletion and treatment with the pure antioestrogen 
ICI164,384. Further studies are obviously required to elucidate whether these 
ER dependent interactions between DNA and cytokeratins are real and aid the
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transcriptional control of specific genes downstream of ER, or alternatively 
whether ER itself is acting as a linker between the DNA and cytokeratin. 
Potentially, once the ERa is isolated from the breast cancer cell in high enough 
quantities, then tandem mass spectrometry of the intact protein, peptide mass 
finger printing following proteolysis, or a combination of these two techniques 
can be used to identify all possible posttranslational modifications of the 
receptor. Such approaches have already proved successful in identifying all 
posttranslational modifications of the chromatin histones (Espino et al 2005). 
In combination with pharmacological studies a posttranslational finger print 
system may be developed to inform the investigator which signalling pathways 
are modulating ERa posttranslational modifications and therefore functionality. 
Similar analysis of ERa isolated from breast cancer patients may then be 
compared against the various post-translational fingerprints and inform the 
oncologist of what pathways maintain ERa functionality in that particular 
patient, therefore providing more accurate therapeutic targets.
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Conclusion
This study suggests that a self propagating autocrine growth regulatory loop 
exists in our TAM-R cell line due to bidirectional cross talk between 
EGFR/ERK1/2 and ERa signal transduction pathways. Furthermore, the 
EGFR/ERK1/2 dependent phosphorylation of ERa appears to be supported by 
the IGF-IR signalling pathway. IGF-IR also played a role in phosphorylation at 
serine 118 in the WT cell line however this involved the PI3K/AKT signalling 
pathway and was totally independent of EGFR/ERK1/2 under basal growth 
conditions. EGFR/ERK1/2 dependent phosphorylation of ERa at serine 118 
within the TAM-R cell line results in recruitment of the coactivators p68 RNA 
helicase and SRC1, activation of ERa in a ligand-independent manner resulting 
in enhanced ERE dependent gene transcription. Similarly in the WT cells, IGF- 
IR signalling contributed to ERE dependent transcriptional activity. A 
consequence of the increased ERa transcriptional activity in TAM-R cells was 
the generation of amphiregulin which when released by the cells can act in an 
autocrine manner to regulate EGFR/ERK1/2 signalling activity and thus, cell 
growth.
It should be noted that this data is only correlative and perhaps more detailed 
studies are required to demonstrate that the EGFR/ERK1/2 mediated regulation 
over ERa transcriptional activity is conclusively dependent on this 
phosphorylation event. Previous studies have used serine to alanine point 
mutated forms of ERa to demonstrate the functional significance of ERa 
phosphorylation at serine 118 (Ali et al 1993; Bunone et al 1996; Joel et al 
1998; Le Goff et al 1994; Rogatsky et al 1999), therefore similar experiments
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involving mutational analysis of ERa in the TAM-R cells are required to 
conclusively confirm the role of this phosphorylation event in the TAM-R 
cells. Unfortunately, however, all of these mutational studies were carried out 
in ER negative cell lines stably transfected with point mutant ERa and 
developing an experimental system where TAM-R cells express such serine to 
alanine point mutations as replacements of the endogenous receptor poses 
many practical problems, therefore the strategy used in this investigation 
appears the best possible.
Despite these considerations the present findings clearly demonstrate that 
cross-talk between growth factor signalling pathways and ERa plays a central 
role in regulating growth of breast cancer cells lines, in particular the MCF-7 
model of acquired tamoxifen resistance, and indicate that targeting these 
phosphorylation events on ERa whilst maintaining tamoxifen induced 
inhibition of AF-2 may prove beneficial in the therapy of this disease.
i
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